

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Library Use Only

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Cumulative Supplement 8

August 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Ribavirin 200mg Oral Capsule.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

CUMULATIVE SUPPLEMENT 8
August 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

BERLEX
(BERLEX)
BERLEX LABORATORIES INC
(BERLEX LABS)
BERLEX LABORATORIES INC SUB SCHERING AG
(BERLEX)
AMERSHAM HEALTH
(AMERSHAM)

NEW APPLICANT NAME (NEW ABBREVIATED NAME)

BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
GE HEALTHCARE
(GE HEALTHCARE)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition.
The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342) and Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at

<http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website,
<http://forms.psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2003</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	10665	10668	10702	
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)	108 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	6	3	1	
NUMBER OF APPLICANTS	601	586	602	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2004

1-1

ABACAVIR SULFATE; LAMIVUDINE

>A>	TABLET; ORAL			
>A>	EPZICOM			
>A>	+ SMITHKLINE BEECHAM	EQ 600MG BASE;300MG	N21652 001 Aug 02, 2004 Aug NEWA	

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL			
CAMPRAL			
+ LIPHA	333MG	N21431 001 Jul 29, 2004 Jul NEWA	

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL			
PHRENILIN FORTE			
>D> AB + AMARIN PHARMS	650MG;50MG	N88831 001 Jun 19, 1985 Aug CAHN	
>A> AB + VALEANT	650MG;50MG	N88831 001 Jun 19, 1985 Aug CAHN	
TABLET; ORAL			
PHRENILIN			
>D> AB + AMARIN PHARMS	325MG;50MG	N87811 001 Jun 19, 1985 Aug CAHN	
>A> AB + VALEANT	325MG;50MG	N87811 001 Jun 19, 1985 Aug CAHN	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL			
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE			
AB ANABOLIC LABS	325MG;50MG;40MG;30MG	N76560 001 Jun 10, 2004 Jun NEWA	
PHRENILIN WITH CAFFEINE AND CODEINE			
>D> AB AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001 Aug 22, 2001 Aug CAHN	
>A> AB VALEANT	325MG;50MG;40MG;30MG	N74911 001 Aug 22, 2001 Aug CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
>D> AA + AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001	Aug CAHN
AA +	120MG/5ML;12MG/5ML	N86024 001	Apr CRLD
>A> AA + VALEANT	120MG/5ML;12MG/5ML	N86024 001	Aug CAHN
TABLET; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
>D> @ HALSEY	300MG;15MG	N85795 001	Aug CAHN
>D> @	300MG;30MG	N85794 001	Aug CAHN
>A> @ MUTUAL PHARM	300MG;15MG	N85795 001	Aug CAHN
>A> @	300MG;30MG	N85794 001	Aug CAHN
>D> AA	300MG;60MG	N89673 001 Feb 10, 1988 Aug DISC	
>A> @	300MG;60MG	N89673 001 Feb 10, 1988 Aug DISC	
ACETAMINOPHEN W/ CODEINE			
>D> @ HALSEY	300MG;60MG	N87653 001 Apr 13, 1982 Aug CAHN	
>A> @ MUTUAL PHARM	300MG;60MG	N87653 001 Apr 13, 1982 Aug CAHN	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL			
ACETAMINOPHEN AND HYDROCODONE BITARTRATE			
>D> AA CENT PHARMS	500MG;5MG	N88898 001 Mar 27, 1985 Aug DISC	
>A> @	500MG;5MG	N88898 001 Mar 27, 1985 Aug DISC	

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AA	AXIOM PHARM	500MG;5MG	N40236	001	Sep 25, 1997	Aug	CAHN
>D>	AA		650MG;7.5MG	N40240	002	Nov 26, 1997	Aug	CAHN
>D>	AA		650MG;10MG	N40240	001	Nov 26, 1997	Aug	CAHN
>D>	AA		750MG;7.5MG	N40236	002	Sep 25, 1997	Aug	CAHN
	+ MIKART		300MG;10MG	N40556	001	Jun 23, 2004	Jun	NEWA
>A>	AA	MUTUAL PHARM	500MG;5MG	N40236	001	Sep 25, 1997	Aug	CAHN
>A>	AA		650MG;7.5MG	N40240	002	Nov 26, 1997	Aug	CAHN
>A>	AA		650MG;10MG	N40240	001	Nov 26, 1997	Aug	CAHN
>A>	AA		750MG;7.5MG	N40236	002	Sep 25, 1997	Aug	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	AXIOM PHARM	500MG;5MG	N40219	001	Jan 22, 1998	Aug	CAHN
>A>	AA	MUTUAL PHARM	500MG;5MG	N40219	001	Jan 22, 1998	Aug	CAHN

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	325MG;7.5MG	N40545	001	Jun 30, 2004	Jun	NEWA
AA		325MG;10MG	N40545	002	Jun 30, 2004	Jun	NEWA
AA		500MG;7.5MG	N40550	001	Jun 30, 2004	Jun	NEWA
AA		650MG;10MG	N40550	002	Jun 30, 2004	Jun	NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

AB	AAIPHARMA	500MG;100MG	N76429	001	Sep 10, 2003	May	CRLD
		500MG;100MG	N76429	001	Sep 10, 2003	Jun	CFTG
>D>	@ HALSEY	325MG;50MG	N70115	001	Jun 12, 1985	Aug	CAHN
>D>	@	650MG;100MG	N70116	001	Jun 12, 1985	Aug	CAHN
>D>	AB	650MG;100MG	N70615	001	Mar 21, 1986	Aug	CAHN
>D>	AB	650MG;100MG	N70771	001	Mar 21, 1986	Aug	CAHN
>D>	AB	650MG;100MG	N70775	001	Mar 21, 1986	Aug	CAHN
>A>	@ MUTUAL PHARM	325MG;50MG	N70115	001	Jun 12, 1985	Aug	CAHN
>A>	@	650MG;100MG	N70116	001	Jun 12, 1985	Aug	CAHN
>A>	AB	650MG;100MG	N70615	001	Mar 21, 1986	Aug	CAHN
>A>	AB	650MG;100MG	N70771	001	Mar 21, 1986	Aug	CAHN
>A>	AB	650MG;100MG	N70775	001	Mar 21, 1986	Aug	CAHN
	VINTAGE PHARMS	325MG;100MG	N76743	001	May 07, 2004	May	NEWA
AB		500MG;100MG	N76750	001	Jun 28, 2004	Jun	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	May	CAHN
----	---------	--------------------	--------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	HOSPIRA	250MG/100ML	N17656	001		May	CAHN
----	---------	-------------	--------	-----	--	-----	------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

+ CUMBERLAND PHARMS 6GM /30ML(200MG/ML)

N21539 001 Jan 23, 2004 Jan NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN HOSPIRA 10%
AN 20%N73664 001 Aug 30, 1994 May CAHN
N74037 001 Aug 30, 1994 May CAHNACITRETIN

CAPSULE; ORAL

SORIATANE

CONNETICS 10MG
+ 25MGN19821 001 Oct 28, 1996 Mar CAHN
N19821 002 Oct 28, 1996 Mar CAHNACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP HOSPIRA EQ 500MG BASE/VIAL
AP EQ 500MG BASE/VIAL
AP EQ 1GM BASE/VIAL
AP EQ 1GM BASE/VIAL
AP MAYNE PHARMA USA EQ 50MG BASE/MLN74663 001 Apr 22, 1997 May CAHN
N74758 001 Apr 22, 1997 May CAHN
N74663 002 Apr 22, 1997 May CAHN
N74758 002 Apr 22, 1997 May CAHN
N75065 001 Feb 25, 1999 Apr CAHNADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP + FUJISAWA HLTHCARE 3MG/ML
ADENOSINE
AP BAXTER HLTHCARE 3MG/ML
AP BEDFORD 3MG/ML
AP SICOR PHARMS 3MG/MLN19937 002 Oct 30, 1989 Jun CFTG
N76500 001 Jun 16, 2004 Jun NEWA
N76501 001 Jun 16, 2004 Jun NEWA
N76404 001 Jun 16, 2004 Jun NEWA
N76564 001 Jun 16, 2004 Jun NEWAALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

@ PFIZER EQ 200MG BASE/VIAL
@ EQ 300MG BASE/VIALN20760 001 Dec 18, 1997 Jun DISC
N20760 002 Dec 18, 1997 Jun DISCALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

ISO TEX 100UCI/10ML(10UCI/ML)
+ 500uCi/0.5ML
1,000uCi/ML
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
@ MALLINCKRODT 10uCi/MLN17836 003 Jun 08, 2004 Jun NEWA
N17836 001 Jun CMFD
N17836 002 Jun CMFD
N17844 001 Jun DISCALBUTEROL SULFATE

SOLUTION; INHALATION

ACCUNEB

AN + DEY EQ 0.042% BASE
AN + ALBUTEROL SULFATE EQ 0.083% BASE
AN + BAUSCH AND LOMBN20949 001 Apr 30, 2001 Jun CFTG
N75358 001 Mar 29, 2000 Jun CRLD

SOLUTION; INHALATION

	ALBUTEROL SULFATE					
AN	+ BAUSCH AND LOMB	EQ 0.5% BASE		N75050	001	Jun 18, 1998 Jun CRLD
AN	NEPHRON	EQ 0.042% BASE		N76355	001	Jun 28, 2004 Jun NEWA
	PROVENTIL					
	@ SCHERING	EQ 0.083% BASE		N19243	002	Jan 14, 1987 Jun DISC
	@	EQ 0.5% BASE		N19243	001	Jan 14, 1987 Jun DISC
	TABLET, EXTENDED RELEASE; ORAL					
	ALBUTEROL SULFATE					
	+ PLIVA	EQ 4MG BASE		N76130	002	Sep 26, 2002 Jan CRLD
	+ VOLMAX	EQ 8MG BASE		N76130	003	Sep 26, 2002 Jan CRLD
	@ MURO	EQ 4MG BASE		N19604	002	Dec 23, 1992 Jan DISC
	@	EQ 8MG BASE		N19604	001	Dec 23, 1992 Jan DISC

ALCLOMETASONE DIPROPIONATE

	OINTMENT; TOPICAL					
	ACLOVATE					
AB	+ GLAXOSMITHKLINE	0.05%		N18702	001	Dec 14, 1982 Jul CFTG
	ALCLOMETASONE DIPROPIONATE					
AB	TARO	0.05%		N76730	001	Jul 29, 2004 Jul NEWA

ALCOHOL; DEXTROSE

	INJECTABLE; INJECTION					
	ALCOHOL 5% IN D5-W					
AP	HOSPIRA	5ML/100ML;5GM/100ML		N83263	001	May CAHN

ALFENTANIL HYDROCHLORIDE

	INJECTABLE; INJECTION					
	ALFENTANIL					
AP	HOSPIRA	EQ 0.5MG BASE/ML		N75221	001	Oct 28, 1999 May CAHN

ALLOPURINOL

	TABLET; ORAL					
	ALLOPURINOL					
>D>	@ HALSEY	100MG		N70466	001	Dec 24, 1985 Aug CAHN
>D>	@	300MG		N70467	001	Dec 24, 1985 Aug CAHN
>A>	@ MUTUAL PHARM	100MG		N70466	001	Dec 24, 1985 Aug CAHN
>A>	@	300MG		N70467	001	Dec 24, 1985 Aug CAHN

ALLOPURINOL SODIUM

	INJECTABLE; INJECTION					
>A>	ALLOPURINOL SODIUM					
>A> AP	BEDFORD LABS	EQ 500MG BASE/VIAL		N76870	001	Aug 26, 2004 Aug NEWA
	ALOPRIM					
>D>	+ NABI	EQ 500MG BASE/VIAL		N20298	001	May 17, 1996 Aug CFTG
>A> AP	+ +	EQ 500MG BASE/VIAL		N20298	001	May 17, 1996 Aug CFTG
	+ +	EQ 500MG BASE/VIAL		N20298	001	May 17, 1996 Jun CAHN

ALMOTRIPTAN MALATE

	TABLET; ORAL					
	AXERT					
	ORTHO MCNEIL PHARM	EQ 6.25MG BASE		N21001	001	May 07, 2001 Jul CAHN
+		EQ 12.5MG BASE		N21001	002	May 07, 2001 Jul CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ BAXTER HLTHCARE

EQ 50MG BASE/ML

N63274 001 May 18, 1992 Aug CAHN

@

EQ 250MG BASE/ML

N63275 001 May 18, 1992 Aug CAHN

@ ELKINS SINK

EQ 50MG BASE/ML

N63274 001 May 18, 1992 Aug CAHN

@

EQ 250MG BASE/ML

N63275 001 May 18, 1992 Aug CAHN

AP HOSPIRA

EQ 50MG BASE/ML

N63263 001 Nov 30, 1994 May CAHN

@

EQ 62.5MG BASE/ML

N63283 001 Oct 31, 1994 May CAHN

AP

EQ 250MG BASE/ML

N63264 001 Nov 30, 1994 May CAHN

AP

EQ 250MG BASE/ML

N64098 001 Jun 26, 1995 May CAHN

@

EQ 250MG BASE/ML

N64099 001 Jun 20, 1995 May CAHN

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 500MG BASE/100ML

N64146 001 Apr 02, 1997 May CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

FRESENIUS KABI

5.2% (5.2GM/100ML)

N18901 001 Apr 06, 1984 Aug CAHN

HOSPIRA

5.2% (5.2GM/100ML)

N18901 001 Apr 06, 1984 Aug CAHN

AMINOSYN 10%

HOSPIRA

10% (10GM/100ML)

N17673 003 May CAHN

AMINOSYN 10% (PH6)

HOSPIRA

10% (10GM/100ML)

N17673 008 Nov 18, 1985 May CAHN

AMINOSYN 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N17789 004 May CAHN

AMINOSYN 5%

HOSPIRA

5% (5GM/100ML)

N17673 001 May CAHN

AMINOSYN 7%

@ HOSPIRA

7% (7GM/100ML)

N17673 002 May CAHN

AMINOSYN 7% (PH6)

HOSPIRA

7% (7GM/100ML)

N17673 006 Nov 18, 1985 May CAHN

AMINOSYN 8.5%

@ HOSPIRA

8.5% (8.5GM/100ML)

N17673 004 May CAHN

AMINOSYN 8.5% (PH6)

HOSPIRA

8.5% (8.5GM/100ML)

N17673 007 Nov 18, 1985 May CAHN

AMINOSYN II 10%

HOSPIRA

10% (10GM/100ML)

N19438 005 Apr 03, 1986 May CAHN

AMINOSYN II 10% IN PLASTIC CONTAINER

HOSPIRA

10% (10GM/100ML)

N20015 001 Dec 19, 1991 May CAHN

AMINOSYN II 15% IN PLASTIC CONTAINER

HOSPIRA

15% (15GM/100ML)

N20041 001 Dec 19, 1991 May CAHN

AMINOSYN II 3.5%

@ HOSPIRA

3.5% (3.5GM/100ML)

N19438 001 Apr 03, 1986 May CAHN

AMINOSYN II 5%

@ HOSPIRA

5% (5GM/100ML)

N19438 002 Apr 03, 1986 May CAHN

AMINOSYN II 7%

HOSPIRA

7% (7GM/100ML)

N19438 003 Apr 03, 1986 May CAHN

AMINOSYN II 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N19438 004 Apr 03, 1986 May CAHN

AMINOSYN-HBC 7%

HOSPIRA

7% (7GM/100ML)

N19374 001 Jul 12, 1985 May CAHN

AMINOSYN-HF 8%

HOSPIRA

8% (8GM/100ML)

N20345 001 Apr 04, 1996 May CAHN

AMINOSYN-PF 10%

HOSPIRA

10% (10GM/100ML)

N19492 002 Oct 17, 1986 May CAHN

INJECTABLE; INJECTION

AMINOSYN-PF 7%		
HOSPIRA	7% (7GM/100ML)	N19398 001 Sep 06, 1985 May CAHN
AMINOSYN-RF 5.2%		
HOSPIRA	5.2% (5.2GM/100ML)	N18429 001 May CAHN
NEOPHAM 6.4%		
>D> @ FRESENIUS KABI	6.4% (6.4GM/100ML)	N18792 001 Jan 17, 1984 Aug CAHN
>A> @ HOSPIRA	6.4% (6.4GM/100ML)	N18792 001 Jan 17, 1984 Aug CAHN
NOVAMINE 11.4%		
>D> FRESENIUS KABI	11.4% (11.4GM/100ML)	N17957 003 Aug 09, 1982 Aug CAHN
>A> HOSPIRA	11.4% (11.4GM/100ML)	N17957 003 Aug 09, 1982 Aug CAHN
NOVAMINE 15%		
>D> FRESENIUS KABI	15% (15GM/100ML)	N17957 004 Nov 28, 1986 Aug CAHN
>A> HOSPIRA	15% (15GM/100ML)	N17957 004 Nov 28, 1986 Aug CAHN
NOVAMINE 8.5%		
>D> @ FRESENIUS KABI	8.5% (8.5GM/100ML)	N17957 002 Aug 09, 1982 Aug CAHN
>A> @ HOSPIRA	8.5% (8.5GM/100ML)	N17957 002 Aug 09, 1982 Aug CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;2 05MG/100ML	N19683 001 Nov 07, 1988 May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER		
HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 002 Nov 07, 1988 May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 003 Nov 07, 1988 May CAHN
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/1 00ML;22.4MG/100ML;261MG/100ML;205 MG/100ML	N19683 004 Nov 07, 1988 May CAHN

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER		
HOSPIRA	3.5%;25GM/100ML	N19681 001 Nov 01, 1988 May CAHN
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER		
HOSPIRA	3.5%;5GM/100ML	N19681 002 Nov 01, 1988 May CAHN
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER		
HOSPIRA	4.25%;10GM/100ML	N19681 004 Nov 01, 1988 May CAHN
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER		
HOSPIRA	4.25%;20GM/100ML	N19681 005 Nov 01, 1988 May CAHN
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER		
HOSPIRA	4.25%;25GM/100ML	N19681 003 Nov 01, 1988 May CAHN
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER		
HOSPIRA	5%;25GM/100ML	N19681 006 Nov 01, 1988 May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER		
@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML	N19682 003 Nov 01, 1988 May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE: INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
 AMINOSYN II 3.5%;5GM/100ML;30MG/100ML;97MG/10 0ML;120MG/100ML;49.3MG/100ML N19682 001 Nov 01, 1988 May CAHN
 HOSPIRA

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
 AMINOSYN II 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML N19682 002 Nov 01, 1988 May CAHN
 HOSPIRA

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE: INJECTION

AMINOSYN 3.5% M
 AMINOSYN 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N17789 003 May CAHN
 HOSPIRA

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE: INJECTION

AMINOSYN 3.5% M
 AMINOSYN 3.5%;21MG/100ML;128MG/100ML;234MG/100ML N17789 005 May CAHN
 @ HOSPIRA

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE: INJECTION

VEINAMINE 8%
 >D> @ FRESENIUS KABI 8%;61MG/100ML;211MG/100ML;56MG/10 0ML;388MG/100ML N17957 001 Aug CAHN

>A> @ HOSPIRA 8%;61MG/100ML;211MG/100ML;56MG/10 0ML;388MG/100ML N17957 001 Aug CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE: INJECTION

AMINOSYN II 10% W/ ELECTROLYTES
 AMINOSYN II 10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 004 Apr 03, 1986 May CAHN
 HOSPIRA

AMINOSYN II 7% W/ ELECTROLYTES
 AMINOSYN II 7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 006 Apr 03, 1986 May CAHN
 @ HOSPIRA

AMINOSYN II 8.5% W/ ELECTROLYTES
 AMINOSYN II 8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N19437 005 Apr 03, 1986 May CAHN
 HOSPIRA

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE: INJECTION

AMINOSYN II 3.5% M
 AMINOSYN II 3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML N19437 007 Apr 03, 1986 May CAHN
 @ HOSPIRA

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE: INJECTION

AMINOSYN 7% W/ ELECTROLYTES
 AMINOSYN 7%;102MG/100ML;522MG/100ML;410MG/100ML N17789 002 May CAHN
 HOSPIRA

AMINOSYN 8.5% W/ ELECTROLYTES
 AMINOSYN 8.5%;102MG/100ML;522MG/100ML;410M G/100ML N17673 005 May CAHN
 HOSPIRA

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
AP HOSPIRA 250MG/ML N70888 001 Jun 16, 1988 May CAHN
AMINOCAPROIC ACID IN PLASTIC CONTAINER
AP HOSPIRA 250MG/ML N70010 001 Mar 09, 1987 May CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP HOSPIRA 25MG/ML N87242 001 Oct 26, 1983 May CAHN
AP + 25MG/ML N87601 001 Jul 23, 1982 May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
+ HOSPIRA 100MG/100ML N88147 002 May 03, 1983 May CAHN
+ 200MG/100ML N88147 003 May 03, 1983 May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
@ HOSPIRA 100MG/100ML N18924 001 Dec 12, 1984 May CAHN
@ 200MG/100ML N18924 002 Dec 12, 1984 May CAHN
@ 400MG/100ML N18924 003 Dec 12, 1984 May CAHN
@ 500MG/100ML N18924 004 Dec 12, 1984 May CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL
AP HOSPIRA 50MG/ML N75955 001 Oct 18, 2002 May CAHN
AMIODARONE HYDROCHLORIDE
AP INTL MEDICATION SYS 50MG/ML N21594 001 Feb 04, 2004 Feb NEWA
TABLET; ORAL
AMIODARONE HCL
@ TARO 400MG N76362 001 Nov 29, 2002 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
>D> @ HALSEY 10MG N85744 001 Aug CAHN
>D> @ 25MG N85627 001 Aug CAHN
>D> @ 50MG N85745 001 Aug CAHN
>D> @ 75MG N85743 001 Aug CAHN
>D> @ 100MG N85742 002 May 11, 1982 Aug CAHN
>A> @ MUTUAL PHARM 10MG N89423 001 Feb 17, 1987 Aug CAHN
>A> @ 25MG N85744 001 Aug CAHN
>A> @ 50MG N85627 001 Aug CAHN
>A> @ 75MG N85745 001 Aug CAHN
>A> @ 100MG N85743 001 Aug CAHN
>A> @ 150MG N85742 002 May 11, 1982 Aug CAHN
ELAVIL
@ ASTRazeneca 10MG N12703 001 Jul DISC
@ 25MG N12703 003 Jul DISC
@ 50MG N12703 004 Jul DISC
@ 75MG N12703 005 Jul DISC
@ 100MG N12703 006 Jul DISC
@ 150MG N12703 007 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPoxide

TABLET; ORAL

CHLORDIAZEPoxide AND AMITRIPTYLINE HCL
 >D> @ HALSEY EQ 12.5MG BASE;5MG
 >D> @ EQ 25MG BASE;10MG
 >A> @ MUTUAL PHARM EQ 12.5MG BASE;5MG
 >A> @ EQ 25MG BASE;10MG

N70765 001 Dec 10, 1986 Aug CAHN
 N70766 001 Dec 10, 1986 Aug CAHN
 N70765 001 Dec 10, 1986 Aug CAHN
 N70766 001 Dec 10, 1986 Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL
 >D> @ HALSEY 10MG;2MG
 >D> @ 10MG;4MG
 >D> @ 25MG;2MG
 >D> @ 25MG;4MG
 >A> @ MUTUAL PHARM 10MG;2MG
 >A> @ 10MG;4MG
 >A> @ 25MG;2MG
 >A> @ 25MG;4MG

N71077 001 Nov 12, 1986 Aug CAHN
 N71078 001 Nov 12, 1986 Aug CAHN
 N70297 001 Nov 12, 1986 Aug CAHN
 N71079 001 Nov 12, 1986 Aug CAHN
 N71077 001 Nov 12, 1986 Aug CAHN
 N71078 001 Nov 12, 1986 Aug CAHN
 N70297 001 Nov 12, 1986 Aug CAHN
 N71079 001 Nov 12, 1986 Aug CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER
 >A>
 >A>
 >A>
 +
 CADUET
 PFIZER
 EQ 2.5MG BASE;EQ 10MG BASE
 EQ 2.5MG BASE;EQ 20MG BASE
 EQ 2.5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 10MG BASE
 EQ 5MG BASE;EQ 20MG BASE
 EQ 5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 80MG BASE
 EQ 10MG BASE;EQ 10MG BASE
 EQ 10MG BASE;EQ 20MG BASE
 EQ 10MG BASE;EQ 40MG BASE
 EQ 10MG BASE;EQ 80MG BASE

N21540 009 Jul 29, 2004 Aug NEWA
 N21540 010 Jul 29, 2004 Aug NEWA
 N21540 011 Jul 29, 2004 Aug NEWA
 N21540 001 Jan 30, 2004 Jan NEWA
 N21540 002 Jan 30, 2004 Jan NEWA
 N21540 003 Jan 30, 2004 Jan NEWA
 N21540 004 Jan 30, 2004 Jan NEWA
 N21540 005 Jan 30, 2004 Jan NEWA
 N21540 006 Jan 30, 2004 Jan NEWA
 N21540 007 Jan 30, 2004 Jan NEWA
 N21540 008 Jan 30, 2004 Jan NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

@ DR REDDYS LABS INC 2.5MG
 @ 5MG
 @ 10MG

N21435 001 Oct 31, 2003 Mar DISC
 N21435 002 Oct 31, 2003 Mar DISC
 N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER
 + HOSPIRA 5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

AB CLAY PARK EQ 12% BASE
 AB TARO EQ 12% BASE

N75570 001 Jun 23, 2004 Jun NEWA
 N76216 001 May 28, 2004 May NEWA

AMOXICILLIN

TABLET, CHEWABLE; ORAL
AMOXIL

>D>	AB	GLAXOSMITHKLINE	125MG	N50542 002	Aug	DISC
>A>		8	125MG	N50542 002	Aug	DISC
>D>	AB		250MG	N50542 001	Aug	DISC
>A>		8	250MG	N50542 001	Aug	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	TEVA	200MG/5ML;EQ 28.5MG BASE/5ML	N65089 001	May 25, 2004	May	NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65089 002	May 25, 2004	May	NEWA
AB		600MG/5ML;EQ 42.9MG BASE/5ML	N65162 001	Mar 12, 2004	Mar	NEWA
AB	AUGMENTIN ES-600					
AB	+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	Jun 22, 2001	Mar	CFTG

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

>D>		8 IBI	EQ 2GM BASE/VIAL	N62797 002	Jul 12, 1993	Aug	CMFD
>A>	AP		EQ 2GM BASE/VIAL	N62797 002	Jul 12, 1993	Aug	CMFD
	AP	+ SANDOZ	EQ 125MG BASE/VIAL	N61395 001		Jun	CAHN
	AP	+	EQ 250MG BASE/VIAL	N61395 002		Jun	CAHN
	AP	+	EQ 500MG BASE/VIAL	N61395 003		Jun	CAHN
	AP	+	EQ 1GM BASE/VIAL	N61395 004		Jun	CAHN
	AP	+	EQ 2GM BASE/VIAL	N61395 005		Jun	CAHN
	AP	+	EQ 10GM BASE/VIAL	N61395 006		Jun	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

>A>	AP	BAXTER HLTHCARE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	Mar 19, 2002	Aug	CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	Mar 19, 2002	Aug	CAHN
>A>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	Mar 19, 2002	Aug	CAHN
>D>	AP	ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	Mar 19, 2002	Aug	CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	Mar 19, 2002	Aug	CAHN
>D>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	Mar 19, 2002	Aug	CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS
APOKYN

>D>		BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Aug	CAHN
>D>		+	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Apr	NEWA
	+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Aug	CAHN
>A>		MYLAN BERTEK	30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Apr	NEWA
>A>		+	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Aug	CAHN
	+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Aug	CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SABEX 2002

80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21646 001 Jan 29, 2004 Jan NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)M.V.I. PEDIATRIC

+ MAYNE PHARMA USA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIA
L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA
L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1
.4MG/VIAL;EQ 1.2MG
BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 Sep 21, 2000 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTIONM.V.I.-12

+ MAYNE PHARMA USA

10MG/ML;0.006MG/ML;0.5UGM/ML;1.5M
G/ML;20
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0
.36MG/ML;0.3MG/ML;330 UNITS/ML;1
IU/ML

N08809 004 Aug 08, 1985 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)M.V.I. ADULT

+ AAIPHARMA LLC

200MG/VIAL;0.06MG/VIAL;0.005MG/VI
AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15
MG/VIAL

N21625 001 Jan 30, 2004 Jan NEWA

+ MAYNE PHARMA USA

200MG/VIAL;0.06MG/VIAL;0.005MG/VI
AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15
MG/VIAL

N21625 001 Jan 30, 2004 Apr CAHN

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ AAIPHARMA LLC

200MG/5ML;0.06MG/5ML;0.005MG/5ML;
15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
1MG/5ML;10MG/5ML;0.15MG/5ML

N21643 001 Feb 18, 2004 Feb NEWA

+ MAYNE PHARMA USA

200MG/5ML;0.06MG/5ML;0.005MG/5ML;
15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
1MG/5ML;10MG/5ML;0.15MG/5ML

N21643 001 Feb 18, 2004 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTIONM.V.I.-12

+ MAYNE PHARMA USA

20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M
G/ML;20
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0
.36MG/ML;0.6MG/ML;330 UNITS/ML;1
IU/ML

N08809 005 Apr 22, 2004 May NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

>D> @ FRESENIUS KABI 80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIA N20176 001 Dec 29, 1993 Aug CAHN
L:400 IU/10ML; 0.14MG/VIAL; 17MG/VIAL; 5MG /VIAL; 0.2MG/10ML; 1MG/VIAL; 1.4MG/V IAL; 1.2MG/VIAL; EQ 2,300 UNITS BASE/10ML; 7 IU/10ML

>A> @ HOSPIRA 80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIA N20176 001 Dec 29, 1993 Aug CAHN
L:400 IU/10ML; 0.14MG/VIAL; 17MG/VIAL; 5MG /VIAL; 0.2MG/10ML; 1MG/VIAL; 1.4MG/V IAL; 1.2MG/VIAL; EQ 2,300 UNITS BASE/10ML; 7 IU/10ML

ASPIRIN; CAFFEINE; PROPOXYPHENONE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

@ AAIPHARMA LLC

389MG; 32.4MG; 32MG

N10996 006 Mar 08, 1983 Jun DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>D> AA	AXIOM PHARM	325MG; 4.5MG; 0.38MG	N40260 001 Jul 17, 1998 Aug CAHN
>D> AA	HALSEY	325MG; 4.5MG; 0.38MG	N87794 001 May 26, 1982 Aug CAHN
>A> AA	MUTUAL PHARM	325MG; 4.5MG; 0.38MG	N40260 001 Jul 17, 1998 Aug CAHN
>A> AA		325MG; 4.5MG; 0.38MG	N87794 001 May 26, 1982 Aug CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ABLE	25MG	N76907 001 Jul 30, 2004 Jul NEWA
AB		50MG	N76907 002 Jul 30, 2004 Jul NEWA
AB		100MG	N76907 003 Jul 30, 2004 Jul NEWA
AB	TEVA	25MG	N74056 003 Jul 19, 2004 Jul NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

>A> AP	BAXTER HLTHCARE	10MG/ML	N74824 001 Sep 30, 1997 Aug CAHN
>D> AP	ESI LEDERLE	10MG/ML	N74824 001 Sep 30, 1997 Aug CAHN
AP	HOSPIRA	10MG/ML	N74632 001 Dec 23, 1996 May CAHN
>A>	@ BAXTER HLTHCARE	10MG/ML	N74825 001 Sep 30, 1997 Aug CAHN
>D> AP	ESI LEDERLE	10MG/ML	N74825 001 Sep 30, 1997 Aug CAHN
AP	HOSPIRA	10MG/ML	N74633 001 Dec 23, 1996 May CAHN
AP		10MG/ML	N74639 001 Mar 25, 1997 May CAHN
	TRACRIUM		
AP	+ HOSPIRA	10MG/ML	N18831 002 Jun 20, 1985 May CAHN
	TRACRIUM PRESERVATIVE FREE		
AP	+ HOSPIRA	10MG/ML	N18831 001 Nov 23, 1983 May CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

HOSPIRA	0.05MG/ML
+	0.1MG/ML

N21146 002 Jul 09, 2001 May CAHN
N21146 001 Jul 09, 2001 May CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL MOTOFEN + VALEANT	0.025MG; 1MG	N17744 002	May CAHN
MOTOFEN HALF-STRENGTH @ VALEANT	0.025MG; 0.5MG	N17744 001	May CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL DIPHENOXYLATE HCL AND ATROPINE SULFATE @ HALSEY	0.025MG; 2.5MG	N85506 001	Aug CAHN
@ MUTUAL PHARM	0.025MG; 2.5MG	N85506 001	Aug CAHN

>D>
>A>AZACITIDINE

INJECTABLE; SUBCUTANEOUS VIDAZA + PHARMION	100MG/VIAL	N50794 001 May 19, 2004	May NEWA
--	------------	-------------------------	----------

AZATADINE MALEATE

TABLET; ORAL OPTIMINE @ SCHERING	1MG	N17601 001	May DISC
--	-----	------------	----------

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL TRINALIN @ SCHERING	1MG; 120MG	N18506 001 Mar 23, 1982	May DISC
--	------------	-------------------------	----------

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION AZATHIOPRINE SODIUM + BEDFORD	EQ 100MG BASE/VIAL	N74419 001 Mar 31, 1995	May CRLD
IMURAN @ PROMETHEUS LABS	EQ 100MG BASE/VIAL	N17391 001	May DISC

AZITHROMYCIN

CAPSULE; ORAL ZITHROMAX @ PFIZER	EQ 250MG BASE	N50670 001 Nov 01, 1991	Mar DISC
--	---------------	-------------------------	----------

AZTREONAM

INJECTABLE; INJECTION AZACTAM			
+ BRISTOL MYERS SQUIBB	500MG/VIAL	N50580 001 Dec 31, 1986	Jul CMFD
+	1GM/VIAL	N50580 002 Dec 31, 1986	Jul CMFD
+	2GM/VIAL	N50580 003 Dec 31, 1986	Jul CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC CORTISPORIN AT MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002	Mar CRLD
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE AT + BAUSCH AND LOMB	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64068 001 Oct 30, 1995	Mar CRLD

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

AT	AKORN	NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC 400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N65088 001 Feb 06, 2004 Feb NEWA
AT	+ BAUSCH AND LOMB	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC 400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64064 001 Oct 30, 1995 Mar CRLD
AT	MONARCH PHARMS	NEOSPORIN 400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001 Mar CRLD

BACITRACIN ZINC; POLYMYXIN B SULFATE

AT	OINTMENT; OPHTHALMIC		
AT	+ BAUSCH AND LOMB	BACITRACIN ZINC AND POLYMYXIN B SULFATE 500 UNITS/GM; 10,000 UNITS/GM	N64046 001 Jan 26, 1995 Mar CRLD
AT	MONARCH PHARMS	POLYSPORIN 500 UNITS/GM; 10,000 UNITS/GM	N61229 001 Mar CRLD

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION		
VANCERIL		
+ SCHERING	0.042MG/INH	N17573 001 Jun CTEC
VANCERIL DOUBLE STRENGTH		
@ SCHERING	0.084MG/INH	N20486 001 Dec 24, 1996 Jun DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL		
BECONASE AQ		
+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389 001 Jul 27, 1987 Jun CTEC
VANCENASE AQ		
@ SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001 Dec 23, 1987 Jun DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76267 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76267 003 Feb 11, 2004 Feb NEWA
AB	EON	40MG	N76267 004 Feb 11, 2004 Feb NEWA
AB		5MG	N76402 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76402 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76402 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76402 004 Feb 11, 2004 Feb NEWA
AB	GENPHARM	5MG	N76476 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76476 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76476 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76476 004 Feb 11, 2004 Feb NEWA
AB	IVAX PHARMS	5MG	N76333 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76333 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76333 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76333 004 Feb 11, 2004 Feb NEWA
AB	KV PHARM	5MG	N76118 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76118 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76118 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76118 004 Feb 11, 2004 Feb NEWA
AB	MYLAN	5MG	N76430 001 Feb 11, 2004 Feb NEWA

TABLET; ORAL

BENAZEPRIL HCL

AB	MYLAN	10MG	N76430 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76430 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76430 004	Feb 11, 2004	Feb	NEWA
AB	RANBAXY	5MG	N76344 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344 004	Feb 11, 2004	Feb	NEWA
AB	TEVA	5MG	N76211 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76211 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76211 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76211 004	Feb 11, 2004	Feb	NEWA
AB	LOTENSIN					
AB	NOVARTIS	5MG	N19851 001	Jun 25, 1991	Feb	CFTG
AB		10MG	N19851 002	Jun 25, 1991	Feb	CFTG
AB		20MG	N19851 003	Jun 25, 1991	Feb	CFTG
AB	+	40MG	N19851 004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG;6.25MG	N76342 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76342 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76342 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76342 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG;6.25MG	N76631 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76631 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76631 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76631 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG;6.25MG	N76612 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76612 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76612 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76612 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG;6.25MG	N76348 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76348 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76348 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76348 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG;6.25MG	N76688 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76688 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76688 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76688 004	Feb 11, 2004	Feb	NEWA
AB	LOTENSIN HCT					
AB	NOVARTIS	5MG;6.25MG	N20033 001	May 19, 1992	Feb	CFTG
AB		10MG;12.5MG	N20033 002	May 19, 1992	Feb	CFTG
AB		20MG;12.5MG	N20033 004	May 19, 1992	Feb	CFTG
AB	+	20MG;25MG	N20033 003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	DERMIK LABS	5%;3%	N50557 001	Oct 26, 1984	Mar	CFTG
AB	ATRUX	5%;3%	N65112 001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ATRIX EQ 0.05% BASE N76603 001 Jan 23, 2004 Jan NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB TARO EQ 0.05% BASE;1% N76493 001 Jul 28, 2004 Jul NEWA

LOTRISONE

AB + SCHERING PLOUGH RES EQ 0.05% BASE;1% N20010 001 Dec 08, 2000 Jul CFTG

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

@ STERIS EQ 3MG BASE/ML N85738 001 Feb DISC

CELESTONE

@ SCHERING EQ 3MG BASE/ML N17561 001 Feb DISC

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

@ ODYSSEY PHARMS 5MG/ML N06536 001 Jun CAHN

TABLET; ORAL

BETHANECHOL CHLORIDE

AA ABLE 5MG N40492 001 Jul 27, 2004 Jul NEWA

AA 10MG N40483 001 Jul 27, 2004 Jul NEWA

AA 25MG N40485 001 Jul 27, 2004 Jul NEWA

AA 50MG N40509 001 Jul 27, 2004 Jul NEWA

DUVOID

AA WELLSPRING PHARM 10MG N86262 001 Jul CMFD

AA 25MG N86263 001 Jul CMFD

URECHOLINE

@ ODYSSEY PHARMS 5MG N06536 003 Jun CAHN

@ 10MG N06536 002 Jun CAHN

@ 25MG N06536 004 Jun CAHN

@ 50MG N06536 005 Jun CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTLEY

+ BRAINTREE 5MG;210GM;0.74GM;2.86GM;5.6GM N21551 001 May 10, 2004 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

AP + HOSPIRA 50MG/ML N19033 001 Apr 29, 1986 May CAHN

@ 50MG/ML N19033 001 Apr 29, 1986 Jun DISC

AP + INTL MEDICATION 50MG/ML N70119 001 Apr 29, 1986 Jun CRLD

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA 200MG/100ML N19008 002 Apr 29, 1986 May CAHN

AP + 400MG/100ML N19008 003 Apr 29, 1986 May CAHN

@ 800MG/100ML N19008 001 Apr 29, 1986 May CAHN

AP + HOSPIRA 50MG/ML N19030 001 Apr 29, 1986 May CAHN

BRETYLIUM TOSYLATE IN PLASTIC CONTAINER

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE	0.25MG/ML	N74160 001 Oct 30, 1997 May CAHN
HOSPIRA	0.25MG/ML	N74332 001 Oct 31, 1994 May CAHN
AP		
AP		

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL		
HOSPIRA	0.25%	N18053 002 May CAHN
AP	0.25%	N70583 001 Feb 17, 1987 May CAHN
AP	0.25%	N70586 001 Mar 03, 1987 May CAHN
AP	0.25%	N70590 001 Feb 17, 1987 May CAHN
AP	0.5%	N18053 001 May CAHN
AP	0.5%	N70584 001 Feb 17, 1986 May CAHN
AP	0.5%	N70597 001 Mar 03, 1987 May CAHN
AP	0.5%	N70609 001 Mar 03, 1987 May CAHN
AP	0.75%	N18053 003 May CAHN
AP	0.75%	N70585 001 Mar 03, 1987 May CAHN
AP	0.75%	N70587 001 Mar 03, 1987 May CAHN
AP		
BUPIVACAINE HCL KIT		
@ HOSPIRA	0.075%	N19978 001 Sep 03, 1992 May CAHN
@	0.114%	N19978 002 Sep 03, 1992 May CAHN
@	0.23%	N19978 003 Sep 03, 1992 May CAHN
MARCAINE HCL		
AP + HOSPIRA	0.25%	N16964 001 May CAHN
AP +	0.5%	N16964 006 May CAHN
MARCAINE HCL PRESERVATIVE FREE		
AP + HOSPIRA	0.25%	N16964 012 May CAHN
AP +	0.5%	N16964 005 May CAHN
AP +	0.75%	N16964 009 May CAHN
AP		
INJECTABLE; SPINAL		
BUPIVACAINE		
HOSPIRA	0.75%	N71810 001 Dec 11, 1987 May CAHN
MARCAINE		
AP + HOSPIRA	0.75%	N18692 001 May 04, 1984 May CAHN
AP		

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+ HOSPIRA	0.25%;0.005MG/ML	N71165 001 Jun 16, 1988 May CAHN
	0.25%;0.005MG/ML	N71166 001 Jun 16, 1988 May CAHN
	0.25%;0.005MG/ML	N71167 001 Jun 16, 1988 May CAHN
+	0.5%;0.005MG/ML	N71168 001 Jun 16, 1988 May CAHN
	0.5%;0.005MG/ML	N71169 001 Jun 16, 1988 May CAHN
	0.5%;0.005MG/ML	N71170 001 Jun 16, 1988 May CAHN
+	0.75%;0.005MG/ML	N71171 001 Jun 16, 1988 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP + HOSPIRA	0.25%;0.0091MG/ML	N16964 004 May CAHN
AP +	0.5%;0.0091MG/ML	N16964 008 May CAHN
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE		
AP + HOSPIRA	0.25%;0.0091MG/ML	N16964 013 May CAHN

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

AP	+	HOSPIRA	0.5%;0.0091MG/ML	N16964 007	May CAHN
	+		0.75%;0.0091MG/ML	N16964 010	May CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP		HOSPIRA	EQ 0.3MG BASE/ML	N74137 001	Jun 03, 1996	May CAHN
----	--	---------	------------------	------------	--------------	----------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1		EON	100MG	N75932 001	Nov 25, 2003	May CFTG
AB			150MG	N75932 002	Mar 22, 2004	Mar NEWA
AB1			150MG	N75932 002	Mar 22, 2004	May CTEC
AB		IMPAK LABS	100MG	N75913 001	Jan 28, 2004	Jan NEWA
AB1			100MG	N75913 001	Jan 28, 2004	May CTEC
AB			150MG	N75913 002	Mar 22, 2004	Mar NEWA
AB1			150MG	N75913 002	Mar 22, 2004	May CTEC
AB2			150MG	N75914 001	May 27, 2004	May NEWA
		WELLBUTRIN SR				
AB1		GLAXOSMITHKLINE	100MG	N20358 002	Oct 04, 1996	May CTEC
AB	+		150MG	N20358 003	Oct 04, 1996	Mar CFTG
AB	+		150MG	N20358 003	Oct 04, 1996	May CTEC
AB1	+		150MG	N20358 003	Oct 04, 1996	Jun CTEC
		ZYBAN				
AB2	+	GLAXOSMITHKLINE	150MG	N20711 003	May 14, 1997	Jun CTEC
AB	+		150MG	N20711 003	May 14, 1997	May CFTG

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB		TEVA	30MG	N75022 004	Mar 25, 2004	Mar NEWA
----	--	------	------	------------	--------------	----------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP		HOSPIRA	1MG/ML	N75559 001	Mar 20, 2000	May CAHN
AP			2MG/ML	N75559 002	Mar 20, 2000	May CAHN
		BUTORPHANOL TARTRATE PRESERVATIVE FREE				
AP		HOSPIRA	1MG/ML	N74620 001	Jan 22, 1997	May CAHN
AP			1MG/ML	N74626 001	Jan 23, 1997	May CAHN
AP			2MG/ML	N74620 002	Jan 22, 1997	May CAHN
AP			2MG/ML	N74626 002	Jan 23, 1997	May CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP		MAYNE PHARMA USA	0.001MG/ML	N75816 001	Jan 16, 2004	Jan NEWA
AP			0.002MG/ML	N75816 002	Jan 16, 2004	Jan NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+		HOSPIRA	100MG/ML	N21117 001	Jan 28, 2000	May CAHN
---	--	---------	----------	------------	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;8 N18254 001
60MG/100ML

May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;6 N17608 001
00MG/100ML;310MG/100ML

May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 005 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML@ 20MG/100ML;5GM/100ML;179MG/100ML; N19685 006 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 007 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML; N19685 002 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100MLAP 20MG/100ML;5GM/100ML;328MG/100ML; N19685 008 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 003 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML; N19685 004 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 001 Oct 17, 1988 May CAHN
600MG/100ML;310MG/100MLCALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

HOSPIRA 16.5MG/ML;25.4MG/ML;74.6MG/ML;121 N18895 001 Jul 20, 1984 May CAHN
MG/ML;16.1MG/MLCALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERfusion, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT + HOSPIRA 17.6MG/100ML;325.3MG/100ML;119.3M N18608 001 Feb 26, 1982 May CAHN
G/100ML;643MG/100MLCALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N18251 001 May CAHN

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT HOSPIRA 33MG/100ML;30MG/100ML;860MG/100ML N17635 001 May CAHN
G/100ML;643MG/100MLCALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N17641 001 May CAHN
;310MG/100ML

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT HOSPIRA 20MG/100ML;30MG/100ML;600MG/100ML N19416 001 Jan 17, 1986 May CAHN
 ;310MG/100ML

CAPTOPRIL

TABLET; ORAL

Captopril

>D>	AB	DURAMED PHARMS BARR	12.5MG	N74477 001 Feb 13, 1996 Aug CAHN
	AB		12.5MG	N74477 001 Feb 13, 1996 May CAHN
>D>	AB		25MG	N74477 002 Feb 13, 1996 Aug CAHN
	AB		25MG	N74477 002 Feb 13, 1996 May CAHN
	AB		50MG	N74477 003 Feb 13, 1996 May CAHN
>D>	AB		100MG	N74477 004 Feb 13, 1996 Aug CAHN
	AB		100MG	N74477 004 Feb 13, 1996 May CAHN
>A>	AB	KALI LABS	12.5MG	N74477 001 Feb 13, 1996 Aug CAHN
>A>	AB		25MG	N74477 002 Feb 13, 1996 Aug CAHN
	AB		50MG	N74477 003 Feb 13, 1996 Jul CAHN
>A>	AB		100MG	N74477 004 Feb 13, 1996 Aug CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

SHIRE PHARM

100MG

N20712 003 Sep 30, 1997 Mar CRLD
 N20712 001 Sep 30, 1997 Mar CRLD

200MG

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	IMPAK LABS	25MG;100MG	N76521 001 May 14, 2004 May NEWA
AB		50MG;200MG	N76521 002 May 14, 2004 May NEWA
AB	KV PHARM	50MG;200MG	N76663 001 Jun 24, 2004 Jun NEWA
AB	TORPHARM	25MG;100MG	N76212 001 Jun 16, 2004 Jun NEWA
AB		50MG;200MG	N76212 002 Jun 16, 2004 Jun NEWA
>A>	TABLET, ORALLY DISINTEGRATING; ORAL		
>A>	PARCOPA		
>A>	SCHWARZ PHARMA	10MG;100MG	N76699 001 Aug 27, 2004 Aug NEWA
>A>		25MG;100MG	N76699 002 Aug 27, 2004 Aug NEWA
>A>	+	25MG;250MG	N76699 003 Aug 27, 2004 Aug NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

+ BRISTOL MYERS SQUIBB EQ 600MG /60ML(10MG/ML)

N20452 004 Jan 15, 2004 Jan NEWA

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

@ ABBOTT

2.5MG

N19204 001 Dec 28, 1988 Jun DISC

@

5MG

N19204 002 Dec 28, 1988 Jun DISC

CEFACLOR

CAPSULE; ORAL

CEFACLOR

AB	CARLSBAD	EQ 250MG BASE	N65146 001 Jan 22, 2004 Jan NEWA
AB		EQ 500MG BASE	N65146 002 Jan 22, 2004 Jan NEWA

FOR SUSPENSION; ORAL

AB	CECLR CEPH INTL	EQ 125MG BASE/5ML EQ 187MG BASE/5ML EQ 250MG BASE/5ML EQ 375MG BASE/5ML	N62206 001 N62206 003 Apr 20, 1988 N62206 002 N62206 004 Apr 20, 1988	May CAHN May CAHN May CAHN May CAHN
----	--------------------	--	--	--

TABLET, EXTENDED RELEASE; ORAL

AB	CECLR CD @ LILLY	EQ 500MG BASE	N50673 002 Jun 28, 1996	Jun DISC
AB	CEFACLOR + IVAX PHARMS	EQ 500MG BASE	N65057 001 Jan 05, 2001	Jun CRLD

CEFAMANDOLE NAFATEINJECTABLE; INJECTION

AB	MANDOL @ LILLY	EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL	N50504 002 N50504 003	Jul DISC Jul DISC
----	-------------------	--------------------------------------	--------------------------	----------------------

CEFAZOLIN SODIUMINJECTABLE; INJECTION

AB	CEFAZOLIN SODIUM @ MARSAM PHARMS LLC	EQ 250MG BASE/VIAL EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 5GM BASE/VIAL EQ 10GM BASE/VIAL EQ 20GM BASE/VIAL	N62988 001 Dec 29, 1989 N62988 002 Dec 29, 1989 N62988 003 Dec 29, 1989 N62989 001 Dec 29, 1989 N62989 002 Dec 29, 1989 N62989 003 Dec 29, 1989	Jun DISC Jun DISC Jun DISC Jun DISC Jun DISC Jun DISC
AB	KEFZOL @ LILLY	EQ 250MG BASE/VIAL EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 10GM BASE/VIAL EQ 20GM BASE/VIAL	N61773 001 N61773 002 N61773 003 N61773 004 N61773 005 Sep 08, 1987	Jun DISC Jun DISC Jun DISC Jun DISC Jun DISC

CEFDINIRFOR SUSPENSION; ORAL

OMNICEF ABBOTT	125MG/SML 250MG/SML	N50749 001 Dec 04, 1997 N50749 002 Jul 29, 2004	Jul CRLD Jul NEWA
-------------------	------------------------	--	----------------------

CEFIXIMESUSPENSION; ORAL

SUPRAX + LUPIN	100MG/5ML	N65129 001 Feb 23, 2004	Feb NEWA
-------------------	-----------	-------------------------	----------

TABLET; ORAL

SUPRAX + LUPIN	400MG	N65130 001 Feb 12, 2004	Feb NEWA
-------------------	-------	-------------------------	----------

CEFOTAXIME SODIUMINJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER + B BRAUN	EQ 2GM BASE	N50792 001 Jul 29, 2004	Jul NEWA
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER + B BRAUN	EQ 1GM BASE	N50792 002 Jul 29, 2004	Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP	ACS DOBFAR	500MG/VIAL	N62640 001 Nov 20, 1985 Apr CTNA
AP		1GM/VIAL	N62640 002 Nov 20, 1985 Apr CTNA
AP		2GM/VIAL	N62640 003 Nov 20, 1985 Apr CTNA
	TAZICEF		
AP	HOSPIRA	500MG/VIAL	N62662 001 Mar 06, 1986 May CAHN
AP		1GM/VIAL	N62662 002 Mar 06, 1986 May CAHN
AP		1GM/VIAL	N64032 001 Oct 31, 1993 May CAHN
AP		2GM/VIAL	N62662 003 Mar 06, 1986 May CAHN
AP		2GM/VIAL	N64032 002 Oct 31, 1993 May CAHN
AP		6GM/VIAL	N62662 004 Mar 06, 1986 May CAHN
	TAZIDIME		
	@ LILLY	1GM/VIAL	N62655 001 Nov 20, 1985 Apr DISC
	@	2GM/VIAL	N62655 002 Nov 20, 1985 Apr DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>D>	AB	BIOCHEMIE US	EQ 250MG BASE	N65126 001 Oct 28, 2003 Aug CAHN
>D>	AB		EQ 500MG BASE	N65126 002 Oct 28, 2003 Aug CAHN
>A>	AB	SANDOZ	EQ 250MG BASE	N65126 001 Oct 28, 2003 Aug CAHN
>A>	AB		EQ 500MG BASE	N65126 002 Oct 28, 2003 Aug CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048 001 Jan 09, 2004 Jan NEWA
	KEFUROX		
	@ LILLY	EQ 750MG BASE/VIAL	N62591 001 Jan 10, 1986 Jun DISC

INJECTABLE; INJECTION

CEFUROXIME

AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048 002 Jan 09, 2004 Jan NEWA
AP		EQ 7.5GM BASE/VIAL	N65046 001 Jan 09, 2004 Jan NEWA
	KEFUROX		
	@ LILLY	EQ 1.5GM BASE/VIAL	N62591 002 Jan 10, 1986 Jun DISC
	@	EQ 1.5GM BASE/VIAL	N62592 002 Jan 10, 1986 Jun DISC
	@	EQ 7.5GM BASE/VIAL	N62591 003 Dec 17, 1987 Jun DISC

INJECTABLE; INTRAVENOUS

KEFUROX

	@ LILLY	EQ 750MG BASE/VIAL
--	---------	--------------------

N62592 001 Jan 10, 1986 Jun DISC

>D>
>A>CEPHALEXIN

CAPSULE; ORAL

KEFLEX

AB	ADVANCIS PHARM	EQ 250MG BASE	N50405 002 Jun CAHN
AB	+	EQ 500MG BASE	N50405 003 Jun CAHN

FOR SUSPENSION; ORAL

KEFLEX

	@ ADVANCIS PHARM	EQ 100MG BASE/ML	N50406 003 Jun CAHN
	@	EQ 125MG BASE/5ML	N50406 001 Jun CAHN
	@	EQ 250MG BASE/5ML	N50406 002 Jun CAHN

TABLET; ORAL

KEFLET

	@ LILLY	EQ 250MG BASE
--	---------	---------------

N50440 003 Feb 26, 1987 Jun DISC

>D>
>A>

>A>

>A>

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL
 KEFTAB
 @ LILLY EQ 500MG BASE N50614 002 Oct 29, 1987 Jul DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL
 ZYRTEC
 PFIZER 5MG N21621 001 Mar 16, 2004 Mar NEWA
 + 10MG N21621 002 Mar 16, 2004 Mar NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
 EVOXAC
 + DAIICHI EQ 30MG BASE N20989 002 Jan 11, 2000 Jun CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 LIBRIUM
 @ VALEANT PHARM INTL 100MG/AMP N12301 001 Jun DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
 CHLORHEXIDINE GLUCONATE
 AT MORTON GROVE 0.12% N75006 001 Mar 03, 2004 Mar NEWA

CHLOROPROCaine HYDROCHLORIDE

INJECTABLE; INJECTION
 CHLOROPROCaine HCL
 AP HOSPIRA 2% N87447 001 Apr 16, 1982 May CAHN
 AP 3% N87446 001 Apr 16, 1982 May CAHN
 NESACaine
 AP ASTRazeneca 2% N09435 002 Jun CTEC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
 CHLORPHENIRAMINE MALEATE
 >D> @ HALSEY 4MG N80700 001 Aug CAHN
 >A> @ MUTUAL PHARM 4MG N80700 001 Aug CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
 CODEPREX
 + CELLTECH PHARMS EQ 4MG MALEATE/5ML;EQ 20MG
 BASE/5ML N21369 001 Jun 21, 2004 Jun NEWA

CHLORTHALIDONE

TABLET; ORAL
 CHLORTHALIDONE
 >D> @ HALSEY 25MG N87292 001 Aug CAHN
 >D> @ 50MG N87293 001 Aug CAHN
 >A> @ MUTUAL PHARM 25MG N87292 001 Aug CAHN
 >A> @ 50MG N87293 001 Aug CAHN

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION OVIDREL SERONO INC	0.25MG/VIAL	N21149 001 Sep 20, 2000 May DISC
INJECTABLE; SUBCUTANEOUS OVIDREL + SERONO INC	EQ 0.25MG /0.5ML	N21149 002 Oct 06, 2003 Apr CPTG

CHROMIC CHLORIDE

INJECTABLE; INJECTION CHROMIC CHLORIDE IN PLASTIC CONTAINER + HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961 001 Jun 26, 1986 May CAHN
---	------------------------	----------------------------------

CICLOPIROX

SUSPENSION; TOPICAL			
>A>	CICLOPIROX		
>A> AT	ALTANA	0.77%	N76422 001 Aug 06, 2004 Aug NEWA
	LOPROX		
>D>	+ MEDICIS	0.77%	N19824 001 Dec 30, 1988 Aug CFTG
>A> AT	+ +	0.77%	N19824 001 Dec 30, 1988 Aug CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION CIMETIDINE HCL			
AP	HOSPIRA	EQ 300MG BASE/2ML	N74296 001 Mar 28, 1997 May CAHN
AP		EQ 300MG BASE/2ML	N74344 001 Jan 31, 1995 May CAHN
AP		EQ 300MG BASE/2ML	N74345 001 Jan 31, 1995 May CAHN
AP		EQ 300MG BASE/2ML	N74412 001 Mar 28, 1997 May CAHN
AP		EQ 300MG BASE/2ML	N74422 001 Jan 31, 1995 May CAHN
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	HOSPIRA	EQ 6MG BASE/ML	N74269 001 Dec 27, 1994 May CAHN
+		EQ 90MG BASE/100ML	N74468 005 Dec 29, 1994 May CAHN
+		EQ 120MG BASE/100ML	N74468 006 Dec 29, 1994 May CAHN
+		EQ 180MG BASE/100ML	N74468 003 Dec 29, 1994 May CAHN
+		EQ 240MG BASE/100ML	N74468 004 Dec 29, 1994 May CAHN
+		EQ 360MG BASE/100ML	N74468 001 Dec 29, 1994 May CAHN
+		EQ 480MG BASE/100ML	N74468 002 Dec 29, 1994 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL SENSIPAR			
	AMGEN	EQ 30MG BASE	N21688 001 Mar 08, 2004 Mar NEWA
+		EQ 60MG BASE	N21688 002 Mar 08, 2004 Mar NEWA
		EQ 90MG BASE	N21688 003 Mar 08, 2004 Mar NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC CIPROFLOXACIN			
AT	BAUSCH AND LOMB	EQ 0.3% BASE	N76754 001 Jun 09, 2004 Jun NEWA
AT	NOVEX	EQ 0.3% BASE	N75928 001 Jun 09, 2004 Jun NEWA
TABLET; ORAL CIPRO			
AB	BAYER PHARMS	EQ 100MG BASE	N19537 001 Apr 08, 1996 Jun CFTG
AB		EQ 250MG BASE	N19537 002 Oct 22, 1987 Jun CFTG
AB		EQ 500MG BASE	N19537 003 Oct 22, 1987 Jun CFTG

TABLET; ORAL

AB	CIPRO + BAYER PHARMS	EQ 750MG BASE	N19537 004 Oct 22, 1987 Jun CFTG
AB	CIPROFLOXACIN BARR	EQ 250MG BASE	N74124 001 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N74124 002 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N74124 003 Jun 09, 2004 Jun NEWA
AB	COBALT	EQ 250MG BASE	N76794 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76794 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76794 004 Jun 09, 2004 Jun NEWA
AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593 002 Jun 09, 2004 Jun NEWA
AB		EQ 250MG BASE	N75593 003 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N75593 004 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N75593 001 Jun 09, 2004 Jun NEWA
AB	EON	EQ 250MG BASE	N76593 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76593 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76593 004 Jun 09, 2004 Jun NEWA
AB	GENPHARM	EQ 250MG BASE	N75817 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N75817 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N75817 004 Jun 09, 2004 Jun NEWA
AB	HIKMA	EQ 250MG BASE	N76558 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76558 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76558 004 Jun 09, 2004 Jun NEWA
AB	IVAX PHARMS	EQ 250MG BASE	N76089 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76089 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76089 004 Jun 09, 2004 Jun NEWA
AB	MARTEC	EQ 250MG BASE	N76138 001 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76138 002 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76138 003 Jun 09, 2004 Jun NEWA
AB	MYLAN	EQ 250MG BASE	N75685 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N75685 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N75685 001 Jun 09, 2004 Jun NEWA
AB	RANBAXY	EQ 250MG BASE	N75747 001 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N75747 002 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N75747 003 Jun 09, 2004 Jun NEWA
AB	SANDOZ	EQ 250MG BASE	N75939 002 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N75939 003 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N75939 004 Jun 09, 2004 Jun NEWA
AB	TEVA	EQ 250MG BASE	N76136 001 Jun 09, 2004 Jun NEWA
AB		EQ 500MG BASE	N76136 002 Jun 09, 2004 Jun NEWA
AB		EQ 750MG BASE	N76136 003 Jun 09, 2004 Jun NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+ BAYER PHARMS

425.2MG; EQ 574.9MG BASE

N21473 002 Aug 28, 2003 Feb CDER

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

UROLOGIC G IN PLASTIC CONTAINER

AT HOSPIRA 3.24GM/100ML; 380MG/100ML; 430MG/10 OML N18904 001 May 27, 1983 May CAHN

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP AM PHARM

1MG/ML

N76571 001 Apr 22, 2004 Apr NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL
AB + ABBOTT 500MG N50775 001 Mar 03, 2000 Jun CFTG >D>
CLARITHROMYCIN
AB ANDRX PHARMS 500MG N65145 001 Jun 24, 2004 Jun NEWA >D>
TABLET; ORAL
BIAXIN
AB + ABBOTT 250MG N50662 001 Oct 31, 1991 May CFTG >A>
AB + 500MG N50662 002 Oct 31, 1991 May CFTG >A>
CLARITHROMYCIN
AB ROXANE 250MG N65178 002 May 25, 2004 May NEWA >D>
AB 500MG N65178 001 May 25, 2004 May NEWA >A>

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE
AB + TEVA 2.68MG N73283 001 Jan 31, 1992 Mar CRLD >D>
TAVIST
@ NOVARTIS 2.68MG N17661 001 Mar DISC >A>

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL
AB COREPHARMA EQ 150MG BASE N65194 001 Mar 22, 2004 Mar NEWA >D>
AB EQ 300MG BASE N65194 002 Mar 22, 2004 Mar NEWA >A>

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
+ PHARMACIA AND UPJOHN EQ 75MG BASE/5ML N62644 001 Apr 07, 1986 May CRLD >D>

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
>A> @ BAXTER HLTHCARE EQ 150MG BASE/ML N62953 001 Apr 21, 1988 Aug CAHN >D>
>D> @ ELKINS SINKN EQ 150MG BASE/ML N62953 001 Apr 21, 1988 Aug CAHN
AP HOSPIRA EQ 150MG BASE/ML N62800 001 Jul 24, 1987 May CAHN
AP @ EQ 150MG BASE/ML N62801 001 Jul 24, 1987 May CAHN
SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT TARO PHARM INDs EQ 1% BASE N62943 001 Sep 29, 1988 May CAHN
N65184 001 Mar 31, 2004 Mar NEWA >A>

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL
CLODEX
+ GALDERMA LABS 0.05% N21644 001 Feb 05, 2004 Feb NEWA >D>

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURAACLON
AAIPHARMA 0.1MG/ML N20615 001 Oct 02, 1996 Jun CRLD >D>
+ 0.5MG/ML N20615 002 Apr 27, 1999 Jun NEWA >A>

TABLET; ORAL
CLONIDINE HCL

>D>	AB	HALSEY	0.1MG	N70925 001 Sep 04, 1987 Aug CAHN
>D>		@	0.2MG	N70924 001 Sep 04, 1987 Aug CAHN
>D>		@	0.3MG	N70923 001 Sep 04, 1987 Aug CAHN
>A>	AB	MUTUAL PHARM	0.1MG	N70925 001 Sep 04, 1987 Aug CAHN
>A>		@	0.2MG	N70924 001 Sep 04, 1987 Aug CAHN
>A>		@	0.3MG	N70923 001 Sep 04, 1987 Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

>D>	AB	SANDOZ	7.5MG	N72220 001 Aug 26, 1988 Aug DISC
>A>		@	7.5MG	N72220 001 Aug 26, 1988 Aug DISC

CLOTRIMAZOLE

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB	ROXANE	10MG	N76387 001 Jul 29, 2004 Jul NEWA
	MYCELEX		
AB	+ BAYER PHARMS	10MG	N18713 001 Jun 17, 1983 Jul CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

ALAMO PHARMS

25MG

N21590 001 Feb 10, 2004 Feb NEWA
N21590 002 Feb 10, 2004 Feb NEWA

+

100MG

FAZACLO ODT

ALAMO PHARMS

25MG

N21590 001 Feb 10, 2004 Jul CTNA
N21590 002 Feb 10, 2004 Jul CTNA

+

100MG

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP PADDOCK EQ 150MG BASE/VIAL

N65177 001 Mar 19, 2004 Mar NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+ KING PHARMS

0.8MG/INH

N18887 001 Dec 05, 1985 Jan CAHN

SOLUTION; INHALATION

INTAL

AN + KING PHARMS

10MG/ML

N18596 001 May 28, 1982 Jan CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N18960 001 Jun 26, 1986 May CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP BIONICHE ANIM HLTH 1MG/ML

N40451 001 Sep 23, 2003 Apr CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

>D>	AB	HALSEY	10MG	N73541 001 May 23, 1995 Aug CAHN
>A>	AB	MUTUAL PHARM	10MG	N73541 001 May 23, 1995 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

>D>	AA	ALPHARMA	2MG/5ML	N86833 001 Aug CRLD
>A>	+		2MG/5ML	N86833 001 Aug CRLD
>D>		PERIACTIN		
>D>	AA	+	MERCK	2MG/5ML N13220 002 Aug DISC
>A>		Q		2MG/5ML N13220 002 Aug DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL

>D>		Q FRESENIUS KABI	7.25%	N19523 001 Oct 22, 1986 Aug CAHN
>A>		Q HOSPIRA	7.25%	N19523 001 Oct 22, 1986 Aug CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP		AM PHARM	100MG/ML	N76512 001 Jan 15, 2004 Jan NEWA
AP	+	MAYNE PHARMA USA	100MG/ML	N75383 001 Nov 22, 1999 Jan CFTG

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP		BIGMAR BIOREN PHARMS	EQ 20MG BASE/VIAL	N65000 001 May 25, 1999 Jul CAHN
----	--	----------------------	-------------------	----------------------------------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP		ABBOTT	500MG/VIAL	N76019 001 Mar 17, 2004 Mar NEWA
AP			2GM/VIAL	N76019 002 Mar 17, 2004 Mar NEWA
AP		HOSPIRA	500MG/VIAL	N76019 001 Mar 17, 2004 May CAHN
AP			2GM/VIAL	N76019 002 Mar 17, 2004 May CAHN
		DESFERAL		
AP	+	NOVARTIS	500MG/VIAL	N16267 001 Mar CFTG
AP	+		2GM/VIAL	N16267 002 May 25, 2000 Mar CFTG

DEMECTOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN

AB		ESP PHARMA	150MG	N50261 002 Mar CFTG
AB	+		300MG	N50261 003 Mar CFTG
		DEMECLOCYCLINE HCL		
AB		IMPAK LABS	150MG	N65094 001 Mar 22, 2004 Mar NEWA
AB			300MG	N65094 002 Mar 22, 2004 Mar NEWA

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL @ ABBOTT	0.25MG;5MG	N12775 001	Jun DISC
ENDURONYL FORTE @ ABBOTT	0.5MG;5MG	N12775 002	Jun DISC

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPIRIVASK + CANYON	15MG/VIAL	N21271 001 Apr 04, 2003 Apr CAHN
-----------------------	-----------	----------------------------------

DESMOPRESSIN·ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE AP HOSPIRA	0.004MG/ML	N75220 001 Aug 28, 2000 May CAHN
------------------------------------	------------	----------------------------------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA AB + ORGANON USA INC	0.1MG, 0.125MG, 0.15MG;0.025MG, 0.025MG	N21090 001 Dec 20, 2000 Feb CFTG
----------------------------------	---	----------------------------------

VELVET AB DURAMED PHARMS BARR	0.1MG, 0.125MG, 0.15MG;0.025MG, 0.025MG	N76455 001 Feb 24, 2004 Feb NEWA
----------------------------------	---	----------------------------------

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT AB + TARO PHARMS NORTH	0.25%	N17856 001	Jun CAHN
------------------------------------	-------	------------	----------

TOPICORT LP AB + TARO PHARMS NORTH	0.05%	N18309 001	Jun CAHN
---------------------------------------	-------	------------	----------

GEL; TOPICAL TOPICORT AB + TARO PHARMS NORTH	0.05%	N18586 001 Mar 29, 1982 Jun CAHN
--	-------	----------------------------------

OINTMENT; TOPICAL TOPICORT @ TARO PHARMS NORTH	0.05%	N18594 001 Jan 17, 1985 Jun CAHN
--	-------	----------------------------------

AB +	0.25%	N18763 001 Sep 30, 1983 Jun CAHN
------	-------	----------------------------------

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

>D> @ HALSEY	0.25MG	N84013 001	Aug CAHN
>D> @	0.25MG	N84764 001	Aug CAHN
>D> @	0.5MG	N84084 001	Aug CAHN
>D> @	0.5MG	N84766 001	Aug CAHN
>D> @	0.75MG	N84081 001	Aug CAHN
>D> @	0.75MG	N84765 001	Aug CAHN
>D> @	1.5MG	N84086 001	Aug CAHN
>D> @	1.5MG	N84763 001	Aug CAHN
>A> @ MUTUAL PHARM	0.25MG	N84013 001	Aug CAHN
>A> @	0.25MG	N84764 001	Aug CAHN
>A> @	0.5MG	N84084 001	Aug CAHN
>A> @	0.5MG	N84766 001	Aug CAHN
>A> @	0.75MG	N84081 001	Aug CAHN

TABLET; ORAL

DEXAMETHASONE			
>A> @ MUTUAL PHARM	0.75MG	N84765 001	Aug CAHN
>A> @	1.5MG	N84086 001	Aug CAHN
>A> @	1.5MG	N84763 001	Aug CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN			
@ NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001 Oct 29, 1984 Apr DISC	

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

+ HOSPIRA	EQ 100UGM BASE/ML	
-----------	-------------------	--

N21038 001 Dec 17, 1999 May CAHN	
----------------------------------	--

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

>A> AB ABLE	5MG	N76814 001 Aug 25, 2004 Aug NEWA	
>A> AB	10MG	N76814 002 Aug 25, 2004 Aug NEWA	
>A> AB	15MG	N76814 003 Aug 25, 2004 Aug NEWA	

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP HOSPIRA	10GM/100ML	N18080 001	May CAHN
------------	------------	------------	----------

DEXTROSE 2.5% IN PLASTIC CONTAINER

@ B BRAUN	2.5GM/100ML	N18358 001	May DISC
-----------	-------------	------------	----------

DEXTROSE 20% IN PLASTIC CONTAINER

AP HOSPIRA	20GM/100ML	N18564 001 Mar 23, 1982 May CAHN	
------------	------------	----------------------------------	--

DEXTROSE 25%

HOSPIRA	250MG/ML	N19445 002 Nov 23, 1998 May CAHN	
---------	----------	----------------------------------	--

DEXTROSE 30% IN PLASTIC CONTAINER

AP HOSPIRA	30GM/100ML	N19345 001 Jan 26, 1985 May CAHN	
------------	------------	----------------------------------	--

DEXTROSE 40% IN PLASTIC CONTAINER

AP HOSPIRA	40GM/100ML	N18562 001 Mar 23, 1982 May CAHN	
------------	------------	----------------------------------	--

DEXTROSE 5% IN PLASTIC CONTAINER

AP HOSPIRA	50MG/ML	N16367 002	May CAHN
------------	---------	------------	----------

AP	50MG/ML	N19222 001 Jul 13, 1984 May CAHN	
----	---------	----------------------------------	--

AP	5GM/100ML	N19466 001 Jul 15, 1985 May CAHN	
----	-----------	----------------------------------	--

AP	5GM/100ML	N19479 001 Sep 17, 1985 May CAHN	
----	-----------	----------------------------------	--

DEXTROSE 50% IN PLASTIC CONTAINER

@ HOSPIRA	500MG/ML	N19445 001 Jun 03, 1986 May CAHN	
-----------	----------	----------------------------------	--

AP	50GM/100ML	N18563 001 Mar 23, 1982 May CAHN	
----	------------	----------------------------------	--

AP	50GM/100ML	N19894 001 Dec 26, 1989 May CAHN	
----	------------	----------------------------------	--

DEXTROSE 60% IN PLASTIC CONTAINER

AP HOSPIRA	60GM/100ML	N19346 001 Jan 25, 1985 May CAHN	
------------	------------	----------------------------------	--

AP	DEXTROSE 70% IN PLASTIC CONTAINER	N18561 001 Mar 23, 1982 May CAHN	
----	-----------------------------------	----------------------------------	--

AP HOSPIRA	70GM/100ML	N19893 001 Dec 26, 1989 May CAHN	
------------	------------	----------------------------------	--

AP	70GM/100ML		
----	------------	--	--

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;21MG/100ML;128MG/100ML; N17610 001
 234MG/100ML

May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER
 @ B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; N19025 001 Dec 27, 1984 May DISC
 26MG/100ML;320MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;53MG/100ML;100MG/100ML; N19515 001 May 08, 1986 May CAHN
 100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;30MG/100ML;141MG/100ML; N19513 001 May 08, 1986 May CAHN
 15MG/100ML;260MG/100ML;25MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
 @ B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML;2 N18273 001 May DISC
 20MG/100ML;140MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;30MG/100ML;37MG/100ML;2 N17609 001 May CAHN
 22MG/100ML;526MG/100ML;502MG/100ML

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;149MG/100ML N18371 001 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;224MG/100ML N18371 003 May CAHN

AP HOSPIRA 5GM/100ML;298MG/100ML N18371 002 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;298MG/100ML N18371 002 May CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;111MG/100ML;256MG/100ML N19514 001 May 08, 1986 May CAHN
 ;146MG/100ML;207MG/100ML

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
 # B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML N18270 001
 ;280MG/100ML;91MG/100ML May DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100ML N18365 002 Jul 05, 1983 May CAHN
 L

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100ML N18876 001 Jan 17, 1986 May CAHN
 L

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 005 Mar 28, 1988 May CAHN
 L

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 009 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100ML N19691 002 Mar 24, 1988 May CAHN
 L

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 006 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N18365 001 May CAHN
 5GM/100ML;298MG/100ML;225MG/100ML N18365 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML N18362 010 Jul 05, 1983 May CAHN
 5GM/100ML;298MG/100ML;450MG/100ML N18362 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 005 Mar 24, 1988 May CAHN
 5GM/100ML;298MG/100ML;900MG/100ML N19691 008 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N18876 002 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 003 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 003 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN

INJECTABLE; INJECTION
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;298MG/100ML;450MG/100ML N18362 003 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;298MG/100ML;900MG/100ML N19691 009 Mar 24, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;225MG/100ML N18365 005 Mar 28, 1988 May CAHN
 L 5GM/100ML;149MG/100ML;225MG/100ML N18365 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100ML N18876 005 Mar 28, 1988 May CAHN
 L 5GM/100ML;149MG/100ML;300MG/100ML N18876 009 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 008 Mar 28, 1988 May CAHN
 L 5GM/100ML;149MG/100ML;450MG/100ML N18362 004 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;900MG/100ML N19691 001 Mar 24, 1988 May CAHN
 L 5GM/100ML;149MG/100ML;900MG/100ML N19691 003 Mar 24, 1988 May CAHN

AP

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 2.5GM/100ML;450MG/100ML N18096 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;225MG/100ML N17606 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML;300MG/100ML N17799 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML;450MG/100ML N17607 001 May CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 >D> AP ABBOTT 5GM/100ML;900MG/100ML N17585 001 Aug CAHN
 AP 5GM/100ML;900MG/100ML N17585 001 May CAHN
 >A> AP HOSPIRA 5GM/100ML;900MG/100ML N17585 001 Aug CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
 HYPAQUE
 @ GE HEALTHCARE 30% N16403 002 May DISC
 RENO-DIP
 + BRACCO 30% N10040 012 May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
 HYPAQUE-76
 @ GE HEALTHCARE 66%;10% N86505 001 May DISC

DIAZEPAM

INJECTABLE; INJECTION
 DIAZEPAM
 >A> @ BAXTER HLTHCARE 5MG/ML N70311 001 Dec 16, 1985 Aug CAHN
 >A> @ 5MG/ML N70312 001 Dec 16, 1985 Aug CAHN
 >A> @ 5MG/ML N70313 001 Dec 16, 1985 Aug CAHN
 >D> @ ELKINS SINK 5MG/ML N70311 001 Dec 16, 1985 Aug CAHN
 >D> @ 5MG/ML N70312 001 Dec 16, 1985 Aug CAHN
 >D> @ 5MG/ML N70313 001 Dec 16, 1985 Aug CAHN

INJECTABLE; INJECTION

DIAZEPAM

AP	+	HOSPIRA	5MG/ML	N71583 001	Oct 13, 1987	May CAHN
AP			5MG/ML	N71584 001	Oct 13, 1987	May CAHN
AP			5MG/ML	N72079 001	Dec 20, 1988	May CAHN
AP		PARENTA PHARMS	5MG/ML	N76815 001	Apr 15, 2004	Apr NEWA

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB		TORPHARM	50MG	N76561 001	Mar 18, 2004	Mar NEWA
----	--	----------	------	------------	--------------	----------

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

>D>	+	BIOGLAN PHARMA	3%	N21005 001	Oct 16, 2000	Aug CAHN
>A>	+	BIOGLAN PHARMS CORP	3%	N21005 001	Oct 16, 2000	Aug CAHN
		SOLUTION/DROPS; OPHTHALMIC				
		VOLTAREN				
>D>	+	NOVARTIS	0.1%	N20037 001	Mar 28, 1991	Aug CAHN
>A>	+		0.1%	N20037 001	Mar 28, 1991	Aug CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

AB		SANDOZ	EQ 125MG BASE	N61454 002	Mar CAHN
AB	+		EQ 250MG BASE	N61454 001	Mar CAHN
			EQ 500MG BASE	N61454 003	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

>D>	@	HALSEY	10MG	N84505 001	Oct 21, 1986	Aug CAHN
>A>	@	MUTUAL PHARM	10MG	N84505 001	Oct 21, 1986	Aug CAHN
		TABLET; ORAL				
		DICYCLOMINE HCL				
>D>	@	HALSEY	20MG	N84600 001	Jul 29, 1985	Aug CAHN
>A>	@	MUTUAL PHARM	20MG	N84600 001	Jul 29, 1985	Aug CAHN

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

+	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	Oct 09, 1991	Jun CRLD
@		100MG/PACKET	N20155 003	Oct 09, 1991	Jun DISC
@		167MG/PACKET	N20155 004	Oct 09, 1991	Jun DISC
@		250MG/PACKET	N20155 005	Oct 09, 1991	Jun DISC

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB	25MG	N20154 002	Oct 09, 1991	Jul CRLD
+	200MG	N20154 006	Oct 28, 1999	Jul CRLD

DIENESTROL

CREAM; VAGINAL

DIENESTROL

@ ORTHO MCNEIL PHARM	0.01%	N06110 005	Jul CAHN
----------------------	-------	------------	----------

DIGOXIN

>A>	ELIXIR; ORAL					
>A>	DIGOXIN					
>A>	+ ROXANE	0.05MG/ML				
	INJECTABLE; INJECTION					
	DIGOXIN					
>A> AP	BAXTER HLTHCARE	0.25MG/ML	N83391 001			Aug CAHN
>D> AP	ELKINS SINK	0.25MG/ML	N83391 001			Aug CAHN
AP	HOSPIRA	0.25MG/ML	N40093 001	May 16, 1996	May	CAHN
AP		0.25MG/ML	N40206 001	Aug 28, 1998	May	CAHN
AP	DIGOXIN PEDIATRIC					
AP	HOSPIRA	0.1MG/ML	N40092 001	Apr 25, 1996	May	CAHN

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL					
	CARDIZEM SR					
@ AVENTIS PHARMS	60MG	N19471 001	Jan 23, 1989	Jun	DISC	
@	90MG	N19471 002	Jan 23, 1989	Jun	DISC	
@	120MG	N19471 003	Jan 23, 1989	Jun	DISC	
	DILT-CD					
AB3	TORPHARM	120MG	N76151 001	May 20, 2004	May	NEWA
AB3		180MG	N76151 002	May 20, 2004	May	NEWA
AB3		240MG	N76151 003	May 20, 2004	May	NEWA
AB3		300MG	N76151 004	May 20, 2004	May	NEWA
	DILTIAZEM HCL					
@ BIOVAIL	60MG	N74845 001	Sep 15, 1999	Jun	DISC	
@	90MG	N74845 002	Sep 15, 1999	Jun	DISC	
@	120MG	N74845 003	Sep 15, 1999	Jun	DISC	
+	MYLAN	60MG	N74910 001	May 02, 1997	Jun	CRLD
+		90MG	N74910 002	May 02, 1997	Jun	CRLD
+		120MG	N74910 003	May 02, 1997	Jun	CRLD
@ TEVA	60MG	N74079 001	Nov 30, 1993	Jun	DISC	
@	90MG	N74079 002	Nov 30, 1993	Jun	DISC	
@	120MG	N74079 003	Nov 30, 1993	Jun	DISC	
	INJECTABLE; INJECTION					
	DILTIAZEM HCL					
AP	HOSPIRA	5MG/ML	N74941 001	Apr 15, 1998	May	CAHN
AP		5MG/ML	N75004 001	Feb 16, 2000	May	CAHN
AP		100MG/VIAL	N75853 001	Dec 17, 2002	May	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	CARDIZEM LA					
	BIOVAIL	120MG	N21392 001	Feb 06, 2003	Jan	CRLD
		180MG	N21392 002	Feb 06, 2003	Jan	CRLD
		240MG	N21392 003	Feb 06, 2003	Jan	CRLD
		300MG	N21392 004	Feb 06, 2003	Jan	CRLD
		360MG	N21392 005	Feb 06, 2003	Jan	CRLD

DIMENHYDRINATE

	INJECTABLE; INJECTION					
	DIMENHYDRINATE					
AP	AM PHARM	50MG/ML	N40519 001	Jun 23, 2004	Jun	NEWA
AP	STERIS	50MG/ML	N80615 001			CFTG

DIMYRISTOYL LECITHIN; PERPLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT
+ IMCOR PH 0.92MG/VIAL;0.092MG/VIAL

N21191 001 May 31, 2002 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
>D> AA HALSEY 25MG
>A> AA MUTUAL PHARM 25MG
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
AP HOSPIRA 50MG/ML

N84506 001 Aug CAHN
N84506 001 Aug CAHN
N40140 001 Nov 20, 1998 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE
>A> AP BAXTER HLTHCARE 5MG/ML
>D> AP ELKINS SINK 5MG/ML
AP HOSPIRA 5MG/ML

N74521 001 Oct 18, 1996 Aug CAHN
N74521 001 Oct 18, 1996 Aug CAHN
N74601 001 Dec 19, 1997 May CAHN

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC
@ LILLY RES LABS 250MG

N50678 001 Jun 19, 1995 Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE
>D> @ HALSEY EQ 100MG BASE
>D> @ EQ 150MG BASE
>A> @ MUTUAL PHARM EQ 100MG BASE
>A> @ EQ 150MG BASE

N70351 001 Dec 17, 1985 Aug CAHN
N70352 001 Dec 17, 1985 Aug CAHN
N70351 001 Dec 17, 1985 Aug CAHN
N70352 001 Dec 17, 1985 Aug CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE
@ ODYSSEY PHARMS 250MG
@ 500MG

N07883 003 Jun CAHN
N07883 002 Jun CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE
ABBOTT EQ 125MG VALPROIC ACID
EQ 250MG VALPROIC ACID

N18723 003 Oct 26, 1984 Jan CRLD
N18723 001 Mar 10, 1983 Jan CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL
AP HOSPIRA EQ 12.5MG BASE/ML
AP EQ 12.5MG BASE/ML
AP EQ 1.25GM BASE/100ML
DOBUTAMINE HCL IN DEXTROSE 5%
AP + HOSPIRA EQ 50MG BASE/100ML
AP + EQ 100MG BASE/100ML

N74086 001 Nov 29, 1993 May CAHN
N74292 001 Feb 16, 1995 May CAHN
N74634 001 Sep 27, 1996 May CAHN
N20269 001 Oct 19, 1993 May CAHN
N20269 002 Oct 19, 1993 May CAHN

INJECTABLE; INJECTION

AP +	HOSPIRA	DOBUTAMINE HCL IN DEXTROSE 5% EQ 200MG BASE/100ML	N20269 003 Oct 19, 1993 May CAHN
AP +	HOSPIRA	DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER EQ 50MG BASE/100ML	N20201 003 Oct 19, 1993 May CAHN
AP +	HOSPIRA	EQ 100MG BASE/100ML	N20201 002 Oct 19, 1993 May CAHN
AP +		EQ 200MG BASE/100ML	N20201 001 Oct 19, 1993 May CAHN
AP +		EQ 400MG BASE/100ML	N20201 006 Jul 07, 1994 May CAHN
AP +	DOBUTREX @ LILLY	EQ 12.5MG BASE/ML	N17820 002 Jun DISC

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP +	HOSPIRA	DOPAMINE HCL 40MG/ML	N18132 001 May CAHN
AP +		40MG/ML	N74403 001 May 23, 1996 May CAHN
AP +		80MG/100ML	N18132 002 Feb 04, 1982 May CAHN
AP +		80MG/ML	N18132 004 Jul 09, 1982 May CAHN
AP +		160MG/100ML	N18132 003 Feb 04, 1982 May CAHN
AP +	DOPAMINE HCL IN DEXTROSE 5%	1.6MG/ML	N20542 001 Aug 30, 1995 May CAHN
AP +	HOSPIRA	1.6MG/ML	N20542 001 Aug 30, 1995 Jun DISC
AP +	@		
AP +	DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER	80MG/100ML	N18826 001 Sep 30, 1983 May CAHN
AP +	HOSPIRA	160MG/100ML	N18826 002 Sep 30, 1983 May CAHN
AP +		320MG/100ML	N18826 003 Sep 30, 1983 May CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

AB	DOXAZOSIN MESYLATE	CLONMEL HLTHCARE	EQ 1MG BASE	N76161 001 Jun 10, 2004 Jun NEWA
AB			EQ 2MG BASE	N76161 002 Jun 10, 2004 Jun NEWA
AB			EQ 4MG BASE	N76161 003 Jun 10, 2004 Jun NEWA
AB			EQ 8MG BASE	N76161 004 Jun 10, 2004 Jun NEWA

DOXE PIN HYDROCHLORIDE

CAPSULE; ORAL

>D>	DOXE PIN HCL	@ HALSEY	EQ 25MG BASE	N71502 001 Feb 18, 1988 Aug CAHN
>D>		@	EQ 50MG BASE	N71653 001 Feb 18, 1988 Aug CAHN
>D>		@	EQ 75MG BASE	N71654 001 Feb 18, 1988 Aug CAHN
>D>		@	EQ 100MG BASE	N71521 001 Feb 18, 1988 Aug CAHN
>A>	MUTUAL PHARM	@	EQ 25MG BASE	N71502 001 Feb 18, 1988 Aug CAHN
>A>		@	EQ 50MG BASE	N71653 001 Feb 18, 1988 Aug CAHN
>A>		@	EQ 75MG BASE	N71654 001 Feb 18, 1988 Aug CAHN
>A>		@	EQ 100MG BASE	N71521 001 Feb 18, 1988 Aug CAHN

CONCENTRATE; ORAL

AA	DOXE PIN HCL	PHARM ASSOC	EQ 10MG BASE/ML	N75924 001 Jan 15, 2004 Jan NEWA
----	--------------	-------------	-----------------	----------------------------------

CREAM; TOPICAL

>D>	ZONALON	BIOGLAN PHARMS	5%	N20126 001 Apr 01, 1994 Aug CAHN
>A>		BIOGLAN PHARMS CORP	5%	N20126 001 Apr 01, 1994 Aug CAHN

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL
BONE CARE 0.5UGM

N20862 002 Apr 23, 2004 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN RDF
@ PHARMACIA AND UPJOHN 10MG/VIAL
@ 20MG/VIAL
@ 50MG/VIAL

N50467 001 Jun DISC
N50467 003 May 20, 1985 Jun DISC
N50467 002 Jun DISC

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE
AB WATSON LABS EQ 50MG BASE
AB EQ 100MG BASE

N65041 001 Apr 28, 2000 Apr CAHN
N65041 002 Apr 28, 2000 Apr CAHN

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX
FH FAULDING CO LTD EQ 75MG BASE
AB + EQ 100MG BASE N50582 002 Aug 13, 2001 Jul CAHN
N50582 001 Jul 22, 1985 Jul CAHN

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
>D> @ HALSEY EQ 50MG BASE N62418 001 Jan 28, 1983 Aug CAHN
>D> @ EQ 100MG BASE N62418 002 Jan 28, 1983 Aug CAHN
>A> @ MUTUAL PHARM EQ 50MG BASE N62418 001 Jan 28, 1983 Aug CAHN
>A> @ EQ 100MG BASE N62418 002 Jan 28, 1983 Aug CAHN
AB WATSON LABS EQ 50MG BASE N61717 001 Apr CAHN
AB EQ 100MG BASE N61717 002 Apr CAHN

TABLET; ORAL
DOXYCYCLINE HYCLATE
>D> @ HALSEY EQ 100MG BASE N62391 001 Sep 30, 1982 Aug CAHN
>A> @ MUTUAL PHARM EQ 100MG BASE N62391 001 Sep 30, 1982 Aug CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP HOSPIRA 2.5MG/ML
AP 2.5MG/ML

N71981 001 Feb 29, 1988 May CAHN
N72272 001 Aug 31, 1995 May CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL
+ HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML

N71982 001 May 04, 1988 May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE; ORAL
CYMBALTA
>A> LILLY EQ 20MG BASE
>A> EQ 30MG BASE
>A> + EQ 60MG BASE

N21427 001 Aug 03, 2004 Aug NEWA
N21427 002 Aug 03, 2004 Aug NEWA
N21427 004 Aug 03, 2004 Aug NEWA

ECONAZOLE NITRATE

AB CREAM; TOPICAL
ECONAZOLE NITRATE
CLAY PARK 1%

N76479 001 Jun 23, 2004 Jun NEWA

EDETADE DISODIUM

AP INJECTABLE; INJECTION
ENDRATE
+ HOSPIRA 150MG/ML

N11355 001 May CAHN

EDROPHONIUM CHLORIDE

AP INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
HOSPIRA 10MG/ML

N40131 001 Feb 24, 1998 May CAHN

EFAVIRENZ

TABLET; ORAL
SUSTIVA
@ BRISTOL MYERS SQUIBB 300MG

N21360 001 Feb 01, 2002 Jun DISC

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA
+ SKINMEDICA 13.9%

N21145 001 Jul 27, 2000 Jul CAHN

>A> EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET; ORAL
TRUVADA
>A> + GILEAD 200MG;300MG

N21752 001 Aug 02, 2004 Aug NEWA

ENALAPRILAT

AP INJECTABLE; INJECTION
ENALAPRILAT
HOSPIRA 1.25MG/ML
AP 1.25MG/ML

N75456 001 Aug 22, 2000 May CAHN

N75458 001 Aug 22, 2000 May CAHN

EPINEPHRINE

AP INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE
+ HOLLISTER STIER LABS EQ 0.15MG /DELIVERY

N20800 002 May 28, 2004 May NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

AP INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE
HOSPIRA 0.005MG/ML;0.5%
0.005MG/ML;1%
0.005MG/ML;1.5%
0.005MG/ML;1.5%
0.005MG/ML;1.5%
0.005MG/ML;2%
0.01IMG/ML;1%
0.01IMG/ML;2%

N89635 001 Jun 21, 1988 May CAHN

N89649 001 Jun 21, 1988 May CAHN

N88571 001 Sep 13, 1985 May CAHN

N89645 001 Jun 21, 1988 May CAHN

N89650 001 Jun 21, 1988 May CAHN

N89651 001 Jun 21, 1988 May CAHN

N89644 001 Jun 21, 1988 May CAHN

N89646 001 Jun 21, 1988 May CAHN

PATCH; IONTOPHORESIS

+ LIDOSITE TOPICAL SYSTEM KIT
VYTERIS 1.05MG/PATCH;100MG/PATCH

N21504 001 May 06, 2004 May NEWA

SOLUTION; IONTOPHORESIS

IONTOCAINE

+ IOMED

0.01MG/ML; 2%

N20530 001 Dec 21, 1995 May MAG

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

>D> @ HALSEY 1MG
>A> @ MUTUAL PHARM 1MGN88891 001 Nov 01, 1985 Aug CAHN
N88891 001 Nov 01, 1985 Aug CAHN

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

>D> @ HALSEY 0.5MG
>D> @ 1MG
>A> @ MUTUAL PHARM 0.5MG
>A> @ 1MGN87407 001 Aug CAHN
N87552 001 Aug CAHN
N87407 001 Aug CAHN
N87552 001 Aug CAHNERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT 250MG

N62338 001 Jan CMFD

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS 2%

N50617 001 Oct 21, 1987 Jul CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FOUGERA 0.5%
ILOTYCIN
@ DISTA 0.5%N62447 001 Sep 26, 1983 Jul CRLD
N50368 001 Jul DISC

SOLUTION; TOPICAL

C-SOLVE-2

@ BIOGLAN PHARMA 2%

N62468 001 Jul 03, 1985 Jun DISC

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA EQ 125MG BASE/5ML N62353 001 Nov 18, 1982 Jan CTEC
+ EQ 250MG BASE/5ML N62409 001 Dec 16, 1982 Jan CRLD
ILOSONE
@ LILLY EQ 125MG BASE/5ML N50010 001 Jan DISC
@ EQ 250MG BASE/5ML N50010 002 Jan DISCERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP + HOSPIRA EQ 500MG BASE/VIAL N50182 002 May CAHN
AP EQ 500MG BASE/VIAL N50609 001 Sep 24, 1986 May CAHN
AP EQ 500MG BASE/VIAL N62638 001 Oct 31, 1986 May CAHN
AP + EQ 1GM BASE/VIAL N50182 003 May CAHN
AP EQ 1GM BASE/VIAL N50609 002 Sep 24, 1986 May CAHN
AP EQ 1GM BASE/VIAL N62638 002 Oct 31, 1986 May CAHNESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

FOREST LABS 5MG

N21323 001 Aug 14, 2002 Apr CMFD

1-40

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

>D> + BAXTER HLTHCARE CORP 10MG/ML
10MG/ML

>A>

AP + ESMOLOL HCL

>A> AP BEDFORD LABS 10MG/ML

N19386 006 Feb 25, 2003 Aug CFTG
N19386 006 Feb 25, 2003 Aug CFTG

N76323 001 Aug 10, 2004 Aug NEWA

May MAGC

Aug CAHN

Aug CAHN

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

MENOSTAR

>D> + BERLEX LABS 0.014MG/24HR

VIVELLE

AB1 + NOVARTIS

@

@

VIVELLE-DOT

AB1 NOVARTIS

BX

BX

GEL, METERED; TOPICAL

ESTROGEL

SOLVAY

0.06%

0.06%

0.06%

N21674 001 Jun 08, 2004 Jun NEWA

N20323 005 Aug 16, 2000 Jul CTEC

N20323 001 Oct 28, 1994 Jul DISC

N20323 003 Oct 28, 1994 Jul DISC

N20538 009 May 03, 2002 Jul NEWA

N20538 005 Jan 08, 1999 Jul CTEC

N20538 007 Jan 08, 1999 Jul CTEC

Jan CMFD

Jul CAHN

Jul CRLD

Jul DISC

Jun DISC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD

EQ 0.05MG BASE/24HR

N21367 001 Mar 20, 2003 May CPOT

N21367 002 Mar 20, 2003 May CPOT

+

EQ 0.1MG BASE/24HR

>A> TABLET; ORAL

FEMTRACE

WARNER CHILCOTT

0.45MG

N21633 001 Aug 20, 2004 Aug NEWA

>A>

0.9MG

N21633 002 Aug 20, 2004 Aug NEWA

>A>

1.8MG

N21633 003 Aug 20, 2004 Aug NEWA

>A> +

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

@ WYETH PHARMS INC

2.5MG

N04782 002

May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED

0.45MG

N20992 005 Feb 05, 2004 Feb NEWA

May CAHN

May CAHN

May CAHN

May CAHN

May CAHN

May CAHN

Apr CMFD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED	0.625MG	N21443 003	May 10, 2004	May	NEWA
@	0.625MG	N21443 003	May 10, 2004	Jul	DISC
@	1.25MG	N21443 004	May 10, 2004	Jul	DISC
+	1.25MG	N21443 004	May 10, 2004	May	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

@ ELAN PHARMS	100MG	N16320 001	Feb	CAHN
@	200MG	N16320 002	Feb	CAHN
@	400MG	N16320 003	Feb	CAHN
@	500MG	N16320 004	Feb	CAHN
AB STAT TRADE	100MG	N16320 001	May	CMFD
@	200MG	N16320 002	May	CAHN
AB	400MG	N16320 003	May	CMFD
@	500MG	N16320 004	May	CAHN

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

@ SCHERING	0.02MG	N05292 001	Apr	DISC
@	0.05MG	N05292 002	Apr	DISC
@	0.5MG	N05292 003	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

@ DURAMED	0.05MG;0.25MG	N20946 001	Sep 01, 1998	Jul	DISC
+	0.05MG;0.25MG	N20946 001	Sep 01, 1998	Feb	CAHN

TABLET; ORAL-21

>D ALESSE					
>D AB1 + WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	Mar 27, 1997	Aug	DISC

>A @	0.02MG;0.1MG	N20683 001	Mar 27, 1997	Aug	DISC
AVIANE-21					

>D AB1 DURAMED PHARMS BARR	0.02MG;0.1MG	N75796 002	Apr 30, 2001	Aug	CRLD
>A +	0.02MG;0.1MG	N75796 002	Apr 30, 2001	Aug	CRLD

LEVLITE					
AB2 + BERLEX	0.02MG;0.1MG	N20860 001	Jul 13, 1998	May	CTEC

TABLET; ORAL-28

ALESSE

AB1 + WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	Mar 27, 1997	Jul	CRLD
LESSINA-28					

AB2 BARR	0.02MG;0.1MG	N75803 002	Mar 20, 2002	May	CTEC
LEVLITE					

AB2 + BERLEX	0.02MG;0.1MG	N20860 002	Jul 13, 1998	Jul	CRLD
AB2	0.02MG;0.1MG	N20860 002	Jul 13, 1998	May	CTEC

>D TRIPHASIC-28					
>D AB WYETH PHARMS INC	0.03MG;0.04MG;0.03MG;0.05MG;0.125MG;0.075MG	N19190 001	Nov 01, 1984	Aug	DISC

>A @	0.03MG,0.04MG,0.03MG;0.05MG,0.125MG,0.075MG	N19190 001	Nov 01, 1984	Aug	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21					
	BALZIVA-21				
AB	BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004 Apr NEWA
	OVCON-35				
AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127	001	Apr CFTG
TABLET; ORAL-28					
	BALZIVA-28				
AB	BARR	0.035MG;0.4MG	N76238	001	Apr 22, 2004 Apr NEWA
	ORTHO-NOVUM 1/35-28				
AB	+ ORTHO MCNEIL PHARM	0.035MG;1MG	N17919	002	Mar CRLD
	OVCON-35				
AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N17716	001	Apr CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL					
	FEMHRT				
>D>	+ GALEN CHEM	0.005MG;1MG	N21065	002	Oct 15, 1999 Aug CAHN
>A>	+ WARNER CHILCOTT	0.005MG;1MG	N21065	002	Oct 15, 1999 Aug CAHN
TABLET; ORAL-21					
	ESTROSTEP 21				
>D>	@ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130	001	Oct 09, 1996 Aug CAHN
>A>	@ WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	001	Oct 09, 1996 Aug CAHN
LOESTRIN 21 1.5/30					
>D>	AB + GALEN CHEM	0.03MG;1.5MG	N17875	001	Aug CAHN
>A>	AB + WARNER CHILCOTT	0.03MG;1.5MG	N17875	001	Aug CAHN
LOESTRIN 21 1/20					
>D>	AB + GALEN CHEM	0.02MG;1MG	N17876	001	Aug CAHN
>A>	AB + WARNER CHILCOTT	0.02MG;1MG	N17876	001	Aug CAHN
TABLET; ORAL-28					
	ESTROSTEP FE				
>D>	+ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130	002	Oct 09, 1996 Aug CAHN
>A>	+ WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	002	Oct 09, 1996 Aug CAHN
LOESTRIN FE 1.5/30					
>D>	AB + GALEN CHEM	0.03MG;1.5MG	N17355	001	Aug CAHN
>A>	AB + WARNER CHILCOTT	0.03MG;1.5MG	N17355	001	Aug CAHN
LOESTRIN FE 1/20					
>D>	AB + GALEN CHEM	0.02MG;1MG	N17354	001	Aug CAHN
>A>	AB + WARNER CHILCOTT	0.02MG;1MG	N17354	001	Aug CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28					
	ORTHO TRI-CYCLEN LO				
+ AB	+ ORTHO MCNEIL PHARM	0.025MG,0.025MG,0.25MG;0.18MG,0.25MG,0.215MG	N21241	001	Aug 22, 2002 Jun CAHN
	PREVIFEM				
AB	ANDRX PHARMS	0.035MG;0.25MG	N76334	001	Jan 09, 2004 Jan NEWA
	TRI-PREVIFEM				
AB	ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335	001	Mar 26, 2004 Mar NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21					
	LO/OVRAL				
>D>	AB + WYETH PHARMS INC	0.03MG;0.3MG	N17612	001	Aug DISC
>A>	@	0.03MG;0.3MG	N17612	001	Aug DISC

TABLET; ORAL-21
LOW-OGESTREL-21

>D>	AB	WATSON LABS	0.03MG;0.3MG	N75288 001	Jul 28, 1999	Aug	CRLD
>A>	AB	+	0.03MG;0.3MG	N75288 001	Jul 28, 1999	Aug	CRLD
		OGESTREL 0.5/50-21					
>D>	AB	WATSON LABS	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Aug	CRLD
>A>	+		0.05MG;0.5MG	N75406 001	Dec 15, 1999	Aug	CRLD
>D>		OVRAL					
>D>	AB	WYETH PHARMS INC	0.05MG;0.5MG	N16672 001		Aug	DISC
>A>	+		0.05MG;0.5MG	N16672 001		Aug	DISC

TABLET; ORAL-28

OGESTREL 0.5/50-28

>D>	AB	WATSON LABS	0.05MG;0.5MG	N75406 002	Dec 15, 1999	Aug	CRLD
>A>	AB	+	0.05MG;0.5MG	N75406 002	Dec 15, 1999	Aug	CRLD

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEEL

MGI PHARMA INC 50MG/ML

N19545 001 Apr 20, 1987 Jun DISC

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB	WYETH PHARMS INC	400MG	N20584 001	Oct 25, 1996	May	CRLD
AB	+	500MG	N20584 003	Jan 20, 1998	Jul	CRLD
AB		500MG	N20584 003	Jan 20, 1998	May	CRLD
	@	600MG	N20584 002	Oct 25, 1996	Jul	DISC

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+	HOSPIRA	2MG/ML	N18227 001	Sep 07, 1982	May	CAHN
----	---	---------	--------	------------	--------------	-----	------

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP	HOSPIRA	20MG/ML	N74320 001	Aug 30, 1995	May	CAHN
AP		20MG/ML	N74351 001	Aug 30, 1995	May	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSP SINGAPORE	10MG;10MG	N21687 001	Jul 23, 2004	Jul	NEWA
	10MG;20MG	N21687 002	Jul 23, 2004	Jul	NEWA
	10MG;40MG	N21687 003	Jul 23, 2004	Jul	NEWA
+	10MG;80MG	N21687 004	Jul 23, 2004	Jul	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	HOSPIRA	10MG/ML	N75870 001	Nov 23, 2001	May	CAHN
AP		10MG/ML	N75905 001	Nov 23, 2001	May	CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM
AP + HOSPIRA EQ 10MG BASE/ML N19922 001 Sep 23, 1997 May CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC
+ ALZA 0.6MG/24HR N19813 004 Aug 07, 1990 Jul CTEC
1.2MG/24HR N19813 003 Aug 07, 1990 Jul CTEC
1.8MG/24HR N19813 002 Aug 07, 1990 Jul CTEC
2.4MG/24HR N19813 001 Aug 07, 1990 Jul CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
HOSPIRA EQ 0.05MG BASE/ML N19115 001 Jan 12, 1985 May CAHN
AP FENTANYL CITRATE PRESERVATIVE FREE
HOSPIRA EQ 0.05MG BASE/ML N72786 001 Sep 24, 1991 May CAHN
TROCHE/LOZENGE; ORAL
ACTIQ
CEPHALON EQ 0.2MG BASE N20747 001 Nov 04, 1998 Feb CAHN
EQ 0.4MG BASE N20747 002 Nov 04, 1998 Feb CAHN
EQ 0.6MG BASE N20747 003 Nov 04, 1998 Feb CAHN
EQ 0.8MG BASE N20747 004 Nov 04, 1998 Feb CAHN
EQ 1.2MG BASE N20747 005 Nov 04, 1998 Feb CAHN
EQ 1.6MG BASE N20747 006 Nov 04, 1998 Feb CAHN
+

FLUCONAZOLE

FOR SUSPENSION; ORAL
DIFLUCAN
AB PFIZER 50MG/5ML N20090 001 Dec 23, 1993 Jul CFTG
AB + 200MG/5ML N20090 002 Dec 23, 1993 Jul CFTG
FLUCONAZOLE
AB RANBAXY 50MG/5ML N76332 001 Jul 29, 2004 Jul NEWA
200MG/5ML N76332 002 Jul 29, 2004 Jul NEWA
AB ROXANE 50MG/5ML N76246 001 Jul 29, 2004 Jul NEWA
200MG/5ML N76246 002 Jul 29, 2004 Jul NEWA
INJECTABLE; INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
AP + PFIZER 200MG/100ML N19950 003 Sep 29, 1992 Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9%
AP + PFIZER 200MG/100ML N19950 001 Jan 29, 1990 Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP + PFIZER 200MG/100ML N19950 002 Jan 29, 1990 Jul CFTG
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP HOSPIRA 200MG/100ML N76304 001 Jul 29, 2004 Jul NEWA
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%
AP AM PHARM PARTNERS 200MG/100ML N76145 001 Jul 29, 2004 Jul NEWA
AP BEDFORD 200MG/100ML N76087 001 Jul 29, 2004 Jul NEWA
AP SICOR PHARMS 200MG/100ML N76653 001 Jul 29, 2004 Jul NEWA
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE 200MG/100ML N76766 001 Jul 29, 2004 Jul NEWA
AP HOSPIRA 200MG/100ML N76303 001 Jul 29, 2004 Jul NEWA
>D> AP + MAYNE PHARMA USA 200MG/100ML N76617 001 Jul 29, 2004 Aug CRLD
>A> AP 200MG/100ML N76617 001 Jul 29, 2004 Aug CRLD

		INJECTABLE; INJECTION					
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+	MAYNE PHARMA USA	200MG/100ML		N76617	001	Jul 29, 2004 Jul NEWA
		TABLET; ORAL					
		DIFLUCLAN					
AB		Pfizer	50MG		N19949	001	Jan 29, 1990 Jul CFTG
AB			100MG		N19949	002	Jan 29, 1990 Jul CFTG
AB			150MG		N19949	004	Jun 30, 1994 Jul CFTG
AB	+		200MG		N19949	003	Jan 29, 1990 Jul CFTG
		FLUCONAZOLE					
AB		DR REDDYS LABS INC	50MG		N76658	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76658	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76658	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76658	004	Jul 29, 2004 Jul NEWA
AB		GEDEON RICHTER USA	50MG		N76432	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76432	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76432	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76432	004	Jul 29, 2004 Jul NEWA
AB		GENPHARM	50MG		N76042	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76042	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76042	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76042	004	Jul 29, 2004 Jul NEWA
AB		IVAX PHARMS	50MG		N76077	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76077	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76077	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76077	004	Jul 29, 2004 Jul NEWA
AB		MYLAN	50MG		N76351	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76351	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76351	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76351	004	Jul 29, 2004 Jul NEWA
AB		PLIVA	50MG		N76424	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76424	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76424	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76424	004	Jul 29, 2004 Jul NEWA
AB		RANBAXY	50MG		N76386	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76386	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76386	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76386	004	Jul 29, 2004 Jul NEWA
AB		ROXANE	50MG		N76213	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76213	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76213	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76213	004	Jul 29, 2004 Jul NEWA
AB		SANDOZ	50MG		N76086	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76086	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76086	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76086	004	Jul 29, 2004 Jul NEWA
AB		TARO	50MG		N76507	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76507	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76507	003	Jul 29, 2004 Jul NEWA
AB			200MG		N76507	004	Jul 29, 2004 Jul NEWA
AB		TEVA	50MG		N74681	001	Jul 29, 2004 Jul NEWA
AB			100MG		N74681	002	Jul 29, 2004 Jul NEWA
AB			150MG		N74681	003	Jul 29, 2004 Jul NEWA
AB			200MG		N74681	004	Jul 29, 2004 Jul NEWA
AB		TORPHARM	50MG		N76665	001	Jul 29, 2004 Jul NEWA
AB			100MG		N76665	002	Jul 29, 2004 Jul NEWA
AB			150MG		N76665	003	Jul 29, 2004 Jul NEWA

AB	TABLET; ORAL FLUCONAZOLE TORPHARM	200MG	N76665 004 Jul 29, 2004 Jul NEWA
	<u>FLUDARABINE PHOSPHATE</u>		
	INJECTABLE; INJECTION FLUDARABINE PHOSPHATE + GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)	N76661 001 Apr 28, 2004 Apr NEWA
	<u>FLUDEOXYGLUCOSE, F-18</u>		
	INJECTABLE; INJECTION FLUDEOXYGLUCOSE F 18 @ DOWNSTATE CLINCL	4-90mCi/ML	N20306 002 Sep 25, 2001 May DISC
>A>	INJECTABLE; INTRAVENOUS FLUDEOXYGLUCOSE F 18 + WEILL MEDCL COLL	10-100mCi/ML	N21768 001 Aug 05, 2004 Aug NEWA
>A>			
>A>			
	<u>FLUNISOLIDE</u>		
	SPRAY, METERED; NASAL FLUNISOLIDE + BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001 Feb 20, 2002 Jun CRLD
	NASALIDE @ IVAX RES	0.025MG/SPRAY	N18148 001 Jun DISC
	<u>FLUOCINONIDE</u>		
AB2	CREAM; TOPICAL FLUOCINONIDE EMULSIFIED BASE ALTANA	0.05%	N76586 001 Jun 23, 2004 Jun NEWA
	<u>FLUOROURACIL</u>		
	INJECTABLE; INJECTION FLUOROURACIL AP BIGMAR BIOPEN PHARMS	50MG/ML	N40291 001 Mar 24, 1999 Jul CAHN
AP		50MG/ML	N40379 001 Nov 15, 2000 Jul CAHN
	<u>FLUOXETINE HYDROCHLORIDE</u>		
AA	SOLUTION; ORAL FLUOXETINE HCL PAR PHARM	EQ 20MG BASE/5ML	N76458 001 May 14, 2004 May NEWA
	TABLET; ORAL FLUOXETINE IVAX PHARMS	EQ 40MG BASE	N75865 003 Aug 30, 2004 Aug NEWA
>A> AB			
>A> AB	FLUOXETINE HCL IVAX PHARMS	EQ 10MG BASE	N75865 001 Feb 28, 2002 Aug CAHN
>D> AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001 Feb 28, 2002 Aug CAHN
	<u>FLUPHENAZINE DECANOATE</u>		
	INJECTABLE; INJECTION FLUPHENAZINE DECANOATE @ MAYNE PHARMA USA	25MG/ML	N74966 001 Apr 16, 1998 Apr CAHN
	<u>FLUPHENAZINE HYDROCHLORIDE</u>		
	CONCENTRATE; ORAL PERMITIL @ SCHERING	5MG/ML	N16008 001 Jun DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL			
FLURAZEPAM HCL			
>D>	@ HALSEY	15MG	N70454 001 Aug 04, 1986 Aug CAHN
>D>	@	30MG	N70455 001 Aug 04, 1986 Aug CAHN
>A>	@ MUTUAL PHARM	15MG	N70454 001 Aug 04, 1986 Aug CAHN
>A>	@	30MG	N70455 001 Aug 04, 1986 Aug CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION			
FLOVENT HFA			
GLAXOSMITHKLINE	0.044MG/INH		N21433 003 May 14, 2004 May NEWA
	0.11MG/INH		N21433 002 May 14, 2004 May NEWA
+	0.22MG/INH		N21433 001 May 14, 2004 May NEWA
CREAM; TOPICAL			
CUTIVATE			
AB + GLAXOSMITHKLINE	0.05%		N19958 001 Dec 18, 1990 May CFTG
FLUTICASONE PROPIONATE			
AB ALTANA	0.05%		N76451 001 May 14, 2004 May NEWA
AB ATRIX	0.05%		N76633 001 May 14, 2004 May NEWA
AB CLAY PARK	0.05%		N76793 001 May 14, 2004 May NEWA
OINTMENT; TOPICAL			
CUTIVATE			
AB + GLAXOSMITHKLINE	0.005%		N19957 001 Dec 14, 1990 May CFTG
FLUTICASONE PROPIONATE			
AB ALTANA	0.005%		N76300 001 May 14, 2004 May NEWA
AB CLAY PARK	0.005%		N76668 001 May 14, 2004 May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC			
FOLLISTIM			
>D>			
>D> + ORGANON USA INC	75 IU/VIAL		N20582 001 Sep 29, 1997 Aug DISC
>A>	@	75 IU/VIAL	N20582 001 Sep 29, 1997 Aug DISC
	+	75 IU/VIAL	N20582 001 Sep 29, 1997 Jun CTEC
BX		75 IU/VIAL	N20582 001 Sep 29, 1997 Mar CDFR
>D>	+	150 IU/VIAL	N20582 002 Sep 29, 1997 Aug DISC
>A>	@	150 IU/VIAL	N20582 002 Sep 29, 1997 Aug DISC
BX		150 IU/VIAL	N20582 002 Sep 29, 1997 Mar CDFR
	+	150 IU/VIAL	N20582 002 Sep 29, 1997 Jun CTEC
INJECTABLE; SUBCUTANEOUS			
FOLLISTIM AQ			
ORGANON USA INC	300 IU/0.525ML		N21211 001 Mar 23, 2004 Mar NEWA
+	600 IU/0.885ML		N21211 002 Mar 23, 2004 Mar NEWA
GONAL-F			
SERONO INC	37.5 IU/VIAL		N21765 001 Mar 25, 2004 Mar NEWA
	37.5 IU/VIAL		N21765 001 Mar 25, 2004 May DISC
BX		75 IU/VIAL	N20378 001 Sep 29, 1997 Mar CDFR
	75 IU/VIAL		N20378 001 Sep 29, 1997 Jun DISC
	75 IU/VIAL		N21765 002 Mar 25, 2004 Mar NEWA
BX		75 IU/VIAL	N21765 002 Mar 25, 2004 Jun CRLD
	150 IU/VIAL		N20378 002 Sep 29, 1997 Mar CDFR
	150 IU/VIAL		N20378 002 Sep 29, 1997 Jun DISC
BX		150 IU/VIAL	N21765 003 Mar 25, 2004 Mar NEWA
	150 IU/VIAL		N21765 003 Mar 25, 2004 May DISC
	450 IU/VIAL		N20378 005 Mar 26, 2004 Mar NEWA
BX		1,050 IU/VIAL	N20378 004 Feb 28, 2001 Apr CPOT

INJECTABLE; SUBCUTANEOUS

GONAL-F						
+ SERONO INC	1,200 IU/VIAL		N20378	004	Feb 28, 2001	Mar CAIN
GONAL-F RFF PEN						
SERONO INC	300 IU/0.5ML		N21684	001	May 25, 2004	May NEWA
	450 IU/0.75ML		N21684	002	May 25, 2004	May NEWA
	900 IU/1.5ML		N21684	003	May 25, 2004	May NEWA
*						

FOMIVIRSEN SODIUMINJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE						
+ NOVARTIS	6.6MG/ML		N20961	001	Aug 26, 1998	Jan CAHN

FONDAPARINUX SODIUMINJECTABLE; SUBCUTANEOUS

ARIXTRA						
>D> + FONDA BV	2.5MG/0.5ML		N21345	001	Dec 07, 2001	Aug CAHN
>D> +	5MG/0.4ML		N21345	002	May 28, 2004	Aug CAHN
>D> +	5MG/0.4ML		N21345	002	May 28, 2004	May NEWA
>D> +	7.5MG/0.6ML		N21345	003	May 28, 2004	Aug CAHN
>D> +	7.5MG/0.6ML		N21345	003	May 28, 2004	May NEWA
>D> +	10MG/0.8ML		N21345	004	May 28, 2004	Aug CAHN
>D> +	10MG/0.8ML		N21345	004	May 28, 2004	May NEWA
>A> + GLAXOSMITHKLINE	2.5MG/0.5ML		N21345	001	Dec 07, 2001	Aug CAHN
>A> +	5MG/0.4ML		N21345	002	May 28, 2004	Aug CAHN
>A> +	7.5MG/0.6ML		N21345	003	May 28, 2004	Aug CAHN
>A> +	10MG/0.8ML		N21345	004	May 28, 2004	Aug CAHN

FOSINOPRIL SODIUMTABLET; ORALFOSINOPRIL SODIUM

AB EON	10MG		N76483	001	Apr 23, 2004	Apr NEWA
AB	20MG		N76483	002	Apr 23, 2004	Apr NEWA
AB	40MG		N76483	003	Apr 23, 2004	Apr NEWA
AB RANBAXY	10MG		N76580	001	Apr 23, 2004	Apr NEWA
AB	20MG		N76580	002	Apr 23, 2004	Apr NEWA
AB	40MG		N76580	003	Apr 23, 2004	Apr NEWA

FROVATRIPTAN SUCCINATETABLET; ORALFROVA

>A> + ENDO PHARMS	EQ 2.5MG BASE		N21006	001	Nov 08, 2001	Aug CAHN
>D> + VERNALIS	EQ 2.5MG BASE		N21006	001	Nov 08, 2001	Aug CAHN
+ +	EQ 2.5MG BASE		N21006	001	Nov 08, 2001	May CAHN

FUROSEMIDEINJECTABLE; INJECTIONFUROSEMIDE

AP HOSPIRA	10MG/ML		N18667	001	May 28, 1982	May CAHN
AP	10MG/ML		N70578	001	Jul 08, 1987	May CAHN
AP	10MG/ML		N72080	001	Aug 13, 1991	May CAHN
AP	10MG/ML		N74337	001	Oct 31, 1994	May CAHN
AP	10MG/ML		N75241	001	May 28, 1999	May CAHN

TABLET; ORALFUROSEMIDE

>D> @ HALSEY	20MG		N70043	001	Sep 26, 1985	Aug CAHN
--------------	------	--	--------	-----	--------------	----------

TABLET; ORAL

FUROSEMIDE

>D>	@ HALSEY	40MG	N18790 001 Nov 29, 1983 Aug CAHN
>D>	@	80MG	N70100 001 Jan 26, 1988 Aug CAHN
>A>	@ MUTUAL PHARM	20MG	N70043 001 Sep 26, 1985 Aug CAHN
>A>	@	40MG	N18790 001 Nov 29, 1983 Aug CAHN
>A>	@	80MG	N70100 001 Jan 26, 1988 Aug CAHN
AB	VINTAGE PHARMS	20MG	N76796 001 Mar 26, 2004 Mar NEWA
AB		40MG	N76796 002 Mar 26, 2004 Mar NEWA
AB		80MG	N76796 003 Mar 26, 2004 Mar NEWA

GABAPENTIN

TABLET; ORAL

GABAPENTIN

IVAX PHARMS

100MG

N76017 001 Apr 28, 2004 Apr NEWA

300MG

N76017 002 Apr 28, 2004 Apr NEWA

400MG

N76017 003 Apr 28, 2004 Apr NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE INJECTION

+ ORGANON USA INC EQ 250UGM BASE/0.5ML

N21057 001 Jul 29, 1999 Jun CTNA

GATIFLOXACIN

>A> SUSPENSION; ORAL

>A> TEQUIN

>A> + BRISTOL MYERS SQUIBB 200MG/5ML

N21678 001 Aug 27, 2004 Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ OSCIENT

EQ 320MG BASE

N21158 001 Apr 04, 2003 Apr CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP HOSPIRA EQ 10MG BASE/ML

N62420 001 Aug 15, 1983 May CAHN

AP EQ 10MG BASE/ML

N62612 004 Feb 20, 1986 May CAHN

AP EQ 40MG BASE/ML

N62420 002 Aug 15, 1983 May CAHN

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA EQ 1.2MG BASE/ML

N62414 001 Aug 15, 1983 May CAHN

@ EQ 1.2MG BASE/ML

N62588 001 Jan 06, 1986 May CAHN

AP EQ 1.4MG BASE/ML

N62414 002 Aug 15, 1983 May CAHN

@ EQ 1.4MG BASE/ML

N62588 002 Jan 06, 1986 May CAHN

AP EQ 1.6MG BASE/ML

N62414 003 Aug 15, 1983 May CAHN

@ EQ 1.6MG BASE/ML

N62588 003 Jan 06, 1986 May CAHN

AP EQ 1.8MG BASE/ML

N62414 004 Aug 15, 1983 May CAHN

@ EQ 1.8MG BASE/ML

N62588 004 Jan 06, 1986 May CAHN

AP EQ 2MG BASE/ML

N62414 005 Aug 15, 1983 May CAHN

@ EQ 2MG BASE/ML

N62588 005 Jan 06, 1986 May CAHN

AP EQ 60MG BASE/100ML

N62414 006 Aug 15, 1983 May CAHN

@ EQ 60MG BASE/100ML

N62588 006 Jan 06, 1986 May CAHN

AP EQ 70MG BASE/100ML

N62414 007 Aug 15, 1983 May CAHN

@ EQ 70MG BASE/100ML

N62588 007 Jan 06, 1986 May CAHN

AP EQ 80MG BASE/100ML

N62414 008 Aug 15, 1983 May CAHN

@ EQ 80MG BASE/100ML

N62588 008 Jan 06, 1986 May CAHN

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	EQ 90MG BASE/100ML	N62414 009 Aug 15, 1983 May CAHN
	@	EQ 90MG BASE/100ML	N62588 009 Jan 06, 1986 May CAHN
AP		EQ 100MG BASE/100ML	N62414 010 Aug 15, 1983 May CAHN
	@	EQ 100MG BASE/100ML	N62588 010 Jan 06, 1986 May CAHN

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	+ AKORN	EQ 0.3% BASE	N64093 001 Aug 31, 1995 Jul CFTG
AT	ALTANA	EQ 0.3% BASE	N65024 001 Jul 30, 2004 Jul NEWA

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039 002 Jan CDFR
	GENTAMICIN SULFATE		
AT	ALTANA	EQ 3% BASE	N65121 001 Jan 30, 2004 Jan NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>D>	AB	DURAMED PHARMS BARR	5MG	N74550 001 Sep 11, 1997 Aug CAHN
>D>	AB		10MG	N74550 002 Sep 11, 1997 Aug CAHN
>A>	AB	KALI LABS	5MG	N74550 001 Sep 11, 1997 Aug CAHN
>A>	AB		10MG	N74550 002 Sep 11, 1997 Aug CAHN

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	NUTRITIONAL RESTART	5GM/PACKET	N21667 001 Jun 10, 2004 Jul CMS2
---	---------------------	------------	----------------------------------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001 Jul 31, 2000 Feb CFTG
AB		2.5MG;500MG	N21178 002 Jul 31, 2000 Feb CFTG
AB	+	5MG;500MG	N21178 003 Jul 31, 2000 Feb CFTG
	GLYBURIDE AND METFORMIN HCL		
AB	IVAX PHARMS	1.25MG;250MG	N76345 001 Feb 18, 2004 Feb NEWA
AB		2.5MG;500MG	N76345 002 Feb 18, 2004 Feb NEWA
AB		5MG;500MG	N76345 003 Feb 18, 2004 Feb NEWA

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	HOSPIRA	1.5GM/100ML	N17633 001 May CAHN
AT		1.5GM/100ML	N18315 001 May CAHN

GLCOPYRROLATE

INJECTABLE; INJECTION

GLCOPYRROLATE

@	HOSPIRA	0.2MG/ML	N89393 001 Jun 15, 1988 May CAHN
---	---------	----------	----------------------------------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001 Sep 30, 1982 Jun DISC
---	----------------------	--------------------	----------------------------------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ SCHERING	125MG	N61996 001	Jun	DISC	
@	250MG	N61996 002	Jun	DISC	
FULVICIN P/G 165					
@ SCHERING	165MG	N61996 003	Apr 06, 1982	Jun	DISC
FULVICIN P/G 330					
@ SCHERING	330MG	N61996 004	Apr 06, 1982	Jun	DISC
GRIS-PEG					
+ PEDINOL	250MG	N50475 002	Jun	CRLO	

HALAZEPAM

TABLET; ORAL

PAXIPAM

@ SCHERING	20MG	N17736 003	Apr	DISC
@	40MG	N17736 004	Apr	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>D>	@ HALSEY	0.5MG	N71156 001	Jan 02, 1987	Aug	CAHN
>D>	@	1MG	N71157 001	Jan 02, 1987	Aug	CAHN
>D>	@	2MG	N71172 001	Jan 02, 1987	Aug	CAHN
>D>	@	5MG	N71212 001	Jan 07, 1988	Aug	CAHN
>D>	@	10MG	N71173 001	Jan 07, 1988	Aug	CAHN
>D>	@	20MG	N71177 001	Jan 07, 1988	Aug	CAHN
>A>	@ MUTUAL PHARM	0.5MG	N71156 001	Jan 02, 1987	Aug	CAHN
>A>	@	1MG	N71157 001	Jan 02, 1987	Aug	CAHN
>A>	@	2MG	N71172 001	Jan 02, 1987	Aug	CAHN
>A>	@	5MG	N71212 001	Jan 07, 1988	Aug	CAHN
>A>	@	10MG	N71173 001	Jan 07, 1988	Aug	CAHN
>A>	@	20MG	N71177 001	Jan 07, 1988	Aug	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000	Apr	CAHN
@	EQ 100MG BASE/ML	N75176 002	Feb 09, 2000	Apr	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>A> AP	APOTEX	EQ 5MG BASE/ML	N76774 001	Aug 25, 2004	Aug	NEWA
>A> AP		EQ 5MG BASE/ML	N76791 001	Aug 25, 2004	Aug	NEWA
>A> AP		EQ 5MG BASE/ML	N76828 001	Aug 25, 2004	Aug	NEWA

HALOTHANE

LIQUID; INHALATION

HALOTHANE

AN +	HOSPIRA	99.99%	N83254 001	May	CAHN
------	---------	--------	------------	-----	------

HEPARIN SODIUMINJECTABLE: INJECTION
HEPARIN LOCK FLUSH

AP	HOSPIRA	10 UNITS/ML	N05264 001	May	CAHN
AP		10 UNITS/ML	N40082 001	Feb 28, 1995	May CAHN
AP		10 UNITS/ML	N88097 001	Apr 28, 1983	May CAHN
AP		10 UNITS/ML	N88346 001	May 18, 1983	May CAHN
	@	100 UNITS/ML	N05264 010		May CAHN
AP		100 UNITS/ML	N40082 002	Feb 28, 1995	May CAHN
AP		100 UNITS/ML	N88098 001	Apr 28, 1983	May CAHN
AP		100 UNITS/ML	N88347 001	May 18, 1983	May CAHN
	HEPARIN LOCK FLUSH IN PLASTIC CONTAINER				
AP	HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985	May CAHN
AP		100 UNITS/ML	N05264 016	May 21, 1985	May CAHN
	HEPARIN SODIUM				
>D>	AP + HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983	Aug DISC
>A>	@	2,500 UNITS/ML	N88099 001	Apr 28, 1983	Aug DISC
	AP +	2,500 UNITS/ML	N88099 001	Apr 28, 1983	May CAHN
	AP	5,000 UNITS/ML	N88100 001	Apr 28, 1983	May CAHN
	@	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May CAHN
	@ LILLY	10,000 UNITS/ML	N05521 002		Jun DISC
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	200 UNITS/100ML	N18916 010	Jun 23, 1989	May CAHN
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
	@ HOSPIRA	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May CAHN
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	HOSPIRA	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May CAHN
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
	@ HOSPIRA	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May CAHN
	@	10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May CAHN
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
	@ HOSPIRA	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May CAHN
	@	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May CAHN
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
	@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May CAHN
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May CAHN
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May CAHN
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
	@ HOSPIRA	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May CAHN
	@	5,000 UNITS/100ML	N18916 003	Jan 31, 1984	May CAHN
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	200 UNITS/100ML	N18916 011	Jun 23, 1989	May CAHN
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	HOSPIRA	4,000 UNITS/100ML	N19805 001	Jan 25, 1989	May CAHN
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
	@ HOSPIRA	5,000 UNITS/100ML	N18911 009	Jan 30, 1985	May CAHN
	@	10,000 UNITS/100ML	N18911 008	Jan 30, 1985	May CAHN
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	HOSPIRA	5,000 UNITS/100ML	N19339 004	Mar 27, 1985	May CAHN
AP		5,000 UNITS/100ML	N19805 002	Jan 25, 1989	May CAHN
AP		10,000 UNITS/100ML	N19339 002	Mar 27, 1985	May CAHN
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	HOSPIRA	5,000 UNITS/100ML	N18916 007	Jan 31, 1984	May CAHN
		10,000 UNITS/100ML	N18916 008	Jan 31, 1984	May CAHN

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%					
@ HOSPIRA	5,000 UNITS/100ML	N18911 004	Jan 30, 1985	May	CAHN
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@ HOSPIRA	5,000 UNITS/100ML	N18916 009	Jan 31, 1984	May	CAHN
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%					
@ HOSPIRA	100 UNITS/ML	N18911 002	Jan 30, 1985	May	CAHN
@	100 UNITS/ML	N18916 004	Jan 31, 1984	May	CAHN
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%					
@ HOSPIRA	1,000 UNITS/100ML	N18916 001	Jan 31, 1984	May	CAHN
HEPARIN SODIUM PRESERVATIVE FREE					
+ HOSPIRA	2,000 UNITS/ML	N05264 013	Apr 07, 1986	May	CAHN
AP +	2,500 UNITS/ML	N05264 014	Apr 07, 1986	May	CAHN
AP +	10,000 UNITS/ML	N89522 001	May 04, 1987	May	CAHN
PANHEPRIN					
@ HOSPIRA	1,000 UNITS/ML	N05264 004		May	CAHN
@	5,000 UNITS/ML	N05264 006		May	CAHN
@	10,000 UNITS/ML	N05264 007		May	CAHN
@	20,000 UNITS/ML	N05264 008		May	CAHN
@	40,000 UNITS/ML	N05264 009		May	CAHN

HYALURONIDASE

INJECTABLE; INJECTION
VITRASE
+ ISTA PHARMS 6,200 UNITS/VIAL

N21640 001 May 05, 2004 May NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL

>D>	@ HALSEY	10MG	N88728 001	Apr 11, 1985	Aug	CAHN
>D>	@	25MG	N84106 002		Aug	CAHN
>D>	@	50MG	N84107 002		Aug	CAHN
>D>	@	100MG	N88729 001	Apr 11, 1985	Aug	CAHN
>A>	@ MUTUAL PHARM	10MG	N88728 001	Apr 11, 1985	Aug	CAHN
>A>	@	25MG	N84106 002		Aug	CAHN
>A>	@	50MG	N84107 002		Aug	CAHN
>A>	@	100MG	N88729 001	Apr 11, 1985	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

>D>	@ HALSEY	25MG;15MG;0.1MG	N88570 001	Apr 10, 1984	Aug	CAHN
>A>	@ MUTUAL PHARM	25MG;15MG;0.1MG	N88570 001	Apr 10, 1984	Aug	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

>D>	@ HALSEY	25MG	N83972 001		Aug	CAHN
>D>	@	50MG	N83972 002		Aug	CAHN
>D>	@	100MG	N83972 003		Aug	CAHN
>A>	@ MUTUAL PHARM	25MG	N83972 001		Aug	CAHN
>A>	@	50MG	N83972 002		Aug	CAHN
>A>	@	100MG	N83972 003		Aug	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

	TABLET; ORAL LOPRESSOR HCT NOVARTIS	25MG;50MG 25MG;50MG 25MG;100MG 25MG;100MG 50MG;100MG 50MG;100MG	N18303 001 Dec 31, 1984 Aug CFTG N18303 001 Dec 31, 1984 Aug CFTG N18303 002 Dec 31, 1984 Aug CFTG N18303 002 Dec 31, 1984 Aug CFTG N18303 003 Dec 31, 1984 Aug CFTG N18303 003 Dec 31, 1984 Aug CFTG
>D>	AB		
>A>	AB		
>D>			
>A>	AB		
>D>	+		
>A>	AB		
>A>	AB	METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE	
>A>	AB	MYLAN	25MG;50MG
>A>	AB		25MG;100MG
>A>	AB		50MG;100MG

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

	TABLET; ORAL ACCURETIC PFIZER PHARMS	12.5MG;EQ 10MG BASE 12.5MG;EQ 20MG BASE 25MG;EQ 20MG BASE	N20125 001 Dec 28, 1999 Mar CFTG N20125 002 Dec 28, 1999 Mar CFTG N20125 003 Dec 28, 1999 Mar CFTG
AB			
AB			
AB	+		
	QUINARETIC AMIDE PHARM	12.5MG;EQ 10MG BASE 12.5MG;EQ 20MG BASE 25MG;EQ 20MG BASE	N76374 001 Mar 31, 2004 Mar NEWA N76374 002 Mar 31, 2004 Mar NEWA N76374 003 Mar 31, 2004 Mar NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

	TABLET; ORAL SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE		
>D>	AB	HALSEY	25MG;25MG
>A>	AB	MUTUAL PHARM	25MG;25MG

HYDROCHLOROTHIAZIDE; TELMISARTAN

	TABLET; ORAL MICARDIS HCT BOEHRINGER INGELHEIM	12.5MG;80MG 25MG;80MG	N21162 002 Nov 17, 2000 May CRLD N21162 003 Apr 19, 2004 May NEWA
*			

HYDROCODONE BITARTRATE; IBUPROFEN

	TABLET; ORAL HYDROCODONE BITARTRATE AND IBUPROFEN		
+	INTERPHARM	5MG;200MG	N76642 002 Mar 18, 2004 Mar NEWA

HYDROCORTISONE

	CREAM; TOPICAL HYDROCORTISONE		
AT	VINTAGE PHARMS	2.5%	N40503 001 Mar 12, 2004 Mar NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

	AEROSOL, METERED; TOPICAL HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%		
BX	BOCA PHARMA	1%;1%	N89440 001 May 17, 1988 Apr CAHN

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL					
HYDROCORTISONE BUTYRATE					
AT	TARO PHARM INDS	0.1%	N76364	001	Jan 14, 2004 Jan NEWA
LOCOID					
AT	+ FERNDALE LABS	0.1%	N19116	001	Feb 25, 1987 Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION					
A-HYDROCORT					
AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929	001	May CAHN >D>
AP		EQ 250MG BASE/VIAL	N85930	001	May CAHN >A>
AP		EQ 500MG BASE/VIAL	N85931	001	May CAHN >A>
AP		EQ 1GM BASE/VIAL	N85932	001	May CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION					
HYDROMORPHONE HCL					
AP	HOSPIRA	10MG/ML	N74598	001	Jun 19, 1997 May CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION					
HYDROXYZINE HCL					
AP	HOSPIRA	25MG/ML	N87416	001	May CAHN
	@	50MG/ML	N86821	001	May CAHN
AP		50MG/ML	N87546	001	May CAHN
TABLET; ORAL					
HYDROXYZINE HCL					
AB	ABLE	10MG	N40559	001	Jul 22, 2004 Jul NEWA
AB		25MG	N40562	001	Jul 22, 2004 Jul NEWA
AB		50MG	N40563	001	Jul 22, 2004 Jul NEWA
>D>	@ HALSEY	10MG	N88409	001	Nov 15, 1983 Aug CAHN
>D>	@	25MG	N87857	001	Apr 18, 1983 Aug CAHN
>D>	@	50MG	N87860	001	Apr 18, 1983 Aug CAHN
>D>	@	100MG	N87862	001	Apr 18, 1983 Aug CAHN
>A>	@ MUTUAL PHARM	10MG	N88409	001	Nov 15, 1983 Aug CAHN
>A>	@	25MG	N87857	001	Apr 18, 1983 Aug CAHN
>A>	@	50MG	N87860	001	Apr 18, 1983 Aug CAHN
>A>	@	100MG	N87862	001	Apr 18, 1983 Aug CAHN

IBUPROFEN

TABLET; ORAL					
IBUPROFEN					
>D>	@ BARR	400MG	N70079	001	Jul 24, 1985 Aug CAHN
>D>	@	600MG	N70080	001	Jul 24, 1985 Aug CAHN
>D>	@	800MG	N71448	001	Feb 18, 1987 Aug CAHN
>A>	@ MUTUAL PHARM	400MG	N70079	001	Jul 24, 1985 Aug CAHN
>A>	@	600MG	N70080	001	Jul 24, 1985 Aug CAHN
>A>	@	800MG	N71448	001	Feb 18, 1987 Aug CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION					
IDARUBICIN HCL					
+ GENSIA SICOR PHARMS	5MG/VIAL	N65037	003	May 01, 2002 Feb CTBC	

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP + HOSPIRA

EQ 5MG BASE/ML

N74616 001 Aug 03, 1998 May CAHN

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ HALSEY

25MG

N70067 001 Oct 03, 1986 Aug CAHN

@

50MG

N70068 001 Oct 03, 1986 Aug CAHN

>D> @ MUTUAL PHARM

25MG

N70067 001 Oct 03, 1986 Aug CAHN

>A> @

50MG

N70068 001 Oct 03, 1986 Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK

100 UNITS/ML

N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ AVENTIS PHARMS

100 UNITS/ML

N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ AVENTIS PHARMS

100 UNITS/ML

N21629 001 Apr 16, 2004 Apr NEWA

@

100 UNITS/ML

N21629 001 Apr 16, 2004 Jun DISC

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY

50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

HUMALOG MIX 75/25

+ LILLY

75 UNITS/ML;25 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY

100 UNITS/ML

N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN

+ LILLY

100 UNITS/ML

N20563 002 Aug 06, 1998 May CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE

55%

N20808 001 Aug 29, 1997 Jun CMFD

VISIPAQUE 320

GE HEALTHCARE

65.2%

N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

AP HOSPIRA

41%

N74898 001 Dec 30, 1997 May CAHN

INJECTABLE; INJECTION

IOPAMIDOL-200 IN PLASTIC CONTAINER					
AP	HOSPIRA	41%	N74636 001	Dec 30, 1997	May CAHN
IOPAMIDOL-250					
AP	HOSPIRA	51%	N74898 002	Dec 30, 1997	May CAHN
AP		51%	N75005 001	Feb 24, 1998	May CAHN
IOPAMIDOL-250 IN PLASTIC CONTAINER					
AP	HOSPIRA	51%	N74636 002	Dec 30, 1997	May CAHN
IOPAMIDOL-300					
AP	HOSPIRA	61%	N74898 003	Dec 30, 1997	May CAHN
AP		61%	N75005 002	Feb 24, 1998	May CAHN
IOPAMIDOL-300 IN PLASTIC CONTAINER					
AP	HOSPIRA	61%	N74636 003	Dec 30, 1997	May CAHN
AP		61%	N74637 001	Apr 03, 1997	May CAHN
IOPAMIDOL-370					
AP	HOSPIRA	76%	N74898 004	Dec 30, 1997	May CAHN
AP		76%	N75005 003	Feb 24, 1998	May CAHN
IOPAMIDOL-370 IN PLASTIC CONTAINER					
AP	HOSPIRA	76%	N74636 004	Dec 30, 1997	May CAHN

IOPANOIC ACID

TABLET; ORAL			
TELEPAQUE			
@ GE HEALTHCARE	500MG	N08032 001	May DISC

IOPROMIDE

INJECTABLE; INJECTION					
ULTRAVIST (PHARMACY BULK)					
+	BERLEX	49.9%	N21425 003	Mar 12, 2004	Mar NEWA
+		62.3%	N21425 001	Sep 20, 2002	Mar CPOT
+		76.9%	N21425 002	Sep 20, 2002	Mar CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION			
VASCORAY			
@ MALLINCKRODT	52%;26%	N16783 001	Jun DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION					
IPRATROPIUM BROMIDE					
AN	HOLOPACK INTL	0.02%	N75693 001	Jan 26, 2001	Apr CAHN

ISOFLURANE

LIQUID; INHALATION					
ISOFLURANE					
AN	HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May CAHN

ISONIAZID

INJECTABLE; INJECTION				
NYDRAZID				
+	SANDOZ	100MG/ML	N08662 001	Feb CAHN
TABLET; ORAL				
ISONIAZID				
>D>	@ AXIOM PHARM	100MG	N80136 001	Aug CAHN
>D> AA		300MG	N83633 001	Aug CAHN
>A>	@ MUTUAL PHARM	100MG	N80136 001	Aug CAHN

TABLET; ORAL

ISONIAZID
MUTUAL PHARM 300MG

N83633 001

Aug CAHN

>A> AA

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL
HOSPIRA 0.02MG/ML
0.2MG/ML

N83283 001

May CAHN

AP

ISUPREL
HOSPIRA 0.2MG/ML

N10515 001

May CAHN

AP +

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE
@ HALSEY 5MG
10MG
20MG
30MG
@ MUTUAL PHARM 5MG
10MG
20MG
30MG

N86166 002 Sep 19, 1986 Aug CAHN
N86169 001 Sep 19, 1986 Aug CAHN
N86167 001 Sep 19, 1986 Aug CAHN
N87564 001 Sep 18, 1986 Aug CAHN
N86166 002 Sep 19, 1986 Aug CAHN
N86169 001 Sep 19, 1986 Aug CAHN
N86167 001 Sep 19, 1986 Aug CAHN
N87564 001 Sep 18, 1986 Aug CAHN

>D>

>D>

>D>

>D>

>A>

>A>

>A>

>A>

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE
@ HALSEY 2.5MG
5MG
10MG
2.5MG
@ MUTUAL PHARM 5MG
10MG

N84204 001 Sep 18, 1986 Aug CAHN
N86168 001 Sep 18, 1986 Aug CAHN
N87545 001 Sep 18, 1986 Aug CAHN
N84204 001 Sep 18, 1986 Aug CAHN
N86168 001 Sep 18, 1986 Aug CAHN
N87545 001 Sep 18, 1986 Aug CAHN

>D>

>D>

>D>

>A>

>A>

>A>

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR
SCHERING PLOUGH 30MG
60MG

N20225 001 Aug 12, 1993 Apr CRLD
N20225 002 Aug 12, 1993 Apr CRLD

AB

AB

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE
EON 100MG
SPORANOX
JANSSEN PHARMA 100MG

N76104 001 May 28, 2004 May NEWA
N20083 001 Sep 11, 1992 May CFTG

AB

AB +

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL
HOSPIRA EQ 50MG BASE/ML
EQ 100MG BASE/ML

N74549 001 Jun 27, 1996 May CAHN
N74549 002 Jun 27, 1996 May CAHN

AP

AP

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE
ALTANA 2%
TEVA 2%

N76294 001 Apr 28, 2004 Apr NEWA
N75581 001 Apr 25, 2000 Apr CRLD

AB

AB +

CREAM; TOPICAL

NIZORAL				
@ JANSSEN PHARMA	2%		N19084	001 Dec 31, 1985 Apr DISC
SHAMPOO; TOPICAL				
KETOCONAZOLE				
AB CLAY PARK	2%		N76419	001 Jan 07, 2004 Jan NEWA
NIZORAL				
AB + MCNEIL CONS SPECLT	2%		N19927	001 Aug 31, 1990 Jan CFTG
SUSPENSION; ORAL				
NIZORAL				
@ JANSSEN PHARMA	100MG/5ML		N70767	001 Nov 07, 1986 Jul CAHN
TABLET; ORAL				
NIZORAL				
AB + JANSSEN PHARMA	200MG		N18533	001 Jul CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION				
KETOROLAC TROMETHAMINE				
AP AMPHASTAR PHARM	15MG/ML		N76209	001 Jul 21, 2004 Jul NEWA
AP	30MG/ML		N76209	002 Jul 21, 2004 Jul NEWA
AP APOTEX	15MG/ML		N76722	001 Jul 27, 2004 Jul NEWA
AP	30MG/ML		N76722	002 Jul 27, 2004 Jul NEWA
AP BAXTER HLTHCARE	15MG/ML		N75772	001 Jul 21, 2004 Jul NEWA
AP	30MG/ML		N75772	002 Jul 21, 2004 Jul NEWA
AP + BEDFORD	15MG/ML		N75222	001 Apr 26, 1999 Jan CRLD
AP +	30MG/ML		N75222	002 Apr 26, 1999 Jan CRLD
@ HOSPIRA	15MG/ML		N74801	001 Jun 05, 1997 May CAHN
AP	15MG/ML		N74802	001 Jun 05, 1997 May CAHN
AP	15MG/ML		N74993	001 Jan 27, 1999 May CAHN
@	30MG/ML		N74801	002 Jun 05, 1997 May CAHN
AP	30MG/ML		N74802	002 Jun 05, 1997 May CAHN
AP	30MG/ML		N74993	002 Jan 27, 1999 May CAHN
TORADOL				
@ ROCHE PALO	15MG/ML		N19698	001 Nov 30, 1989 Jan DISC
@	30MG/ML		N19698	002 Nov 30, 1989 Jan DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC				
ZADITOR				
+ NOVARTIS	EQ 0.025% BASE		N21066	001 Jul 02, 1999 Feb CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION				
LABETALOL HCL				
AP HOSPIRA	5MG/ML		N75239	001 Nov 29, 1999 May CAHN
AP	5MG/ML		N75240	001 Nov 29, 1999 May CAHN

LAMIVUDINE

TABLET; ORAL				
EPIVIR				
GLAXOSMITHKLINE	150MG		N20564	001 Nov 17, 1995 May CRLD
+	300MG		N20564	003 Jun 24, 2002 May CRLD

LAMOTRIGINE

TABLET; ORAL
LAMICTAL
+ GLAXOSMITHKLINE 25MG N20241 005 Dec 27, 1994 Apr CRLD
200MG N20241 003 Dec 27, 1994 Apr CRLD

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL
PREVACID
TAP PHARM 15MG/PACKET N21281 001 May 03, 2001 Jul CDFR
+ 30MG/PACKET N21281 002 May 03, 2001 Jul CDFR

INJECTABLE; INTRAVENOUS
PREVACID IV
+ TAP PHARM 30MG/VIAL N21566 001 May 27, 2004 May NEWA

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
PREVACID
TAP PHARM 15MG N21428 001 Aug 30, 2002 Jul CDFR
+ 30MG N21428 002 Aug 30, 2002 Jul CDFR

LEFLUNOMIDE

TABLET; ORAL
ARAVA
+ AVENTIS PHARMS 100MG N20905 003 Sep 10, 1998 Jul CMFD

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
>D AP PHARMACHEMIE USA EQ 100MG BASE/VIAL N89915 001 Apr 17, 1997 Aug DISC
>A AP @ EQ 100MG BASE/VIAL N89915 001 Apr 17, 1997 Aug DISC
LEUCOVORIN CALCIUM PRESERVATIVE FREE
AP BIGMAR BIOREN PHARMS EQ 200MG BASE/VIAL N40258 001 Feb 26, 1999 Jul CAHN
+ EQ 500MG BASE/VIAL N40286 001 Feb 26, 1999 Jul CAHN
AP + HOSPIRA EQ 10MG BASE/ML N40147 001 Jun 25, 1997 May CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
@ PURDUE PHARMA LP EQ 2.5MG BASE/ML N20997 001 Aug 05, 1999 May DISC
@ EQ 5MG BASE/ML N20997 002 Aug 05, 1999 May DISC
@ EQ 7.5MG BASE/ML N20997 003 Aug 05, 1999 May DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN
+ NOVARTIS EQ 0.05% BASE N20219 001 Nov 10, 1993 Feb CAHN

LEVOCARNITINE

SOLUTION; ORAL
CARNITOR
>D + SIGMA TAU 1GM/10ML N19257 001 Apr 10, 1986 Aug CFTG
>A AA + 1GM/10ML N19257 001 Apr 10, 1986 Aug CFTG
>A LEVCARNITINE
AA LYNE 1GM/10ML N76851 001 Aug 10, 2004 Aug NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
IQUIX
+ SANTEN 1.5%

N21571 001 Mar 01, 2004 Mar NEWA

LEVONORGESTREL

TABLET; ORAL
PLAN B
+ DURAMED 0.75MG

N21045 001 Jul 28, 1999 Feb CAHN

LEVOTHYROXINE SODIUM*

TABLET; ORAL
LEVOLET
BX VINTAGE 0.025MG
BX 0.05MG
BX 0.075MG
BX 0.088MG
BX 0.1MG
BX 0.112MG
BX 0.125MG
BX 0.137MG
BX 0.15MG
BX 0.175MG
BX 0.2MG
BX 0.3MG

N21137 001 Jun 06, 2003 Jul CAHN
N21137 002 Jun 06, 2003 Jul CAHN
N21137 003 Jun 06, 2003 Jul CAHN
N21137 004 Jun 06, 2003 Jul CAHN
N21137 005 Jun 06, 2003 Jul CAHN
N21137 006 Jun 06, 2003 Jul CAHN
N21137 007 Jun 06, 2003 Jul CAHN
N21137 008 Jun 06, 2003 Jul CAHN
N21137 009 Jun 06, 2003 Jul CAHN
N21137 010 Jun 06, 2003 Jul CAHN
N21137 011 Jun 06, 2003 Jul CAHN
N21137 012 Jun 06, 2003 Jul CAHN

LEVO-T
AB2, ALARA PHARM 0.025MG
AB3
AB2, 0.05MG
AB3
AB2, 0.075MG
AB3
AB2, 0.088MG
AB3
AB2, 0.1MG
AB3
AB2, 0.112MG
AB3
AB2, 0.125MG
AB3
AB2, 0.137MG
AB3
AB2, 0.15MG
AB3
AB2, 0.175MG
AB3
AB2, 0.2MG
AB3
AB2, + 0.3MG

N21342 001 Mar 01, 2002 Jun CTEC
N21342 002 Mar 01, 2002 Jun CTEC
N21342 003 Mar 01, 2002 Jun CTEC
N21342 004 Mar 01, 2002 Jun CTEC
N21342 005 Mar 01, 2002 Jun CTEC
N21342 006 Mar 01, 2002 Jun CTEC
N21342 007 Mar 01, 2002 Jun CTEC
N21342 012 Dec 08, 2003 Jun CTEC
N21342 008 Mar 01, 2002 Jun CTEC
N21342 009 Mar 01, 2002 Jun CTEC
N21342 010 Mar 01, 2002 Jun CTEC
N21342 011 Mar 01, 2002 Jun CTEC

LEVOTHYROXINE SODIUM
AB1, MYLAN 0.025MG
AB2,
AB3
AB1, 0.05MG
AB2,
AB3
AB1, 0.075MG
AB2,
AB3
AB1, 0.088MG

N76187 001 Jun 05, 2002 Jun CTEC
N76187 002 Jun 05, 2002 Jun CTEC
N76187 003 Jun 05, 2002 Jun CTEC
N76187 004 Jun 05, 2002 Jun CTEC

TABLET; ORAL

LEVOTHYROXINE SODIUM

NEWA	AB1, AB2, AB3	MYLAN	0.1MG	N76187 005 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.112MG	N76187 006 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.125MG	N76187 007 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.15MG	N76187 008 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.175MG	N76187 009 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.2MG	N76187 010 Jun 05, 2002 Jun CTEC
CAHN	AB1, AB2, AB3		0.3MG	N76187 011 Jun 05, 2002 Jun CTEC
CAHN	LEVOXYL			
CAHN	AB1, AB3	JONES PHARMA	0.025MG	N21301 001 May 25, 2001 Jun CTEC
CAHN	AB1, AB3		0.05MG	N21301 002 May 25, 2001 Jun CTEC
CAHN	AB1, AB3		0.075MG	N21301 003 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.088MG	N21301 004 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.1MG	N21301 005 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.112MG	N21301 006 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.125MG	N21301 007 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.137MG	N21301 008 May 25, 2001 Jun CTEC
CTEC	AB3		0.137MG	N21301 009 May 25, 2001 Jul CTEC
CTEC	AB1, AB3		0.15MG	N21301 010 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.175MG	N21301 011 May 25, 2001 Jun CTEC
CTEC	AB1, AB3		0.2MG	N21301 012 May 25, 2001 Jun CTEC
CTEC	AB1, + AB3		0.3MG	N21301 012 May 25, 2001 Jun CTEC
CTEC	SYNTHROID			
CTEC	AB2	ABBOTT	0.025MG	N21402 001 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.05MG	N21402 002 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.075MG	N21402 003 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.088MG	N21402 004 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.1MG	N21402 005 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.112MG	N21402 006 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.125MG	N21402 007 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.137MG	N21402 008 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.15MG	N21402 009 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.175MG	N21402 010 Jul 24, 2002 Jun CFTG
CTEC	AB2		0.2MG	N21402 012 Jul 24, 2002 Jun CFTG
CTEC	AB2 +		0.3MG	N21402 011 Jul 24, 2002 Jun CFTG
CTEC	UNITHROID			
CTEC	AB1, AB3	STEVENS J	0.025MG	N21210 001 Aug 21, 2000 Jun CTEC
CTEC	AB1, AB3		0.05MG	N21210 002 Aug 21, 2000 Jun CTEC

TABLET; ORAL

UNITHROID

AB1,	STEVENS J	0.075MG	N21210 003	Aug 21, 2000	Jun	CTEC
AB3		0.088MG	N21210 004	Aug 21, 2000	Jun	CTEC
AB1,		0.1MG	N21210 005	Aug 21, 2000	Jun	CTEC
AB3		0.112MG	N21210 006	Aug 21, 2000	Jun	CTEC
AB1,		0.125MG	N21210 007	Aug 21, 2000	Jun	CTEC
AB3		0.15MG	N21210 008	Aug 21, 2000	Jun	CTEC
AB1,		0.175MG	N21210 009	Aug 21, 2000	Jun	CTEC
AB3		0.2MG	N21210 010	Aug 21, 2000	Jun	CTEC
AB1,		0.3MG	N21210 011	Aug 21, 2000	Jun	CTEC
AB3						

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

>A>	@ BAXTER HLTHCARE	1%	N80407 001		Aug	CAHN
>A>	@	2%	N80407 002		Aug	CAHN
>D>	@ ELKINS SINN	1%	N80407 001		Aug	CAHN
>D>	@	2%	N80407 002		Aug	CAHN
AP	HOSPIRA	0.5%	N88328 001	May 17, 1984	May	CAHN
AP		1%	N40013 001	Jun 23, 1995	May	CAHN
AP		1%	N83158 001		May	CAHN
AP		1%	N88329 001	May 17, 1984	May	CAHN
	@	1.5%	N88330 001	May 17, 1984	May	CAHN
AP		2%	N40078 001	Jun 23, 1995	May	CAHN
AP		2%	N83158 002		May	CAHN
AP		2%	N88294 001	May 17, 1984	May	CAHN
AP		2%	N88331 001	May 17, 1984	May	CAHN
AP		20%	N83158 003		May	CAHN
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER						
@ B BRAUN 200MG/100ML			N18967 001	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.2% IN DEXTROSE 5%						
AP	HOSPIRA	200MG/100ML	N83158 005		May	CAHN
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	200MG/100ML	N18388 001		May	CAHN
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER						
@ B BRAUN 400MG/100ML			N18967 002	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.4% IN DEXTROSE 5%						
AP	HOSPIRA	400MG/100ML	N83158 006		May	CAHN
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	400MG/100ML	N18388 002		May	CAHN
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER						
@ B BRAUN 800MG/100ML			N18967 003	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	800MG/100ML	N18388 003	Nov 05, 1982	May	CAHN
LIDOCAINE HCL IN PLASTIC CONTAINER						
AP	HOSPIRA	0.5%	N88325 001	Jul 31, 1984	May	CAHN
AP		1%	N88299 001	Jul 31, 1984	May	CAHN
AP		1.5%	N88326 001	Jul 31, 1984	May	CAHN
AP		2%	N88327 001	Jul 31, 1984	May	CAHN
AP		10%	N88367 001	Jul 31, 1984	May	CAHN

INJECTABLE; INJECTION

AP	LIDOCAINE HCL IN PLASTIC CONTAINER HOSPIRA	20%	N88368 001 Jul 31, 1984 May CAHN
AP	LIDOCAINE HCL PRESERVATIVE FREE HOSPIRA	1%	N80408 001 May CAHN
AP		1.5%	N80408 002 May CAHN
AP		4%	N88295 001 May 17, 1984 May CAHN
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER HOSPIRA	1%	N40302 001 Sep 28, 1998 May CAHN
AP		2%	N40302 002 Sep 28, 1998 May CAHN

INJECTABLE; SPINAL

+ HOSPIRA	LIDOCAINE HCL 5% AND DEXTROSE 7.5% 5%	N83914 001 May CAHN
-----------	--	---------------------

SOLUTION; TOPICAL

AT	LTA II KIT HOSPIRA	4%	N80409 001 May CAHN
AT		4%	N88542 001 Jul 31, 1984 May CAHN
AT	PEDIATRIC LTA KIT HOSPIRA	2%	N85995 001 May CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN			
+ PFIZER	2%;50MG/ML	N60567 001 Feb CRLD	
+	2%;125MG/ML	N60567 002 Feb CRLD	

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE			
AB ABLE	150MG	N76823 001 Jun 29, 2004 Jun NEWA	
AB	300MG	N76823 002 Jun 29, 2004 Jun NEWA	
AB	600MG	N76823 003 Jun 29, 2004 Jun NEWA	
AB + ROXANE	600MG	N17812 003 Jan 28, 1987 Jun CFTG	
TABLET, EXTENDED RELEASE; ORAL			
LITHIUM CARBONATE			
AB ROXANE	450MG	N76691 001 Jan 05, 2004 Jan NEWA	

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM @ JANSSEN PHARMA	1MG/5ML	N19037 001 Jul 31, 1984 Jul CAHN
-----------------------------	---------	----------------------------------

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM			
>A> AP BAXTER HLTHCARE	2MG/ML	N74496 001 Sep 28, 1998 Aug CAHN	
>A> AP	4MG/ML	N74496 002 Sep 28, 1998 Aug CAHN	
>D> AP ELKINS SINK	2MG/ML	N74496 001 Sep 28, 1998 Aug CAHN	
>D> AP	4MG/ML	N74496 002 Sep 28, 1998 Aug CAHN	
AP HOSPIRA	2MG/ML	N74243 001 Apr 12, 1994 May CAHN	
AP	2MG/ML	N74280 001 May 27, 1994 May CAHN	
AP	2MG/ML	N74282 001 May 27, 1994 May CAHN	
AP	2MG/ML	N74300 001 Apr 12, 1994 May CAHN	
AP	4MG/ML	N74243 002 Apr 12, 1994 May CAHN	
AP	4MG/ML	N74280 002 May 27, 1994 May CAHN	
AP	4MG/ML	N74282 002 May 27, 1994 May CAHN	
AP	4MG/ML	N74300 003 Mar 19, 1997 May CAHN	

TABLET; ORAL

LORAZEPAM

>D>	@ HALSEY	0.5MG	N70472 001	Dec 10, 1985	Aug	CAHN
>D>	@	1MG	N70473 001	Dec 10, 1985	Aug	CAHN
>D>	@	2MG	N70474 001	Dec 10, 1985	Aug	CAHN
>A>	@ MUTUAL PHARM	0.5MG	N70472 001	Dec 10, 1985	Aug	CAHN
>A>	@	1MG	N70473 001	Dec 10, 1985	Aug	CAHN
>A>	@	2MG	N70474 001	Dec 10, 1985	Aug	CAHN

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX	10MG	N21316 001	Jun 26, 2002	Jul	CTNA
	20MG	N21316 002	Jun 26, 2002	Jul	CTNA
	40MG	N21316 003	Jun 26, 2002	Jul	CTNA
+	60MG	N21316 004	Jun 26, 2002	Jul	CTNA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	KOS	20MG;500MG	N21249 001	Dec 17, 2001	Feb	CRLD
@		20MG;750MG	N21249 002	Dec 17, 2001	Jul	DISC
+		20MG;750MG	N21249 002	Dec 17, 2001	Feb	CRLD

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

SULFAMYLYON

>D>	+	MYLAN	5%	N19832 003	Jun 05, 1998	Aug	CAHN
>A>	+	MYLAN BERTEK	5%	N19832 003	Jun 05, 1998	Aug	CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001	May	CAHN
---------	---	------------	-----	------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 001	May	CAHN	
	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637 002	Jul 08, 1982	May	CAHN

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 002	Jul 08, 1982	May	CAHN
---------	---	------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	HOSPIRA	500MG/ML	N75151 001	Apr 25, 2000	May	CAHN
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	HOSPIRA	1GM/100ML	N20488 001	Jul 11, 1995	May	CAHN
+		2GM/100ML	N20488 002	Jul 11, 1995	May	CAHN
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
+	HOSPIRA	80MG/ML	N20309 002	Jun 24, 1994	May	CAHN
+		4GM/100ML	N20309 001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL
OVIDE
+ TARO PHARMS NORTH 0.5% N18613 001 Aug 02, 1982 Jun CAHN

MANGANESE CHLORIDE

INJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER
HOSPIRA EQ 0.1MG MANGANESE/ML N18962 001 Jun 26, 1986 May CAHN

MANNITOL

	INJECTABLE; INJECTION		
	MANNITOL 10%		
	@ HOSPIRA 10GM/100ML	N16269 002	May CAHN
AP	MANNITOL 10% IN PLASTIC CONTAINER		
	HOSPIRA 10GM/100ML	N19603 002 Jan 08, 1987 May CAHN	
	MANNITOL 15%		
	@ HOSPIRA 15GM/100ML	N16269 003	May CAHN
AP	MANNITOL 15% IN PLASTIC CONTAINER		
	HOSPIRA 15GM/100ML	N19603 003 Jan 08, 1990 May CAHN	
	MANNITOL 20%		
	@ HOSPIRA 20GM/100ML	N16269 004	May CAHN
AP	MANNITOL 20% IN PLASTIC CONTAINER		
	HOSPIRA 20GM/100ML	N19603 004 Jan 08, 1990 May CAHN	
	MANNITOL 25%		
	@ HOSPIRA 12.5GM/50ML	N16269 005	May CAHN
AP		N16269 006 Aug 25, 1994 May CAHN	
	MANNITOL 5%		
	@ HOSPIRA 5GM/100ML	N16269 001	May CAHN
AP	MANNITOL 5% IN PLASTIC CONTAINER		
	HOSPIRA 5GM/100ML	N19603 001 Jan 08, 1987 May CAHN	

MANNITOL; SORBITOL

	SOLUTION; IRRIGATION		
	SORBITOL-MANNITOL		
	@ HOSPIRA 540MG/100ML;2.7GM/100ML	N80224 001	May CAHN
AT	SORBITOL-MANNITOL IN PLASTIC CONTAINER		
	HOSPIRA 540MG/100ML;2.7GM/100ML	N17636 001	May CAHN
AT		N18316 001	May CAHN

MAPROTILINE HYDROCHLORIDE

	TABLET; ORAL		
	LUDIOMIL		
	@ NOVARTIS 25MG	N17543 001	Jun DISC
	@ 50MG	N17543 002	Jun DISC
	@ 75MG	N17543 003 Sep 30, 1982 Jun DISC	
AB	MAPROTILINE HCL		
+ MYLAN 50MG	N72285 001 Oct 03, 1988 Jun CRLD		

MEDROXYPROGESTERONE ACETATE

	INJECTABLE; INJECTION		
	DEPO-PROVERA		
AB	+ PHARMACIA AND UPJOHN 150MG/ML	N20246 001 Oct 29, 1992 Jul CFTG	
	MEDROXYPROGESTERONE ACETATE		
AB	GENSIA SICOR PHARMS 150MG/ML	N76553 001 Jul 28, 2004 Jul NEWA	

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM 7.5MG/5ML

N21530 001 Jun 01, 2004 Jun NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

PERGONAL

@ SERONO

75 IU/AMP;75 IU/AMP

N17646 001

May DISC

REPRONEX

+ FERRING

75 IU/VIAL;75 IU/VIAL

N21047 001 Aug 27, 1999 May CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP + HOSPIRA 25MG/ML

N21171 001

May CAHN

AP + 50MG/ML

N21171 002

May CAHN

AP + 75MG/ML

N21171 003

May CAHN

AP + 100MG/ML

N21171 004

May CAHN

MEPERIDINE HCL PRESERVATIVE FREE

AP + HOSPIRA 10MG/ML

N88432 001 Aug 16, 1984 May CAHN

TABLET; ORAL

MEPERIDINE HCL

>D> AA AXIOM PHARM 50MG

N80448 001

Aug CAHN

>D> AA 100MG

N80448 002

Aug CAHN

>A> AA MUTUAL PHARM 50MG

N80448 001

Aug CAHN

>A> AA 100MG

N80448 002

Aug CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

AP + HOSPIRA 1%

N12250 001

May CAHN

AP + 1.5%

N12250 005

May CAHN

AP + 2%

N12250 002

May CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

>D> @ HALSEY 200MG

N80699 001

Aug CAHN

>D> @ 400MG

N80699 002

Aug CAHN

>A> @ MUTUAL PHARM 200MG

N80699 001

Aug CAHN

>A> @ 400MG

N80699 002

Aug CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB PROMETHEUS LABS 50MG

N40461 001 Feb 11, 2004 Feb NEWA

AB ROXANE 50MG

N40528 001 Feb 13, 2004 Feb NEWA

PURINETHOL

AB + TEVA 50MG

N09053 002

Feb CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

>D> + SHIRE LABS 250MG

N20049 001 May 10, 1993 Aug CRLD

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

>A> SHIRE LABS 250MG N20049 001 May 10, 1993 Aug CRLD
>A> + 500MG N20049 002 Jul 08, 2004 Aug NEWA

MESNA

INJECTABLE; INTRAVENOUS

AP MESNA BEDFORD 100MG/ML N75739 001 Jan 09, 2004 Jan NEWA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL
@ NOVARTIS EQ 25MG BASE/ML N16997 001 May DISC
TABLET; ORAL
SERENTIL
@ NOVARTIS EQ 25MG BASE N16774 002 May DISC
@ EQ 100MG BASE N16774 004 May DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORTAMET
BX ANDRX 500MG N21574 001 Apr 27, 2004 Apr NEWA
+ 1GM N21574 002 Apr 27, 2004 Apr NEWA
GLUCOPHAGE XR
AB BRISTOL MYERS SQUIBB 500MG N21202 001 Oct 13, 2000 Jan CFTG
METFORMIN HCL
AB ANDRX PHARMS 500MG N76172 001 Jun 16, 2004 Jun NEWA
AB IMPAX LABS 500MG N76249 001 Jul 30, 2004 Jul NEWA
AB IVAX PHARMS 500MG N76545 001 Dec 01, 2003 Jan NEWA
AB RANBAXY 500MG N76413 001 Jun 18, 2004 Jun NEWA
AB TEVA 500MG N76269 001 Jun 18, 2004 Jun NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HCL
>D> AA EON 5MG N40241 001 May 29, 1998 Aug DISC
>A> @ 5MG N40241 001 May 29, 1998 Aug DISC
AA MALLINCKRODT 5MG N40517 001 Apr 27, 2004 Apr NEWA
AA 10MG N40517 002 Apr 27, 2004 Apr NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN
AB + OVATION PHARMS 5MG N05378 002 Feb CFTG
METHAMPHETAMINE HCL
AB ABLE 5MG N40529 001 Feb 25, 2004 Feb NEWA

METHENAMINE HIPPURATE

TABLET; ORAL

UREX
>D> AB 3M 1GM N16151 001 Aug CAHN
>A> AB VATRING PHARMS 1GM N16151 001 Aug CAHN

METHIMAZOLE

TABLET; ORAL
TAPAZOLE

AB	KING PHARMS	5MG	N07517 002	Mar	CAHN
AB		10MG	N07517 004	Mar	CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

>D>	@ HALSEY	500MG	N84488 001	Aug	CAHN
>D>	@	750MG	N84486 001	Aug	CAHN
>A>	@ MUTUAL PHARM	500MG	N84488 001	Aug	CAHN
>A>	@ .	750MG	N84486 001	Aug	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE

AP	BIGMAR BIOPEN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
	METHOTREXATE PRESERVATIVE FREE					
AP	BIGMAR BIOPEN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL
METHYL AMINOLEVULINATE

+	PHOTOCURE ASA	16.8%	N21415 001	Jul 27, 2004	Jul	NEWA
---	---------------	-------	------------	--------------	-----	------

METHYLDOPA

TABLET; ORAL
METHYLDOPA

	@ ACCORD HEALTH	125MG	N70070 003	Oct 15, 1985	Jun	CAHN
AB		250MG	N70084 001	Oct 15, 1985	Jun	CAHN
AB		500MG	N70085 001	Oct 15, 1985	Jun	CAHN
>D>	@ HALSEY	125MG	N70073 001	Oct 09, 1986	Aug	CAHN
>D>	@	250MG	N70060 001	Oct 09, 1986	Aug	CAHN
>D>	@	500MG	N70074 001	Oct 09, 1986	Aug	CAHN
>A>	@ MUTUAL PHARM	125MG	N70073 001	Oct 09, 1986	Aug	CAHN
>A>	@	250MG	N70060 001	Oct 09, 1986	Aug	CAHN
>A>	@	500MG	N70074 001	Oct 09, 1986	Aug	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987	May	CAHN
AP		50MG/ML	N70699 001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX	CELLTECH PHARMS	10MG	N21259 003	May 27, 2003	May	CTEC
	RITALIN LA					
	NOVARTIS	10MG	N21284 004	Apr 10, 2004	Apr	NEWA
BX		10MG	N21284 004	Apr 10, 2004	May	CTEC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

CAHN	AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001	May	CAHN	
CAHN	AP		EQ 125MG BASE/VIAL	N85855 001	May	CAHN	
CAHN	AP		EQ 500MG BASE/VIAL	N85854 001	May	CAHN	
CAHN	AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
CAHN	AP		EQ 1GM BASE/VIAL	N85852 001	May	CAHN	
CAHN	AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN
CAHN		METHYLPREDNISOLONE SODIUM SUCCINATE					
CAHN	AP	AM PHARM.	EQ 40MG BASE/VIAL	N40583 001	Jul 30, 2004	Jul	NEWA
CAHN	AP		EQ 125MG BASE/VIAL	N40583 002	Jul 30, 2004	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N40612 001	Aug 12, 2004	Aug	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

CAHN	AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
CAHN	@		EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
CAHN	AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
CAHN	AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
CAHN	AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN

TABLET; ORAL

METOCLOPRAMIDE HCL

>D>	@	HALSEY	EQ 10MG BASE	N70660 001	Feb 10, 1987	Aug	CAHN
>A>	@	MUTUAL PHARM	EQ 10MG BASE	N70660 001	Feb 10, 1987	Aug	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

CAHN	AB	ROXANE	10MG	N76482 002	Apr 29, 2004	Apr	NEWA
CAHN	AB	TEVA	2.5MG	N76600 001	Jan 06, 2004	Jan	NEWA
CAHN	AB		5MG	N76833 001	Mar 01, 2004	Mar	NEWA
CAHN	AB	WATSON LABS	10MG	N76891 001	Jul 21, 2004	Jul	NEWA
CAHN		MYKROX					
CAHN		@ CELLTECH PHARMS	0.5MG	N19532 001	Oct 30, 1987	Jan	DISC
CAHN							

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

CAHN	AP	HOSPIRA	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
CAHN	AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN

TABLET; ORAL

LOPRESSOR

CAHN	AB	NOVARTIS	100MG	N17963 002		Mar	CRLD
CAHN		METOPROLOL TARTRATE					
CAHN		CARACO	25MG	N76670 001	Jan 15, 2004	Jan	NEWA
CAHN	AB		25MG	N76670 001	Jan 15, 2004	Mar	CTEC
CAHN	AB	MYLAN	25MG	N76704 001	Jan 16, 2004	Mar	CTEC
CAHN	+		25MG	N76704 001	Jan 16, 2004	Jan	NEWA
CAHN	AB		50MG	N76704 002	Jan 16, 2004	Jan	NEWA
CAHN	AB	+	100MG	N76704 003	Jan 16, 2004	Mar	CRLD
CAHN	AB		100MG	N76704 003	Jan 16, 2004	Jan	NEWA

METRONIDAZOLE

CAPSULE; ORAL				
METRONIDAZOLE				
AB KALI LABS	375MG		N76522 001	Jan 29, 2004 Jan NEWA
CREAM; TOPICAL				
METROCREAM				
AB + GALDERMA LABS LP	0.75%		N20531 001	Sep 20, 1995 May CFTG
METRONIDAZOLE				
AB ALTANA	0.75%		N76408 001	May 28, 2004 May NEWA
INJECTABLE; INJECTION				
METRONIDAZOLE IN PLASTIC CONTAINER				
AP + HOSPIRA	500MG/100ML		N18890 002	Nov 18, 1983 May CAHN
TABLET; ORAL				
METRONIDAZOLE				
>D> @ HALSEY	250MG		N18818 001	Feb 16, 1983 Aug CAHN
>D> @	500MG		N18818 002	Feb 16, 1983 Aug CAHN
>A> @ MUTUAL PHARM	250MG		N18818 001	Feb 16, 1983 Aug CAHN
>A> @	500MG		N18818 002	Feb 16, 1983 Aug CAHN

MICONAZOLE

INJECTABLE; INJECTION				
MONISTAT				
@ JANSSEN PHARMA	10MG/ML		N18040 001	Jul CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION				
MIDAZOLAM HCL				
@ HOSPIRA	EQ 1MG BASE/ML		N75293 001	Jun 20, 2000 May DISC
AP	EQ 1IMG BASE/ML		N75409 002	Jun 20, 2000 May CAHN
AP	EQ 1IMG BASE/ML		N75856 001	Jun 13, 2002 May CAHN
AP +	EQ 1IMG BASE/ML		N75857 001	Jul 22, 2002 May CAHN
@	EQ 5MG BASE/ML		N75293 002	Jun 20, 2000 May DISC
AP	EQ 5MG BASE/ML		N75409 001	Jun 20, 2000 May CAHN
AP	EQ 5MG BASE/ML		N75856 002	Jun 13, 2002 May CAHN
AP +	EQ 5MG BASE/ML		N75857 002	Jul 22, 2002 May CAHN
AP INTL MEDICATION	EQ 1IMG BASE/ML		N76020 001	Jul 16, 2004 Jul NEWA
AP	EQ 5MG BASE/ML		N76020 002	Jul 16, 2004 Jul NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL				
MIDODRINE HCL				
AB EON	10MG		N76514 003	Jul 02, 2004 Jul NEWA
AB IMPAX PHARMS	2.5MG		N76449 001	May 27, 2004 May NEWA
AB	5MG		N76449 002	May 27, 2004 May NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION				
MILRINONE LACTATE				
AP HOSPIRA	EQ 1IMG BASE/ML		N75884 001	May 28, 2002 May CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
>A> AP B BRAUN	EQ 20MG BASE/100ML		N76414 001	Aug 18, 2004 Aug NEWA
AP HOSPIRA	EQ 20MG BASE/100ML		N75885 001	May 28, 2002 May CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL						
MINOCYCLINE HCL						
AB MEDICIS	EQ 50MG BASE		N65131 001	Apr 16, 2003	Jan	CFTG
AB	EQ 75MG BASE		N65131 002	Apr 16, 2003	Jan	CFTG
AB +	EQ 100MG BASE		N65131 003	Apr 16, 2003	Jan	CFTG
AB RANBAXY	EQ 50MG BASE		N65156 001	Jan 06, 2004	Jan	NEWA
AB	EQ 75MG BASE		N65156 002	Jan 06, 2004	Jan	NEWA
AB	EQ 100MG BASE		N65156 003	Jan 06, 2004	Jan	NEWA

MIRTAZAPINE

TABLET; ORAL						
MIRTAZAPINE						
CARACO	7.5MG		N76541 004	Apr 22, 2004	Apr	NEWA
AB	15MG		N76541 001	Apr 22, 2004	Apr	NEWA
AB	30MG		N76541 002	Apr 22, 2004	Apr	NEWA
AB	45MG		N76541 003	Apr 22, 2004	Apr	NEWA

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL						
MOBAN						
@ ENDO PHARMS	20MG/ML		N17938 001		May	DISC
TABLET; ORAL						
MOBAN						
@ ENDO PHARMS	100MG		N17111 008		May	DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL						
DEPODUR						
SKYEPHARMA	10MG/ML		N21671 001	May 18, 2004	May	NEWA
	15MG/1.5ML(10MG/ML)		N21671 002	May 18, 2004	May	NEWA
+	20MG/2ML(10MG/ML)		N21671 003	May 18, 2004	May	NEWA
INJECTABLE; INJECTION						
MORPHINE SULFATE						
AP + HOSPIRA	0.5MG/ML		N19917 001	Oct 30, 1992	May	CAHN
AP	0.5MG/ML		N71849 001	May 11, 1988	May	CAHN
AP	0.5MG/ML		N73509 001	Sep 30, 1992	May	CAHN
AP +	1MG/ML		N19916 001	Oct 30, 1992	May	CAHN
AP	1MG/ML		N71850 001	May 11, 1988	May	CAHN
AP	1MG/ML		N73510 001	Sep 30, 1992	May	CAHN
TABLET, EXTENDED RELEASE; ORAL						
MORPHINE SULFATE						
AB KV PHARM	15MG		N76733 001	May 19, 2004	May	NEWA
AB	60MG		N76720 001	May 19, 2004	May	NEWA
ORAMORPH SR						
BC + AAIPHARMA	60MG		N19977 002	Aug 15, 1991	Mar	CRLD

MYCOPHENOLIC ACID

TABLET, EXTENDED RELEASE; ORAL						
MYFORTIC						
NOVARTIS	180MG		N50791 001	Feb 27, 2004	Feb	NEWA
+	360MG		N50791 002	Feb 27, 2004	Feb	NEWA

NABILONE

CAPSULE; ORAL
CESAMET
@ VALEANT 1MG

N18677 001 Dec 26, 1985 Jan CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM
+ SANDOZ EQ 500MG BASE/VIAL
AP EQ 1GM BASE/VIAL
AP EQ 2GM BASE/VIAL
AP EQ 10GM BASE/VIAL

N62527 001 Aug 02, 1984 Jun CAHN
N62527 002 Aug 02, 1984 Jun CAHN
N62527 003 Aug 02, 1984 Jun CAHN
N62527 004 Aug 02, 1984 Jun CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN
MERZ PHARMS 1%
GEL; TOPICAL
NAFTIN
+ MERZ PHARMS 1%

N19599 001 Feb 29, 1988 Jul CAHN
N19356 001 Jun 18, 1990 Jul CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL
AP HOSPIRA 10MG/ML
AP 10MG/ML
AP 20MG/ML
AP 20MG/ML
@ KING PHARMS 10MG/ML

N70914 001 Feb 03, 1989 May CAHN
N70915 001 Feb 03, 1989 May CAHN
N70916 001 Feb 03, 1989 May CAHN
N70918 001 Feb 03, 1989 May CAHN
N74471 001 Mar 19, 1998 Mar DISC

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID
>D> @ HALSEY 250MG
>D> @ 500MG
>D> @ 1GM
>A> @ MUTUAL PHARM 250MG
>A> @ 500MG
>A> @ 1GM

N70270 001 Jun 29, 1988 Aug CAHN
N70271 001 Jun 29, 1988 Aug CAHN
N70272 001 Jun 29, 1988 Aug CAHN
N70270 001 Jun 29, 1988 Aug CAHN
N70271 001 Jun 29, 1988 Aug CAHN
N70272 001 Jun 29, 1988 Aug CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE
>A> @ BAXTER HLTHCARE 0.4MG/ML
>A> @ 0.4MG/ML
>D> @ ELKINS SINK 0.4MG/ML
>D> @ ELKINS SINK PHARM 0.4MG/ML
NALOXONE HCL
AP HOSPIRA 0.02MG/ML
AP 0.02MG/ML
AP 0.02MG/ML
@ 0.4MG/ML
AP 0.4MG/ML
AP 0.4MG/ML
AP 0.4MG/ML

N70298 001 Sep 24, 1986 Aug CAHN
N70299 001 Sep 24, 1986 Aug CAHN
N70299 001 Sep 24, 1986 Aug CAHN
N70298 001 Sep 24, 1986 Aug CAHN
N70171 001 Sep 24, 1986 May CAHN
N70252 001 Jan 16, 1987 May CAHN
N70253 001 Jan 16, 1987 May CAHN
N70172 001 Sep 24, 1986 May CAHN
N70254 001 Jan 07, 1987 May CAHN
N70255 001 Jan 07, 1987 May CAHN
N70256 001 Jan 07, 1987 May CAHN

INJECTABLE; INJECTION

NALOXONE HCL

AP HOSPIRA

0.4MG/ML

N70257 001 Jan 07, 1987 May CAHN

NAPROXEN

TABLET; ORAL

>D>	NAPROXEN					
>D>	@ BAXTER HLTHCARE	250MG		N74105	001	Dec 21, 1993 Aug DISC
>A>	@	375MG		N74105	002	Dec 21, 1993 Aug DISC
>A>	@	500MG		N74105	003	Dec 21, 1993 Aug DISC
>A>	LEDERLE	250MG		N74105	001	Dec 21, 1993 Aug DISC
>D> AB		375MG		N74105	002	Dec 21, 1993 Aug DISC
>D> AB		500MG		N74105	003	Dec 21, 1993 Aug DISC
>D> AB	AB WESTWARD	250MG		N76494	001	Jan 14, 2004 Jan NEWA
AB		375MG		N76494	002	Jan 14, 2004 Jan NEWA
AB		500MG		N76494	003	Jan 14, 2004 Jan NEWA

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN						
AB + STAT TRADE	EQ 375MG BASE			N20353	001	Jan 05, 1996 Jun CAHN
AB +	EQ 500MG BASE			N20353	002	Jan 05, 1996 Jun CAHN
@	EQ 750MG BASE			N20353	003	Jan 05, 1996 Jun CAHN

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE						
+ KING PHARMS	1.75MG/INH			N19660	001	Dec 30, 1992 Jan CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

@ ROXANE	50MG		N76196	001	Sep 16, 2003 Jul DISC
@	100MG		N76196	002	Sep 16, 2003 Jul DISC
@	150MG		N76196	003	Sep 16, 2003 Jul DISC
@	200MG		N76196	004	Sep 16, 2003 Jul DISC
@	250MG		N76196	005	Sep 16, 2003 Jul DISC

NIACIN

TABLET; ORAL

NIACIN

@ MK LABS	500MG		N83525	001	Feb DISC
@ TABLICAPS	500MG		N84237	001	Feb DISC
AA + UPSHER SMITH	500MG		N40378	001	May 03, 2000 Feb CRLD
*					

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE					
AB2 MARTEC	90MG		N75414	003	Mar 23, 2004 Mar NEWA
PROCARDIA XL					
AB2 + PFIZER	90MG		N19684	003	Sep 06, 1989 Mar CPTG

NITAZOXANIDE

TABLET; ORAL

ALINIA

+ ROMARK 500MG N21497 001 Jul 21, 2004 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

>D> AB MYLAN 100MG N74967 002 Jul 09, 1997 Aug DISC
>A> @ 100MG N74967 002 Jul 09, 1997 Aug DISC
>A> AB 100MG N77025 001 Aug 18, 2004 Aug NEWANITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB + PROCTER AND GAMBLE 75MG;25MG N20064 001 Dec 24, 1991 Mar CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
AB MYLAN 75MG;25MG N76648 001 Mar 22, 2004 Apr CPOT
AB EQ 75MG BASE;25MG N76648 001 Mar 22, 2004 Mar NEWANITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

>A> AB1 KREMERS URBAN 0.2MG/HR N75115 001 Aug 10, 2004 Aug NEWA
>A> AB1 0.4MG/HR N75115 002 Aug 10, 2004 Aug NEWA

INJECTABLE; INJECTION

NITROGLYCERIN

AP + HOSPIRA 5MG/ML N18531 001 May CAHN
NITROGLYCERIN IN DEXTROSE 5%
AP HOSPIRA 0.1MG/ML N74083 001 Oct 26, 1994 May CAHN
AP 10MG/100ML N71846 001 Aug 31, 1990 May CAHN
AP 20MG/100ML N71847 001 Aug 31, 1990 May CAHN
AP 40MG/100ML N71848 001 Aug 31, 1990 May CAHNNIZATIDINE

SOLUTION; ORAL

AXID

+ RELIANT PHARMS 15MG/ML N21494 001 May 25, 2004 May NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP + HOSPIRA EQ 1MG BASE/ML N07513 001 May CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL

@ LILLY EQ 10MG BASE N14684 001 Jun DISC
@ EQ 25MG BASE N14684 002 Jun DISCNYSTATIN

PASTILLE; ORAL

MYCOSTATIN

@ BRISTOL MYERS SQUIBB 200,000 UNITS N50619 001 Apr 09, 1987 Jun DISC

POWDER; TOPICALNYSTATIN

AT	KALI LABS	100,000 UNITS/GM	N65138 001 Jul 23, 2004 Jul NEWA
AT	TANON	100,000 UNITS/GM	N65203 001 Jul 15, 2004 Jul NEWA
SUSPENSION; ORAL			
>D>	MYCOSTATIN		
>D>	AA + APOTHECON	100,000 UNITS/ML	N61533 001 Aug DISC
>A>	@	100,000 UNITS/ML	N61533 001 Aug DISC
	NILSTAT		
AA	+ GLENMARK PHARMA	100,000 UNITS/ML	N50299 001 Jul CAHN
	NYSTATIN		
>D>	AA BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001 Feb 28, 1994 Aug DISC
>A>	@	100,000 UNITS/ML	N64042 001 Feb 28, 1994 Aug DISC
>D>	AA MORTON GROVE	100,000 UNITS/ML	N62512 001 Oct 29, 1984 Aug CRLD
>A>	AA +	100,000 UNITS/ML	N62512 001 Oct 29, 1984 Aug CRLD
>D>	AA UDL	100,000 UNITS/ML	N64142 001 Jun 25, 1998 Aug CAHN
>A>	AA VISTAPHARM	100,000 UNITS/ML	N64142 001 Jun 25, 1998 Aug CAHN
>D>	NYSTEX		
>D>	AA SAVAGE LABS	100,000 UNITS/ML	N62519 001 Jul 06, 1984 Aug DISC
>A>	@	100,000 UNITS/ML	N62519 001 Jul 06, 1984 Aug DISC

OFLOXACINSOLUTION/DROPS; OPHTHALMICOCUFLOX

AT	+ ALLERGAN	0.3%	N19921 001 Jul 30, 1993 May CFTG
	OFLOXACIN		
AT	ALCON	0.3%	N76231 001 May 14, 2004 May NEWA
AT	BAUSCH AND LOMB	0.3%	N76622 001 May 14, 2004 May NEWA
AT	HI TECH PHARMA	0.3%	N76615 001 May 14, 2004 May NEWA
AT	NOVEX	0.3%	N76513 001 May 14, 2004 May NEWA
SOLUTION/DROPS; OTIC			
	FLOXIN OTIC		
+ DAIICHI	0.3%	N20799 001 Dec 16, 1997 Jun CTNA	
SOLUTION; OPHTHALMIC			
	OFLOXACIN		
>A> AT	PHARMAFORCE	EQ 0.3% BASE	N76830 001 Aug 31, 2004 Aug NEWA

OLANZAPINEINJECTABLE; INTRAMUSCULARZYPREXA

+ LILLY	10MG/VIAL	N21253 001 Mar 29, 2004 Mar NEWA
---------	-----------	----------------------------------

OLSALAZINE SODIUMCAPSULE; ORALDIPENTUM

+ CELLTECH PHARMS	250MG	N19715 001 Jul 31, 1990 Jun CAHN
-------------------	-------	----------------------------------

OMEPRAZOLEFOR SUSPENSION; ORALZEGERID

+ SANTARUS	20MG/PACKET	N21636 001 Jun 15, 2004 Jun NEWA
------------	-------------	----------------------------------

OXACILLIN SODIUMINJECTABLE; INJECTIONOXACILLIN SODIUM

AP + APOTHECON	EQ 250MG BASE/VIAL	N61490 001 Mar CRLD
----------------	--------------------	---------------------

INJECTABLE; INJECTIONOXACILLIN SODIUM

AP	+	APOTHECON	EQ 2GM BASE/VIAL	N61490 004	Mar	NEWA	
AP			EQ 2GM BASE/VIAL	N62737 002	Dec 23, 1986	Mar	CRLD
AP	+	SANDOZ	EQ 250MG BASE/VIAL	N61490 001		Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N61490 002		Jun	CAHN
AP	+		EQ 1GM BASE/VIAL	N61490 003		Jun	CAHN
AP	+		EQ 2GM BASE/VIAL	N61490 004		Jun	CAHN
AP	+		EQ 10GM BASE/VIAL	N61490 006	May 09, 1991	Jun	CAHN

OXAMNIQUINECAPSULE; ORALVANSIL@ PFIZER

250MG

N18069 001

Mar DISC

OXAZEPAMCAPSULE; ORALOXAZEPAM

>D>	@ HALSEY	10MG	N70957 001	Aug 10, 1987	Aug	CAHN
>D>	@	15MG	N71025 001	Aug 10, 1987	Aug	CAHN
>D>	@	30MG	N71026 001	Aug 10, 1987	Aug	CAHN
>A>	@ MUTUAL PHARM	10MG	N70957 001	Aug 10, 1987	Aug	CAHN
>A>	@	15MG	N71025 001	Aug 10, 1987	Aug	CAHN
>A>	@	30MG	N71026 001	Aug 10, 1987	Aug	CAHN

SERAX

>D> AB	ALPHARMA	15MG	N15539 004		Aug	DISC
>A>	@	15MG	N15539 004		Aug	DISC

TABLET; ORALOXAZEPAM

>D>	@ HALSEY	15MG	N70683 001	Jan 16, 1987	Aug	CAHN
>A>	@ MUTUAL PHARM	15MG	N70683 001	Jan 16, 1987	Aug	CAHN

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALOXYCODONE HCL

AB	ENDO PHARMS	10MG	N75923 001	Mar 23, 2004	Mar	NEWA
AB		20MG	N75923 002	Mar 23, 2004	Mar	NEWA
AB		40MG	N75923 003	Mar 23, 2004	Mar	NEWA
AB	TEVA	80MG	N76168 001	Mar 23, 2004	Mar	NEWA

OXYCONTIN

AB	PURDUE PHARMA LP	10MG	N20553 001	Dec 12, 1995	Mar	CFTG
AB		20MG	N20553 002	Dec 12, 1995	Mar	CFTG
AB	+	40MG	N20553 003	Dec 12, 1995	Mar	CFTG
AB	+	80MG	N20553 004	Jan 06, 1997	Mar	CFTG
AB		80MG	N20553 004	Jan 06, 1997	Jun	CRLD

TABLET; ORALOXYCODONE HCL

AB	AMIDE PHARM	15MG	N76636 001	Feb 06, 2004	Feb	NEWA
AB		30MG	N76636 002	Feb 06, 2004	Feb	NEWA
AB	MALLINCKRODT	15MG	N76758 001	Jun 30, 2004	Jun	NEWA
AB		30MG	N76758 002	Jun 30, 2004	Jun	NEWA

ROXICODONE

AB	AAIPHARMA	15MG	N21011 001	Aug 31, 2000	Feb	CFTG
AB		30MG	N21011 002	Aug 31, 2000	Feb	CFTG

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

AP	HOSPIRA	1MG/ML	N72320 001 Jan 19, 1989 May CAHN
AP		2MG/ML	N72321 001 Jan 19, 1989 May CAHN

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
ABBOTT

	0.002MG/ML	N20819 002 Feb 01, 2000 Mar NEWA
--	------------	----------------------------------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAROXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75716 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75716 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75716 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75716 004 Mar 08, 2004 Mar NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001 Mar 08, 2004 Mar NEWA
AB		EQ 20MG BASE	N75566 002 Mar 08, 2004 Mar NEWA
AB		EQ 30MG BASE	N75566 003 Mar 08, 2004 Mar NEWA
AB		EQ 40MG BASE	N75566 004 Mar 08, 2004 Mar NEWA

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA
+ LILLY

EQ 500MG BASE/VIAL	N21462 001 Feb 04, 2004 Feb NEWA
--------------------	----------------------------------

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP	HOSPIRA	300MG/VIAL	N73479 001 Jun 30, 1992 May CAHN
----	---------	------------	----------------------------------

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN

+ HOSPIRA

EQ 30MG BASE/ML	N16194 001	May CAHN
-----------------	------------	----------

>A> PENTETATE CALCIUM TRISODIUM

>A> SOLUTION; INHALATION, INTRAVENOUS

>A> PENTETATE CALCIUM TRISODIUM

>A> + HAMELN PHARMS	EQ 1GM/5ML (EQ 200MG/ML)	N21749 001 Aug 11, 2004 Aug NEWA
---------------------	--------------------------	----------------------------------

>A> PENTETATE ZINC TRISODIUM

>A> SOLUTION; INHALATION, INTRAVENOUS

>A> PENTETATE ZINC TRISODIUM

>A> + HAMELN PHARMS	EQ 1GM/5ML (EQ 200MG/ML)	N21751 001 Aug 11, 2004 Aug NEWA
---------------------	--------------------------	----------------------------------

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

@ OVATION PHARMS

30MG

N84095 001	May	DISC
------------	-----	------

@

100MG

N83245 001	May	DISC
------------	-----	------

SODIUM PENTOBARBITAL

+ VALEANT PHARM INTL

100MG

N83264 001	May	CRLD
------------	-----	------

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
 ELMIRON
 + ORTHO MCNEIL PHARM 100MG

N20193 001 Sep 26, 1996 Jun CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
 BONTRIL PDM
 >D> AA AMARIN PHARMS 35MG N85272 001 Aug CAHN
 >A> AA VALEANT 35MG N85272 001 Aug CAHN

PHENYLBUTAZONE

CAPSULE; ORAL
 PHENYLBUTAZONE
 >D> @ HALSEY 100MG N88994 001 Dec 04, 1985 Aug CAHN
 >A> @ MUTUAL PHARM 100MG N88994 001 Dec 04, 1985 Aug CAHN
 TABLET; ORAL
 PHENYLBUTAZONE
 >D> @ HALSEY 100MG N88863 001 Dec 04, 1985 Aug CAHN
 >A> @ MUTUAL PHARM 100MG N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL
 PHENYTOIN
 AB TARO 125MG/5ML N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION
 PHENYTOIN SODIUM
 @ HOSPIRA 50MG/ML N89521 001 Mar 17, 1987 May CAHN
 @ 50MG/ML N89744 001 Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION
 VITAMIN K1
 BP HOSPIRA 1MG/0.5ML N87954 001 Jul 25, 1983 May CAHN
 BP 10MG/ML N87955 001 Jul 25, 1983 May CAHN
 @ 10MG/ML N87956 001 Jul 25, 1983 May CAHN

PIPERACILLIN SODIUM

INJECTABLE; INJECTION
 PIPERACILLIN
 + AM PHARM EQ 40GM BASE/VIAL N65157 001 Jul 12, 2004 Jul NEWA

PIPERAZINE CITRATE

SYRUP; ORAL
 MULTIFUGE
 @ BLULINE EQ 500MG BASE/SML N09452 001 Jul DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
 GLYCOLAX
 AA SCHWARZ PHARMA 17GM/SCOOPFUL N76652 001 Jul 02, 2004 Jul NEWA
 MIRALAX
 AA + BRAINTREE 17GM/SCOOPFUL N20698 001 Feb 18, 1999 Jul CFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001	Apr 22, 1991	Feb	CFTG
AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 002	Nov 18, 1994	Feb	CFTG
		TRILYTE					
AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491 001	Feb 05, 2004	Feb	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001	Apr 30, 1986	May	CAHN
---	---------	---	------------	--------------	-----	------

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N18896 001	Jul 20, 1984	May	CAHN
---	---------	---------	------------	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@ HOSPIRA	1MEQ/ML	N80205 003	May	CAHN
	@	1MEQ/ML	N83345 003	May	CAHN
	+	1.5MEQ/ML	N83345 001	May	CAHN
AP	+	2MEQ/ML	N80205 001	May	CAHN
AP		2MEQ/ML	N83345 002	May	CAHN
	@	2.4MEQ/ML	N80205 004	May	CAHN
	@	3.2MEQ/ML	N80205 005	May	CAHN

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

	@ HOSPIRA	14.9MG/ML	N20161 005	Nov 30, 1992	May	CAHN
	@	745MG/100ML	N20161 001	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	29.8MG/ML	N20161 006	Aug 11, 1998	May	CAHN
		@	1.49GM/100ML	N20161 002	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.24GM/100ML	N20161 003	Aug 11, 1998	May	CAHN
----	---	---------	--------------	------------	--------------	-----	------

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.98GM/100ML	N20161 004	Aug 11, 1998	May	CAHN
----	---	---------	--------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

>A	AB	EURAND	20MEQ	N76368 001	Aug 18, 2004	Aug	NEWA
----	----	--------	-------	------------	--------------	-----	------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HOSPIRA	149MG/100ML;900MG/100ML	N19686 001	Oct 17, 1988	May	CAHN	

AP	POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	HOSPIRA	298MG/100ML;900MG/100ML	N19686 002	Oct 17, 1988	May	CAHN	

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

@ HOSPIRA

370MG/VIAL;1.75GM/VIAL;36GM/VIAL N13025 001

May CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

@ EVERYLIFE

2.5MG

N84439 002

May DISC

@

5MG

N84439 003

May DISC

@ SPERTI

1MG

N80358 001

May DISC

@

2.5MG

N80358 002

May DISC

@

5MG

N80358 003

May DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA PADDOCK EQ 5MG BASE/5ML

N75988 001 May 25, 2004 May NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

VASOCIDIN

>D> AT + NOVARTIS EQ 0.23% PHOSPHATE;10% N18988 001 Aug 26, 1988 Aug CAHN
>A> AT + EQ 0.23% PHOSPHATE;10% N18988 001 Aug 26, 1988 Aug CAHNPREDNISONE

TABLET; ORAL

DELTASONE

@ PHARMACIA AND UPJOHN 20MG

N09986 007

Jul DISC

PREDNISONE

>D> @ HALSEY 5MG N80701 001 Aug CAHN
>D> @ 10MG N86595 001 Aug CAHN
>D> @ 20MG N84634 001 Aug CAHN
>D> @ 50MG N86596 001 Aug CAHN
>A> @ MUTUAL PHARM 5MG N80701 001 Aug CAHN
>A> @ 10MG N86595 001 Aug CAHN
>A> @ 20MG N84634 001 Aug CAHN
>A> @ 50MG N86596 001 Aug CAHN
AB + ROXANE 20MG N87342 001 Jul CRLD
>D> AB SANDOZ 20MG N85813 001 Aug DISC
>A> @ 20MG N85813 001 Aug DISC
AB WEST WARD 2.5MG N40538 001 Jan 08, 2004 Jan NEWAPROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP HOSPIRA 100MG/ML
AP 500MG/ML
AP 500MG/MLN89069 001 Feb 12, 1986 May CAHN
N89070 001 Feb 12, 1986 May CAHN
N89537 001 Aug 25, 1987 May CAHNPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP + HOSPIRA 1% N85362 003 May CAHN
AP + 2% N85362 004 May CAHN

INJECTABLE; INJECTION

NOVOCAIN

+ HOSPIRA	10%	
PROCaine HCl		
AP HOSPIRA	1%	
AP	2%	

N86797 001	May	CAHN
N80416 001	May	CAHN
N80416 002	May	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989	Aug	CAHN
AP BEDFORD	EQ 5MG BASE/ML	N40540 001	May 28, 2004	May	NEWA
>D> AP ELKINS SINK	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989	Aug	CAHN
AP HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCl

AP BEDFORD LABS	25MG/ML	N40524 001	Mar 17, 2004	Mar	NEWA
AP	50MG/ML	N40524 002	Mar 17, 2004	Mar	NEWA
AP HOSPIRA	25MG/ML	N40372 001	Jun 08, 2000	May	CAHN
AP	50MG/ML	N40372 002	Jun 08, 2000	May	CAHN
AP	50MG/ML	N83838 002		May	CAHN

SYRUP; ORAL

PROMETH PLAIN					
@ ALPHARMA	6.25MG/5ML	N85953 001		Feb	DISC
PROMETHAZINE HCl					
AA + HI TECH PHARMA	6.25MG/5ML	N40026 001	Sep 25, 1998	Feb	CRLD
AA	6.25MG/5ML	N40026 001	Sep 25, 1998	May	CRLD

PROMETHAZINE PLAIN

AA + MORTON GROVE	6.25MG/5ML	N87953 001	Nov 15, 1982	May	CRLD
-------------------	------------	------------	--------------	-----	------

TABLET; ORAL

PHENERGAN

AB WYETH PHARMS INC	12.5MG	N07935 002		Jul	CFTG
---------------------	--------	------------	--	-----	------

AB	25MG	N07935 003		Jul	CTEC
----	------	------------	--	-----	------

AB +	50MG	N07935 004		Jul	CTEC
------	------	------------	--	-----	------

PROMETHAZINE HCl

AB ABLE	12.5MG	N40558 001	Jul 01, 2004	Jul	NEWA
---------	--------	------------	--------------	-----	------

AB	25MG	N40558 002	Jul 01, 2004	Jul	NEWA
----	------	------------	--------------	-----	------

AB	50MG	N40558 003	Jul 01, 2004	Jul	NEWA
----	------	------------	--------------	-----	------

>D> @ HALSEY	12.5MG	N84555 001		Aug	CAHN
--------------	--------	------------	--	-----	------

>D> @	25MG	N84554 001		Aug	CAHN
-------	------	------------	--	-----	------

>D> @	50MG	N84557 001		Aug	CAHN
-------	------	------------	--	-----	------

>A> @ MUTUAL PHARM	12.5MG	N84555 001		Aug	CAHN
--------------------	--------	------------	--	-----	------

>A> @	25MG	N84554 001		Aug	CAHN
-------	------	------------	--	-----	------

>A> @	50MG	N84557 001		Aug	CAHN
-------	------	------------	--	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HCl

AB PLIVA	150MG	N76550 001	Apr 23, 2004	Apr	NEWA
AB	225MG	N76550 002	Apr 23, 2004	Apr	NEWA
AB	300MG	N76550 003	Apr 23, 2004	Apr	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL					
DARVON					
>D>	+	AAIPHARMA LLC	32MG	N10997 001	Aug DISC
>A>	@		32MG	N10997 001	Aug DISC
PROPOXYPHENE HCL					
>D>	@	HALSEY	65MG	N83186 001	Aug CAHN
>A>	@	MUTUAL PHARM	65MG	N83186 001	Aug CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION					
PROPRANOLOL					
AP		AM PHARM PARTNERS	1MG/ML	N75826 001	Aug 31, 2001 Jan NEWA
TABLET; ORAL					
PROPRANOLOL HCL					
>D>	@	HALSEY	10MG	N70319 001	Oct 22, 1985 Aug CAHN
>D>	@		20MG	N70320 001	Oct 22, 1985 Aug CAHN
>D>	@		40MG	N70103 001	Oct 22, 1985 Aug CAHN
>D>	@		60MG	N70321 001	Sep 24, 1986 Aug CAHN
>D>	@		80MG	N70322 001	Aug 04, 1986 Aug CAHN
>A>	@	MUTUAL PHARM	10MG	N70319 001	Oct 22, 1985 Aug CAHN
>A>	@		20MG	N70320 001	Oct 22, 1985 Aug CAHN
>A>	@		40MG	N70103 001	Oct 22, 1985 Aug CAHN
>A>	@		60MG	N70321 001	Sep 24, 1986 Aug CAHN
>A>	@		80MG	N70322 001	Aug 04, 1986 Aug CAHN

PROPYLTIOURACIL

TABLET; ORAL					
PROPYLTIOURACIL					
>D>	@	HALSEY	50MG	N83982 001	Aug CAHN
>A>	@	MUTUAL PHARM	50MG	N83982 001	Aug CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION					
PROTAMINE SULFATE					
+>	AM PHARM PARTNERS	10MG/ML	N89454 001	Apr 07, 1987 Mar CRLD	
@>	LILLY	10MG/ML	N06460 002	Mar DISC	

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL					
VIVACTIL					
@>	ODYSSEY PHARMS	5MG	N16012 001	Jun CAHN	
@>		10MG	N16012 002	Jun CAHN	

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL					
ZANTAC 25					
GLAXOSMITHKLINE EQ 25MG BASE				N20251 003	Apr 01, 2004 Apr NEWA

RIBAVIRIN

CAPSULE; ORAL					
REBETOL					
AB	+	SCHERING PLOUGH RES	200MG	N20903 002	Jul 25, 2001 Apr CFTG
RIBASPHERE					
AB		THREE RIVERS PHARMS	200MG	N76203 001	Apr 06, 2004 Apr NEWA

CAPSULE; ORAL RIBAVIRIN AB SANDOZ	200MG	N76192 001 Apr 06, 2004 Apr NEWA
RIFAXIMIN		
TABLET; ORAL XIFAXAN + SALIX PHARMS	200MG	N21361 001 May 25, 2004 May NEWA
RISPERIDONE		
INJECTABLE; INTRAMUSCULAR RISPERDAL CONSTA JANSSEN PHARMA	25MG/VIAL 37.5MG/VIAL + 50MG/VIAL	N21346 001 Oct 29, 2003 Jul CAHN N21346 002 Oct 29, 2003 Jul CAHN N21346 003 Oct 29, 2003 Jul CAHN
TABLET, ORALLY DISINTEGRATING; ORAL RISPERDAL JANSSEN PHARMA	0.5MG 1MG 2MG	N21444 001 Apr 02, 2003 Jun CAHN N21444 002 Apr 02, 2003 Jun CAHN N21444 003 Apr 02, 2003 Jun CAHN
RITODRINE HYDROCHLORIDE		
INJECTABLE; INJECTION RITODRINE HCL + HOSPIRA	10MG/ML 15MG/ML	N71618 001 Feb 28, 1991 May CAHN N71619 001 Feb 28, 1991 May CAHN
+ RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	30MG/100ML	N71438 001 Jan 22, 1991 May CAHN
ROCURONIUM BROMIDE		
INJECTABLE; INJECTION ZEMURON @ ORGANON USA INC	10MG/ML 10MG/ML	N20214 002 Mar 17, 1994 Jul DISC N20214 002 Mar 17, 1994 Jun CMFD
ZEMURON (P/F) + ORGANON USA INC	50MG/5ML(10MG/ML) 100MG/10ML(10MG/ML)	N20214 001 Mar 17, 1994 Jul CPOT N20214 003 Mar 17, 1994 Jul NEWA
ROPINIROLE HYDROCHLORIDE		
TABLET; ORAL REQUIP GLAXOSMITHKLINE	EQ 5MG BASE	N20658 005 Sep 19, 1997 May CRLD
SAFFLOWER OIL; SOYBEAN OIL		
INJECTABLE; INJECTION LIPOSYN II 10% + HOSPIRA	5%;5% (5GM/100ML)	N18997 001 Aug 27, 1984 May CAHN
LIPOSYN II 20% + HOSPIRA	10%;10% (10GM/100ML)	N18991 001 Aug 27, 1984 May CAHN
SECRETIN SYNTHETIC HUMAN		
FOR SOLUTION; INTRAVENOUS HUMAN SECRETIN + CHIRHOCLIN	16UGM/VIAL	N21256 001 Apr 09, 2004 Apr NEWA

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
 SECREMAX
 + CHIRHOCLIN 16UGM/VIAL

N21136 001 Apr 04, 2002 Jul CAIN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
 SELEGILINE HCL
 >D> AB + SOMERSET 5MG
 >A> @ 5MG

N19334 001 Jun 05, 1989 Aug DISC
N19334 001 Jun 05, 1989 Aug DISCSEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
 RENAGEL
 @ GENZYME 403MG

N20926 001 Oct 30, 1998 Jun DISC

SIROLIMUS

TABLET; ORAL
 RAPAMUNE
 WYETH PHARMS INC 2MG
 + 5MG

N21110 002 Aug 22, 2002 Feb CRLD
N21110 003 Feb 23, 2004 Feb NEWASODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
 SODIUM ACETATE IN PLASTIC CONTAINER
 + HOSPIRA 2MEQ/ML

N18893 001 May 04, 1983 May CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP + HOSPIRA 9MG/ML N18800 001 Oct 29, 1982 May CAHN

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP HOSPIRA 450MG/100ML N18090 001 May CAHN

AP 450MG/100ML N19759 001 Jun 08, 1988 May CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA 9MG/ML N18803 001 Oct 29, 1982 May CAHN

9MG/ML

N19217 001 Jul 13, 1984 May CAHN

9MG/ML

N19217 001 Jul 13, 1984 Jul CRLD

9MG/ML

N19465 002 Jul 15, 1985 May CAHN

900MG/100ML

N16366 001 May CAHN

900MG/100ML

N19465 001 Jul 15, 1985 May CAHN

900MG/100ML

N19480 001 Sep 17, 1985 May CAHN

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA 2.5MEQ/ML

N18897 001 Jul 20, 1984 May CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT HOSPIRA 450MG/100ML N17670 001 May CAHN

@ 450MG/100ML

N18380 001 May CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT HOSPIRA 900MG/100ML N17514 001 May CAHN

900MG/100ML

N18314 001 May CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

+ WATSON PHARMS 62.5MG/5ML

N20955 001 Feb 18, 1999 Feb CAHN

Jul CAIN

SODIUM IODIDE, I-131

SOLUTION; ORAL

SODIUM IODIDE I 131

@ CIS 50mCi/ML

N17315 001

Apr DISC

Aug DISC

Aug DISC

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP HOSPIRA 1.87GM/100ML

N18249 001

May CAHN

Jun DISC

SODIUM LACTATE IN PLASTIC CONTAINER

HOSPIRA 5MEQ/ML

N18947 001 Sep 05, 1984 May CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

AP + HOSPIRA 25MG/ML
+ 50MG/VIAL

N71961 001 Aug 01, 1988 May CAHN

N70566 001 Jun 09, 1986 May CAHN

Feb CRLD

Feb NEWA

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

HOSPIRA 142MG/ML;276MG/ML

N18892 001 May 10, 1983 May CAHN

May CAHN

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

SAIZEN

@ SERONO 6MG/VIAL

N19764 001 Oct 08, 1996 May DISC

May CAHN

SEROSTIM

BX SERONO 4MG/VIAL
@ 8.8MG/VIAL

N20604 003 Jul 25, 1997 Jan CTEC

N20604 004 Sep 06, 2001 Jan DISC

May CAHN

ZORBTIVE

AP @ SERONO INC 4MG/VIAL
@ 5MG/VIAL

N21597 001 Dec 01, 2003 May DISC

N21597 002 Dec 01, 2003 May DISC

May CAHN

N21597 003 Dec 01, 2003 May DISC

May CAHN

May CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB2 MUTUAL PHARM 80MG
AB2 120MG
AB2 160MG
AB2 TEVA 80MG
AB2 120MG
AB2 160MG

N76576 001 Apr 08, 2004 Apr NEWA

N76576 002 Apr 08, 2004 Apr NEWA

N76576 003 Apr 08, 2004 Apr NEWA

N76883 001 Jul 26, 2004 Jul NEWA

N76883 002 Jul 26, 2004 Jul NEWA

N76883 003 Jul 26, 2004 Jul NEWA

May CAHN

May CAHN

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

AP + HOSPIRA 10%

N18969 001 Sep 24, 1984 May CAHN

May CAHN

May CAHN

INJECTABLE; INJECTION

LIPOSYN III 20%

AP + HOSPIRA 20%

N18970 001 Sep 25, 1984 May CAHN

LIPOSYN III 30%

AP + HOSPIRA 30%

N20181 001 Jan 13, 1998 May CAHN

SPARFLOXACIN

TABLET; ORAL

ZAGAM

@ MYLAN

200MG

N20677 001 Dec 19, 1996 Mar DISC

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

>D> AB HALSEY 25MG

N87265 001 Aug CAHN

>A> AB MUTUAL PHARM 25MG

N87265 001 Aug CAHN

STAVUDINE

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

@ BRISTOL MYERS SQUIBB 37.5MG

N21453 001 Dec 31, 2002 Jun DISC

@ 50MG

N21453 002 Dec 31, 2002 Jun DISC

@ 75MG

N21453 003 Dec 31, 2002 Jun DISC

@ 100MG

N21453 004 Dec 31, 2002 Jun DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP + SABEX 2002 20MG/ML

N08453 002 Jul CAHN

@ 50MG/ML

N08453 003 Jul CAHN

+ 500MG/VIAL

N08453 001 Jul CAHN

+ 1GM/VIAL

N08453 004 Jul CAHN

QUELICIN

AP + HOSPIRA 20MG/ML

N08845 006 May CAHN

QUELICIN PRESERVATIVE FREE

AP + HOSPIRA 20MG/ML

N08845 001 May CAHN

@ 50MG/ML

N08845 002 May CAHN

+ 100MG/ML

N08845 004 May CAHN

SUCRALFATE

TABLET; ORAL

CARAFATE

AB + AXCAN SCANDIPHARM 1GM

N18333 001 Feb CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

>A> AP BAXTER HLTHCARE EQ 0.05MG BASE/ML

N74413 001 Dec 15, 1995 Aug CAHN

>D> AP ELKINS SINK EQ 0.05MG BASE/ML

N74413 001 Dec 15, 1995 Aug CAHN

SULFENTANIL CITRATE

AP HOSPIRA EQ 0.05MG BASE/ML

N74534 001 Dec 11, 1996 May CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

AT NOVARTIS 10%

N80025 001 Mar CMFD

SULFACYTINE

CAHN >D> TABLET; ORAL
 CAHN >D> RENOQUID
 CAHN >D> + GLENWOOD 250MG N17569 001 Aug DISC
 CAHN >D> @ 250MG N17569 001 Aug DISC
 >R>

SULFAMETHOXAZOLE; TRIMETHOPRIM

DISC INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

DISC >A> AP BAXTER HLTHCARE 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Aug CAHN
 >A> AP 80MG/ML;16MG/ML N70628 001 Dec 29, 1987 Aug CAHN
 >D> AP ELKINS SINK 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Aug CAHN
 >D> AP 80MG/ML;16MG/ML N70628 001 Dec 29, 1987 Aug CAHN
 CAHN AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN

CAHN TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

DISC >D> @ HALSEY 400MG;80MG N70006 001 Nov 14, 1984 Aug CAHN
 >A> @ MUTUAL PHARM 400MG;80MG N70006 001 Nov 14, 1984 Aug CAHN
 DISC >D> SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
 DISC >D> @ HALSEY 800MG;160MG N70007 001 Nov 14, 1984 Aug CAHN
 DISC >A> @ MUTUAL PHARM 800MG;160MG N70007 001 Nov 14, 1984 Aug CAHN

TECHNETIUM TC-99M APCITIDE

DISC INJECTABLE; INJECTION

ACUTECT

BERLEX LABS N/A

N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

DISC INJECTABLE; INJECTION

NEO TECT KIT

CAHN + BERLEX LABS N/A

N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

CAHN INJECTABLE; INJECTION

DRAXIMAGE MDP

CAHN AP + DRAXIMAGE N/A

N18035 001 May CTNA

TECHNETIUM TC-99M SESTAMIBI KIT

CAHN INJECTABLE; INJECTION

CARDIOLITE

CAHN + BRISTOL MYERS SQUIBB N/A

N19785 001 Dec 21, 1990 Jul CRLD

TELITHROMYCIN

CAHN TABLET; ORAL

KETEK

CAHN + AVENTIS PHARMS 400MG

N21144 001 Apr 01, 2004 Apr NEWA

TEMAZEPAM

CAHN CAPSULE; ORAL

TEMAZEPAM

CAHN >D> @ HALSEY 15MG N71174 001 Jul 10, 1986 Aug CAHN
 >D> @ 30MG N71175 001 Jul 10, 1986 Aug CAHN
 >A> @ MUTUAL PHARM 15MG N71174 001 Jul 10, 1986 Aug CAHN
 >A> @ 30MG N71175 001 Jul 10, 1986 Aug CAHN

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N20846 001 Apr 29, 1998 Jan CMFG

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AP	+	AAIPHARMA LLC	1MG/ML	N18571 001	Apr	CFTG
TERBUTALINE SULFATE						
AP		AM PHARM	1MG/ML	N76887 001	May 26, 2004	May NEWA
AP		BEDFORD	1MG/ML	N76770 001	Apr 23, 2004	Apr NEWA
AP		SICOR PHARMS	1MG/ML	N76853 001	Jul 20, 2004	Jul NEWA

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

AB	+	ORTHO MCNEIL PHARM	0.8%	N19964 001	Feb 21, 1991	Apr CFTG
TERCONAZOLE						
AB		TARO	0.8%	N75953 001	Apr 06, 2004	Apr NEWA

TESTOSTERONEFILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

>D>	BX	+	WATSON LABS	5MG/24HR	N20489 002	May 02, 1997	Aug CTEC
>A>		+		5MG/24HR	N20489 002	May 02, 1997	Aug CTEC
>D>			TESTODERM				
>D>		+	ALZA	4MG/24HR	N19762 001	Oct 12, 1993	Aug DISC
>A>		@		4MG/24HR	N19762 001	Oct 12, 1993	Aug DISC
>D>		+		6MG/24HR	N19762 002	Oct 12, 1993	Aug DISC
>A>		@		6MG/24HR	N19762 002	Oct 12, 1993	Aug DISC
>D>			TESTODERM TTS				
>D>	BX	+	ALZA	5MG/24HR	N20791 001	Dec 18, 1997	Aug DISC
>A>		@		5MG/24HR	N20791 001	Dec 18, 1997	Aug DISC

TETRACYCLINE HYDROCHLORIDECAPSULE; ORAL
TETRACYCLINE HCL

>D>	AB		AXIOM PHARM	250MG	N60736 001	Aug	CAHN
>D>	AB			500MG	N60736 002	Aug	CAHN
>A>	AB		MUTUAL PHARM	250MG	N60736 001	Aug	CAHN
>A>	AB			500MG	N60736 002	Aug	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

@ FLEMING PHARMS 65MG

N85075 003 Nov 24, 1986 Jun DISC

AEROLATE JR

@ FLEMING PHARMS 130MG

N85075 002 Nov 24, 1986 Jun DISC

AEROLATE SR

@ FLEMING PHARMS 260MG

N85075 001 Nov 24, 1986 Jun DISC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA 4MG/ML

N19211 007 Dec 14, 1984 May CAHN

AP + 40MG/100ML

N19211 001 Dec 14, 1984 May CAHN

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

CMPD	AP	+	HOSPIRA	80MG/100ML	N19211 002	Dec 14, 1984	May	CAHN
	AP	+		160MG/100ML	N19211 003	Dec 14, 1984	May	CAHN
	AP	+		200MG/100ML	N19211 004	Dec 14, 1984	May	CAHN
	AP	+		320MG/100ML	N19211 006	Jan 20, 1988	May	CAHN
	AP	+		400MG/100ML	N19211 005	Dec 14, 1984	May	CAHN

SOLUTION; ORAL

AEROLATE

@ FLEMING PHARMS 150MG/15ML

N89141 001 Dec 03, 1986 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

@ 3M 200MG
@ 250MG
@ 300MG
@ 500MGN88369 001 Jul 16, 1987 Jun DISC
N86363 002 Jul 16, 1987 Jun DISC
N88364 001 Jul 16, 1987 Jun DISC
N89132 001 Jul 16, 1987 Jun DISC

THEOPHYLLINE

CFTG	AB	ABLE	300MG	N40548 001	Apr 30, 2004	Apr	NEWA	
NEWA	AB		400MG	N40543 001	Apr 27, 2004	Apr	NEWA	
NEWA	AB		450MG	N40546 001	Apr 30, 2004	Apr	NEWA	
NEWA	AB		600MG	N40539 001	Apr 27, 2004	Apr	NEWA	
		UNIPHYL						
	AB	+	PURDUE FREDERICK	400MG	N87571 001	Sep 01, 1982	Apr	CFTG
	AB	+		600MG	N40086 001	Apr 15, 1996	Apr	CFTG

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION

THIAMINE HCL

DISC	>A>	AP	BAXTER HLTHCARE	100MG/ML	N80575 001		Aug	CAHN
DISC	>D>	AP	ELKINS SINK	100MG/ML	N80575 001		Aug	CAHN
DISC		AP	HOSPIRA	100MG/ML	N40079 001	May 03, 1996	May	CAHN

THIORIDAZINE HYDROCHLORIDETABLET; ORAL

THIORIDAZINE HCL

DISC	>D>		@ HALSEY	10MG	N88375 001	Nov 18, 1983	Aug	CAHN
	>D>		@	15MG	N88461 001	Nov 18, 1983	Aug	CAHN
	>D>		@	25MG	N87264 001	Nov 18, 1983	Aug	CAHN
	>D>	AB		50MG	N88370 001	Nov 18, 1983	Aug	CAHN
	>D>		@	100MG	N88379 001	Nov 16, 1983	Aug	CAHN
	>D>		@	150MG	N88737 001	Sep 26, 1984	Aug	CAHN
	>D>		@	200MG	N88738 001	Oct 16, 1984	Aug	CAHN
	>A>		@ MUTUAL PHARM	10MG	N88375 001	Nov 18, 1983	Aug	CAHN
	>A>		@	15MG	N88461 001	Nov 18, 1983	Aug	CAHN
	>A>		@	25MG	N87264 001	Nov 18, 1983	Aug	CAHN
	>A>	AB		50MG	N88370 001	Nov 18, 1983	Aug	CAHN
	>A>		@	100MG	N88379 001	Nov 16, 1983	Aug	CAHN
	>A>		@	150MG	N88737 001	Sep 26, 1984	Aug	CAHN
	>A>		@	200MG	N88738 001	Oct 16, 1984	Aug	CAHN

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC

ISTALOL

+ SENJU EQ 0.5% BASE
TIMOLOL MALEATE
AT HI TECH PHARMA EQ 0.5% BASEN21516 001 Jun 04, 2004 Jun NEWA
N75163 001 Sep 10, 2002 Jun CDFR

TINIDAZOLE

TABLET; ORAL

TINDAMAX

PRESUTTI LABS	250MG	
+	500MG	

N21618 001	May 17, 2004	May	NEWA
N21618 002	May 17, 2004	May	NEWA

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION

SPIRIVA

+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE	
---	----------------------	-----------------	--

N21395 001	Jan 30, 2004	Jan	NEWA
------------	--------------	-----	------

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

>A>	ACORDA	EQ 2MG BASE	N21447 001	Aug 29, 2002	Aug	CAHN
>A>		EQ 4MG BASE	N21447 002	Aug 29, 2002	Aug	CAHN
>A>	+	EQ 6MG BASE	N21447 003	Aug 29, 2002	Aug	CAHN
>D>	ELAN PHARMS	EQ 2MG BASE	N21447 001	Aug 29, 2002	Aug	CAHN
>D>		EQ 4MG BASE	N21447 002	Aug 29, 2002	Aug	CAHN
>D>	+	EQ 6MG BASE	N21447 003	Aug 29, 2002	Aug	CAHN

TABLET; ORAL

TIZANIDINE HCL

AB	TORPHARM	EQ 2MG BASE	N76533 001	Jan 16, 2004	Jan	NEWA
AB		EQ 4MG BASE	N76533 002	Jan 16, 2004	Jan	NEWA

ZANAFLEX

>A> AB	ACORDA	EQ 2MG BASE	N20397 002	Feb 04, 2000	Aug	CAHN
>A> AB	+	EQ 4MG BASE	N20397 001	Nov 27, 1996	Aug	CAHN
>D> AB	ELAN PHARMS	EQ 2MG BASE	N20397 002	Feb 04, 2000	Aug	CAHN
>D> AB	+	EQ 4MG BASE	N20397 001	Nov 27, 1996	Aug	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

@ LILLY	EQ 10MG BASE/ML	N50477 005	Jun	DISC	
@	EQ 10MG BASE/ML	N62008 004	Jun	DISC	
@	EQ 10MG BASE/ML	N62707 001	Apr 29, 1987	Jun	DISC
@	EQ 40MG BASE/ML	N62008 001		Jun	DISC
@	EQ 1.2GM BASE/VIAL	N50519 001		Jun	DISC

TOBRAMYCIN

AM PHARM	EQ 1.2GM BASE/VIAL	N50789 001	Jul 13, 2004	Jul	NEWA
+ PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	Aug 17, 2001	Jul	CTEC

AP +	EQ 1.2GM BASE/VIAL	N65013 001	Aug 17, 2001	Jun	CRLD
------	--------------------	------------	--------------	-----	------

TOBRAMYCIN SULFATE

AP + HOSPIRA	EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	Jun	CRLD
AP	EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	May	CAHN
AP	EQ 10MG BASE/ML	N63112 001	Apr 30, 1991	May	CAHN
AP	EQ 40MG BASE/ML	N63111 001	Apr 30, 1991	May	CAHN
AP +	EQ 40MG BASE/ML	N63116 001	May 18, 1992	May	CAHN
AP	EQ 40MG BASE/ML	N63161 001	May 29, 1991	May	CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA	EQ 1.2MG BASE/ML	N63081 003	Jul 31, 1990	May	CAHN
+	EQ 1.6MG BASE/ML	N63081 006	Jun 02, 1993	May	CAHN
+	EQ 80MG BASE/100ML	N63081 001	Jul 31, 1990	May	CAHN

TOLAZAMIDE

TABLET; ORAL						
TOLAZAMIDE						
>D>	AB	WATSON LABS	100MG	N70513	001	Jan 09, 1986 Aug DISC
>A>		@	100MG	N70513	001	Jan 09, 1986 Aug DISC

TOLCAPONE

TABLET; ORAL						
TASMAR						
>D>		ROCHE	100MG	N20697	001	Jan 29, 1998 Aug CAHN
>D>	+		200MG	N20697	002	Jan 29, 1998 Aug CAHN
>A>		VALEANT	100MG	N20697	001	Jan 29, 1998 Aug CAHN
>A>	+		200MG	N20697	002	Jan 29, 1998 Aug CAHN

TOPIRAMATE

CAPSULE; ORAL						
TOPAMAX SPRINKLE						
ORTHO MCNEIL PHARM	15MG	N20844	001	Oct 26, 1998 Jul	CAHN	
+	25MG	N20844	002	Oct 26, 1998 Jul	CAHN	
@	50MG	N20844	003	Oct 26, 1998 Jul	CAHN	
TABLET; ORAL						
TOPAMAX						
ORTHO MCNEIL PHARM	50MG	N20505	005	Dec 24, 1996 Jun	CMFD	

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC						
TRAVATAN						
+	ALCON	0.004%	N21257	001	Mar 16, 2001 May	CAHN

TRETINOIN

CREAM; TOPICAL						
AVITA						
>D>	AB	BERTEK PHARMS	0.025%	N20404	003	Jan 14, 1997 Aug CAHN
>A>	AB	MYLAN BERTEK	0.025%	N20404	003	Jan 14, 1997 Aug CAHN
GEL; TOPICAL						
AVITA						
>D>	BT	BERTEK PHARMS	0.025%	N20400	001	Jan 29, 1998 Aug CAHN
>A>	BT	MYLAN BERTEK	0.025%	N20400	001	Jan 29, 1998 Aug CAHN

TRIAMCINOLONE

TABLET; ORAL						
ARISTOCORT						
BP	+	FUJISAWA HLTHCARE	4MG	N11161	007	Jun CRLD
KENACORT						
@ BRISTOL MYERS SQUIBB		8MG	N11283	010	Jun DISC	
TRIAMCINOLONE						
@ WATSON LABS		4MG	N84270	001	Jun DISC	

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION						
AZMACORT						
+	KOS	0.1MG/INH	N18117	001	Apr 23, 1982 Apr CAHN	
SPRAY, METERED; NASAL						
NASACORT HFA						
+	AVENTIS PHARMS	0.055MG/SPRAY	N20784	001	Apr 07, 2004 Apr NEWA	

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SABEX 2002

25MG/ML

N11685 003

Jun DISC

@

40MG/ML

N12802 001

Jun DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP HOSPIRA 100MG/ML

N88804 001 Apr 03, 1987 May CAHN

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

>D> @ HALSEY 100MG N70494 001 Jan 22, 1986 Aug CAHN
>D> @ 200MG N70495 001 Sep 24, 1986 Aug CAHN
>A> @ MUTUAL PHARM 100MG N70494 001 Jan 22, 1986 Aug CAHN
>A> @ 200MG N70495 001 Sep 24, 1986 Aug CAHNTRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

ODYSSEY PHARMS EQ 25MG BASE N16792 001 Jun CAHN
EQ 50MG BASE N16792 002 Jun CAHN
+ EQ 100MG BASE N16792 003 Sep 15, 1982 Jun CAHNTROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

@ PURDUE FREDERICK 10%

N11340 002

May DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA 3.6GM/100ML

N13025 002

May CAHN

TROSPiUM CHLORIDE

TABLET; ORAL

SANCTURA

+ INDEVUS 20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

@ PFIZER EQ 100MG BASE

N20759 001 Dec 18, 1997 Jun DISC

@ EQ 200MG BASE

N20759 002 Dec 18, 1997 Jun DISC

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

@ BRISTOL MYERS SQUIBB 3MG/ML

N05657 001

Jul DISC

+ 3MG/ML

N05657 001

Jun CTEC

@ HOSPIRA 3MG/ML

N06095 001

Jun DISC

AP + 3MG/ML

N06095 001

May CAHN

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESKULA

DISC DISC >D>	+ NOVARTIS	0.15%	N21214 001 Aug 03, 2000 Aug CAHN
>A>	+	0.15%	N21214 001 Aug 03, 2000 Aug CAHN

UREA

INJECTABLE; INJECTION

STERILE UREA

@ HOSPIRA

40GM/VIAL

N17698 001

May CAHN

UREAPHIL

+ HOSPIRA

40GM/VIAL

N12154 001

May CAHN

URSODIOL

TABLET; ORAL

URSO 250

AXCAN SCANDIPHARM

250MG

N20675 001 Dec 10, 1997 Jul CTNA

URSODIOL

+ AXCAN SCANDIPHARM

500MG

N20675 002 Jul 21, 2004 Jul NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

+ GLAXOSMITHKLINE

EQ 1GM BASE

N20487 002 Jun 23, 1995 Feb CRLD

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

@ LILLY

EQ 250MG BASE/5ML

N61667 002 Jul 13, 1983 Jun DISC

@

EQ 500MG BASE/6ML

N61667 001 Jun DISC

INJECTABLE; INJECTION

VANCOCIN HCL

@ LILLY

EQ 500MG BASE/VIAL

N60180 001 Jun DISC

@

EQ 500MG BASE/VIAL

N62476 001 Mar 15, 1984 Jun DISC

@

EQ 500MG BASE/VIAL

N62716 001 Mar 13, 1987 Jun DISC

@

EQ 500MG BASE/VIAL

N62812 001 Nov 17, 1987 Jun DISC

@

EQ 1GM BASE/VIAL

N60180 002 Mar 21, 1986 Jun DISC

@

EQ 1GM BASE/VIAL

N62476 002 Mar 21, 1986 Jun DISC

@

EQ 1GM BASE/VIAL

N62716 002 Mar 13, 1987 Jun DISC

@

EQ 1GM BASE/VIAL

N62812 002 Nov 17, 1987 Jun DISC

@

EQ 10GM BASE/VIAL

N62812 003 Nov 17, 1987 Jun DISC

VANCOMYCIN HCL

AP HOSPIRA

EQ 500MG BASE/VIAL

N62911 001 Aug 04, 1988 May CAHN

AP

EQ 500MG BASE/VIAL

N62931 001 Oct 29, 1992 May CAHN

AP

EQ 1GM BASE/VIAL

N62912 001 Aug 04, 1988 May CAHN

AP

EQ 1GM BASE/VIAL

N62933 001 Oct 29, 1992 May CAHN

AP

EQ 5GM BASE/VIAL

N63076 001 Dec 21, 1990 May CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

+ ABBOTT

4MG/VIAL

N75558 001 Sep 11, 2001 Apr CAHN

+ HOSPIRA

4MG/VIAL

N75558 001 Sep 11, 2001 May CAHN

AP

10MG/VIAL

N75164 001 Oct 21, 1999 May CAHN

AP

20MG/VIAL

N75164 002 Oct 21, 1999 May CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

+

EQ 50MG BASE
EQ 100MG BASEN20151 003 Dec 28, 1993 May CRLD
N20151 005 Dec 28, 1993 May CRLDVERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP HOSPIRA 2.5MG/ML
AP 2.5MG/ML
AP 2.5MG/ML
AP 2.5MG/ML
AP 2.5MG/ML
AP 2.5MG/MLN70577 001 Feb 02, 1987 May CAHN
N70737 001 May 06, 1987 May CAHN
N70738 001 May 06, 1987 May CAHN
N70739 001 May 06, 1987 May CAHN
N70740 001 May 06, 1987 May CAHN
N75136 001 Oct 20, 1998 May CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

>D> AB BARR 120MG
AB 120MG
>D> AB 240MG
AB 240MG
>A> AB KALI LABS 120MG
>A> AB 240MGN75072 001 May 25, 1999 Aug CAHN
N75072 001 May 25, 1999 May CMFD
N75072 003 May 25, 1999 Aug CAHN
N75072 003 May 25, 1999 May CMFD
N75072 001 May 25, 1999 Aug CAHN
N75072 003 May 25, 1999 Aug CAHN

TABLET; ORAL

VERAPAMIL HCL

>D> @ HALSEY 80MG
>D> @ 120MG
>A> @ MUTUAL PHARM 80MG
>A> @ 120MGN70482 001 Sep 24, 1986 Aug CAHN
N70483 001 Sep 24, 1986 Aug CAHN
N70482 001 Sep 24, 1986 Aug CAHN
N70483 001 Sep 24, 1986 Aug CAHNVINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

@ LILLY

1MG/ML

N14103 003 Mar 07, 1984 Mar DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>A> AP BAXTER HLTHCARE EQ 10MG BASE/ML
>D> AP ESI LEDERLE EQ 10MG BASE/MLN75992 001 Jun 10, 2003 Aug CAHN
N75992 001 Jun 10, 2003 Aug CAHNVITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ MAYNE PHARMA USA

EQ 50,000 UNITS BASE/ML

N06823 001

Apr CAHN

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP HOSPIRA 100%
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
@ B BRAUN 100%
AP HOSPIRA 100%
AP 100%
AP 100%N18802 001 Oct 27, 1982 May CAHN
N19077 001 Mar 02, 1984 May DISC
N18233 001 May CAHN
N18801 001 Oct 27, 1982 May CAHN
N19869 001 Dec 26, 1989 May CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	HOSPIRA	100%	N17513 001	May CAHN
AT		100%	N18313 001	May CAHN

ZIDOVUDINE

SYRUP; ORAL

RETROVIR

+ GLAXOSMITHKLINE	50MG/5ML	N19910 001 Sep 28, 1989 Jul CRLD
-------------------	----------	----------------------------------

ZILEUTON

TABLET; ORAL

ZYFLO

@ CRITICAL

	300MG	N20471 001 Dec 09, 1996 Jul CAHN
+	600MG	N20471 003 Dec 09, 1996 Jul CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	EQ 1IMG ZINC/ML	N18959 001 Jun 26, 1986 May CAHN
-----------	-----------------	----------------------------------

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO	5MG	N19908 001 Dec 16, 1992 Apr CAHN
+	10MG	N19908 002 Dec 16, 1992 Apr CAHN

PREScription DRUG PRODUCT LIST - 24TH EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 8 - August 2004

2-1

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ NOVARTIS

0.5%;0.05%

N18746 002 Jul 11, 1994 Feb CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER

2%

N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+ MEDI FLEX HOSP 2%;70%

N20832 001 Jul 14, 2000 Jun CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ MEDI FLEX HOSP 2%;70%

N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ SANDOZ 12MG

N70797 001 Aug 12, 1988 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+ ALZA 16MG

N19746 002 Nov 18, 1994 Mar CRLD

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML

N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

ADAMS LABS 30MG;600MG

N21620 002 Apr 29, 2004 Apr NEWA

+ 60MG;1.2GM

N21620 001 Apr 29, 2004 Apr NEWA

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

>A> LNK 25MG

N40564 001 Aug 27, 2004 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

ADAMS 600MG;60MG

N21585 001 Jun 22, 2004 Jun NEWA

+ 1.2GM;120MG

N21585 002 Jun 22, 2004 Jun NEWA

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

TARO 100MG/5ML

N21604 001 Jan 07, 2004 Jan NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN						
PERRIGO	50MG		N76359 001	Jan 16, 2004	Jan	NEWA
	100MG		N76359 002	Jan 16, 2004	Jan	NEWA

TABLET; ORAL

IBUPROFEN						
>D>	@ BARR	200MG	N70493 001	Dec 24, 1985	Aug	CAHN
>D>	@	200MG	N70908 001	Sep 26, 1986	Aug	CAHN
>D>	@	200MG	N71462 001	Oct 02, 1986	Aug	CAHN
	LINK	100MG	N76741 001	Jun 17, 2004	Jun	NEWA
>A>	@ MUTUAL PHARM	200MG	N70493 001	Dec 24, 1985	Aug	CAHN
>A>	@	200MG	N70908 001	Sep 26, 1986	Aug	CAHN
>A>	@	200MG	N71462 001	Oct 02, 1986	Aug	CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS						
+ WYETH CONS	200MG;30MG		N21374 001	May 30, 2002	Mar	CAIN

LORATADINE

SYRUP; ORAL

LORATADINE						
>A>	MORTON GROVE	1MG/ML	N75815 001	Aug 20, 2004	Aug	NEWA
>A>	PERRIGO	1MG/ML	N75728 001	Aug 20, 2004	Aug	NEWA
>A>	RANBAXY	1MG/ML	N76529 001	Aug 20, 2004	Aug	NEWA
>A>	TARO	1MG/ML	N76805 001	Aug 20, 2004	Aug	NEWA

TABLET; ORAL

LORATADINE						
PERRIGO	10MG		N21512 001	Jun 24, 2004	Jun	NEWA
	10MG		N76301 001	Jun 25, 2004	Jun	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D						
>D>	+ SCHERING	5MG;120MG	N19670 002	Nov 27, 2002	Aug	DISC
>A>	@	5MG;120MG	N19670 002	Nov 27, 2002	Aug	DISC

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ANDRX PHARMS	5MG;120MG		N76208 001	Jan 28, 2004	Jan	NEWA
IMPAX LABS	5MG;120MG		N76050 001	Jan 30, 2003	Aug	CRLD
>A>	+ 5MG;120MG		N76050 001	Jan 30, 2003	Aug	CRLD
	10MG;240MG		N75989 001	Mar 04, 2004	Mar	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL						
MICONAZOLE 7 COMBINATION PACK						
G AND W LABS	2%,100MG		N76585 001	Mar 26, 2004	Mar	NEWA

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK						
PERRIGO	2%,4%		N76357 001	Mar 30, 2004	Mar	NEWA

MONISTAT 3 COMBINATION PACK

PERSONAL PRODS	2%,4%		N21261 003	Jun 17, 2003	Aug	CRLD
>D>	+ 4%,2%		N21261 003	Jun 17, 2003	Aug	CRLD

MINOXIDIL

SOLUTION; TOPICAL
>A> THEROXIDIL
>A> HARMONY LABS 5% N76239 001 Aug 24, 2004 Aug NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL
PERRIGO EQ 200MG BASE;120MG N76518 001 Mar 17, 2004 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX
WATSON LABS EQ 2MG BASE N76568 001 Jul 29, 2004 Jul NEWA
EQ 2MG BASE N76569 001 Jul 29, 2004 Jul NEWA
EQ 4MG BASE N76568 002 Jul 29, 2004 Jul NEWA
EQ 4MG BASE N76569 002 Jul 29, 2004 Jul NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
>A> ZANTAC 150
>A> + PFIZER CONS HLTHCARE EQ 150MG BASE N21698 001 Aug 31, 2004 Aug NEWA
ZANTAC 75
>D> + WARNER LAMBERT EQ 75MG BASE N20520 001 Dec 19, 1995 Aug CRLD
>A> EQ 75MG BASE N20520 001 Dec 19, 1995 Aug CRLD

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL
LAMISIL AT
+ NOVARTIS 1% N21124 002 Mar 17, 2000 Feb NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2004

Aug NEWA

Mar NEWA

NO AUGUST 2004 APPROVALS

Jul NEWA
Jul NEWA
Jul NEWA
Jul NEWA

Aug NEWA

Aug CRLD
Aug CRLD

Feb NEWA

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List
August 2004

Generic Name:

(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-
to include
1,4-imino-D-ribitol-hydrochloride
leukemia

Designated Indication:

Treatment of chronic lymphocytic leukemia and related leukemias
prolymphocytic leukemia, adult T-cell leukemia, and hairy cell

Trade Name (if present):

Date Designated 8/10/2004
Date Approved

Sponsor Contact Information
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Generic Name:

(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-
1,4-imino-D-ribitol-hydrochloride

Designated Indication:
Treatment of acute lymphoblastic leukemia.

Trade Name (if present):

Date Designated 8/13/2004
Date Approved

Sponsor Contact Information
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Generic Name:

(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-
1,4-imino-D-ribitol-hydrochloride

Designated Indication:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Date Designated 1/29/2004
Date Approved

Sponsor Contact Information
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Generic Name:

(6R,S)5,10-methylene-tetrahydrofolic acid
patients with

Designated Indication:
For use in combination with 5-fluorouracil for the treatment of
pancreatic cancer

Trade Name (if present):

CoFactor

Date Designated 8/13/2004
Date Approved

Sponsor Contact Information
Adventrx Pharmaceuticals, Inc.
6725 Mesa Ridge Road
Suite 100
San Diego CA 92121

Orphan Products Designations and Approvals List
August 2004

Generic Name:
1-Deoxygalactonojirimycin

Designated Indication:
Treatment of Fabry Disease

Trade Name (if present):

Sponsor Contact Information
Amicus Therapeutics, Inc.
675 US Route 1
North Brunswick NJ 08902

Date Designated 2/25/2004
Date Approved

Generic Name:
3-4'aminooisoindoline-1'-one)-1-piperidine-2,6-dione (CC-5013)

Designated Indication:
Treatment of myelodysplastic syndromes

Trade Name (if present):
REVIMID

Sponsor Contact Information
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

Date Designated 1/29/2004
Date Approved

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Designated Indication:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Sponsor Contact Information
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

Date Designated 3/5/2004
Date Approved

Generic Name:
90Y-hPAMA4

Designated Indication:
Treatment of pancreatic cancer

Trade Name (if present):
PAN-Cide

Sponsor Contact Information
Immunomedics, Inc.
300 American Road
Morris Plains NJ 07950

Date Designated 1/29/2004
Date Approved

Generic Name:
alpha-1-acid glycoprotein

Designated Indication:
Treatment of cocaine overdose

Trade Name (if present):

Sponsor Contact Information
Bio Products Laboratory
Dagger Lane, Elstree
Hertfordshire

Date Designated 3/5/2004
Date Approved

UNITED KINGDOM

Orphan Products Designations and Approvals List
August 2004

Generic Name: **Alpha-1-acid glycoprotein** Designated Indication:
Treatment of tricyclic antidepressant poisoning

Trade Name (if present): Sponsor Contact Information
 Bio Products Laboratory
 Dagger Lane
 Elstree, Hertfordshire

Date Designated 3/17/2004
Date Approved

UNITED KINGDOM

Generic Name: **Ambrisentan** Designated Indication:
Treatment of pulmonary arterial hypertension

Trade Name (if present): Sponsor Contact Information
 Myogen, Inc.
 7575 West 103rd Avenue
 Suite 102
 Westminster CO 80021-5426

Date Designated 7/16/2004
Date Approved

Generic Name: **antivenin crotaline (pit-viper) equine immune F(ab)2** Designated Indication:
Treatment of envenomation by Crotaline snakes

Trade Name (if present): **Antivipmyn** Sponsor Contact Information
 Rare Disease Therapeutics, Inc.
 1101 Kermit Drive,
 Suite 608
 Nashville TN 37217

Date Designated 1/29/2004
Date Approved

Generic Name: **Aplidin** Designated Indication:
Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present): Sponsor Contact Information
 PharmaMar USA, Inc
 320 Putnam Avenue
 Cambridge MA 02139

Date Designated 6/18/2004
Date Approved

Generic Name: **C1 esterase inhibitor (human)** Designated Indication:
Treatment of Angioedema

Trade Name (if present): Sponsor Contact Information
 Lev Pharmaceuticals, Inc.
 236 Old Lancaster Road
 Merion Station PA 19066

Date Designated 7/16/2004
Date Approved

Orphan Products Designations and Approvals List
August 2004

Generic Name:
chenodeoxycholic acid

Designated Indication:
Treatment of cerebrotendinous xanthomatosis

Trade Name (if present):
Chenofalk

Sponsor Contact Information
Dr. Falk Pharma GmbH
Leinenweberstrasse 5
Postfach 6529

Date Designated 1/29/2004
Date Approved

GERMANY

Generic Name:
Coagulation factor VIIa (recombinant)
to Factor VIII

Designated Indication:
Prevention of bleeding episodes in patients with acquired inhibitors
or Factor IX

Trade Name (if present):
NovoSeven

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated 7/21/2004
Date Approved

Generic Name:
Coagulation factor VIIa (recombinant)

Designated Indication:
Prevention of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated 6/18/2004
Date Approved

Generic Name:
Coagulation Factor VIIa (Recombinant)
to Factor VIII

Designated Indication:
Treatment of bleeding episodes in patients with acquired inhibitors
or Factor IX

Trade Name (if present):
NovoSeven

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated 7/16/2004
Date Approved

Generic Name:
Coagulation factor VIIa (recombinant)
with or

Designated Indication:
Prevention of bleeding episodes in patients with hemophilia A or B,
without inhibitors

Trade Name (if present):
NovoSeven

Sponsor Contact Information
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated 6/18/2004
Date Approved

Orphan Products Designations and Approvals List
August 2004

Generic Name: Coagulation factor VIIa (Recombinant)	Designated Indication: Treatment of bleeding episodes in Glanzmann's thrombasthenia
Trade Name (if present): NovoSeven	Sponsor Contact Information Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540
Date Designated 6/18/2004	
Date Approved	
Generic Name: DEAE-rebeccamycin	Designated Indication: Treatment of bile duct tumors
Trade Name (if present):	Sponsor Contact Information Exelixis, Inc. 170 Harbor Way South San Francisco CA 94083-0511
Date Designated 3/1/2004	
Date Approved	
Generic Name: Deferitriptin	Designated Indication: For the treatment of iron overload
Trade Name (if present):	Sponsor Contact Information Genzyme Corporation 153 Second Avenue Waltham MA 02451
Date Designated 4/14/2004	
Date Approved	
Generic Name: dexanabinol sequelae	Designated Indication: For the attenuation or amelioration of the long-term neurological associated with severe traumatic brain injury
Trade Name (if present):	Sponsor Contact Information Pharmos Corporation 99 Wood Avenue Suite 311 Iselin NJ 08830
Date Designated 8/11/2004	
Date Approved	
Generic Name: Dexrazoxane	Designated Indication: Treatment of anthracycline extravasation during chemotherapy
Trade Name (if present):	Sponsor Contact Information Topo Target A/S Fruebjergvej 3, 2100 Copenhagen
Date Designated 3/25/2004	
Date Approved	

Orphan Products Designations and Approvals List

August 2004

DENMARK

Generic Name: diethylenetriaminepentaacetate (DPTA) contamination with plutonium, americium or curium to increase the rates of elimination.	Designated Indication: For treatment of patients with known or suspected internal plutonium, americium or curium to increase the rates of elimination.
---	---

Trade Name (if present):	Sponsor Contact Information CIS-US 10 DeAngelo Drive Bedford MA 01730
Date Designated 4/14/2004 Date Approved	

Generic Name: Diethylenetriaminepentaacetic acid (DTPA) contamination with plutonium, americum, or curium to increase the rates of elimination.	Designated Indication: Treatment of patients with known or suspected internal plutonium, americum, or curium to increase the rates of elimination.
---	---

Trade Name (if present):	Sponsor Contact Information Hameln Pharmaceuticals gmbh Langes Feld 13 Hameln
Date Designated 4/28/2004 Date Approved	

GERMANY

Generic Name: Diethylnorspermine (DENSPM)	Designated Indication: Treatment for hepatocellular carcinoma
--	--

Trade Name (if present):	Sponsor Contact Information Genzyme Corporation 153 Second Avenue Waltham MA 02451
Date Designated 5/25/2004 Date Approved	

Generic Name: Doripenem fibrosis who are	Designated Indication: Treatment of bronchopulmonary infection in patients with cystic colonized with Pseudomonas aeruginosa or Burkholderia cepacia.
--	---

Trade Name (if present):	Sponsor Contact Information Peninsula Pharmaceuticals, Inc. 1751 Harbor Bay Parkway Alameda CA 94502
Date Designated 7/16/2004 Date Approved	

Generic Name: efaproxiral brain metastases	Designated Indication: An adjunct to whole brain radiation therapy for the treatment of in patients with breast cancer.
--	---

Orphan Products Designations and Approvals List

August 2004

Trade Name (if present):

Sponsor Contact Information
Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster CO 80020

Date Designated 7/28/2004
Date Approved

Generic Name:
human anti-CD4 monoclonal antibody

Designated Indication:
Treatment of mycosis fungoides

Trade Name (if present):
HuMax-CD4

Sponsor Contact Information
Genmab A/S
Tolbodgade 33
DK-1253 Copenhagen K.

Date Designated 8/13/2004
Date Approved

DENMARK

Generic Name:
human anti-transforming growth factor-B1,2,3

Designated Indication:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):

Sponsor Contact Information
Genzyme Corporation
500 Kendall Street
Cambridge MA 02142

Date Designated 7/9/2004
Date Approved

Generic Name:
human immunoglobulin (IgG1k)antiCTLA-4
monoclonal antibody

Designated Indication:
Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor Contact Information
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated 6/3/2004
Date Approved

Generic Name:
hydralazine
pressure greater
160)

Designated Indication:
Treatment of severe intrapartum hypertension (diastolic blood
than or equal to 110 or systolic blood pressure less than or equal to
associated with severe preeclampsia/eclampsia of pregnancy

Trade Name (if present):

Sponsor Contact Information
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150
Edison NJ 08817

Date Designated 4/9/2004
Date Approved

Generic Name:
Icatibant acetate

Designated Indication:
Treatment of burn patients hospitalized with burn-induced edema

Orphan Products Designations and Approvals List

August 2004

Trade Name (if present):	Sponsor Contact Information
Date Designated 5/5/2004	Jerini AG
Date Approved	Invalidenstr, 130 10115 Berlin
	GERMANY
*****	*****
Generic Name: Idebenone (INN)	Designated Indication: Treatment of cardiomyopathy associated with Friedreich's ataxia
Trade Name (if present):	Sponsor Contact Information
Date Designated 3/25/2004	MyoContract Ltd.
Date Approved	Hammerstrasse 25 CH-4410 Liestal
	SWITZERLAND
*****	*****
Generic Name: Iloprost inhalation solution	Designated Indication: Treatment of pulmonary arterial hypertension
Trade Name (if present):	Sponsor Contact Information
Ventavis	CoTherix, Inc.
Date Designated 8/12/2004	5000 Shoreline Court
Date Approved	South San Francisco CA 94080

Generic Name: Immortalized human liver cells found in the extracorporeal liver assist device	Designated Indication: Treatment of fulminant hepatic failure (acute liver failure)
Trade Name (if present):	Sponsor Contact Information
ELAD	Vital Therapies, Inc.
Date Designated 7/16/2004	15222 Avenue of Science
Date Approved	Suite C San Diego CA 92128

Generic Name: Immune Globulin (Human)	Designated Indication: Treatment of chronic inflammatory demyelinating polyneuropathy
Trade Name (if present):	Sponsor Contact Information
Gamunex	Bayer Corporation
Date Designated 7/27/2004	800 Dwight Way
Date Approved	Berkley CA 94701-1986

Generic Name: Immune Globulin (Human) containing high titers of West Nile virus antibodies	Designated Indication: Treatment of the West Nile virus infection

Orphan Products Designations and Approvals List

August 2004

Trade Name (if present):
Omr-IgG-am (tm) 5% (WNV)

Sponsor Contact Information
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621

Date Designated 3/17/2004
Date Approved

ISRAEL

Generic Name:
Immune Globulin Intravenous (human)

Designated Indication:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Sponsor Contact Information
ZLB Bioplasma AG
Wankdorfstrasse 10
CH-3000 Bern 22

Date Designated 5/4/2004
Date Approved

SWITZERLAND

Generic Name:
Implitapide

Designated Indication:
Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Sponsor Contact Information
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated 8/13/2004
Date Approved

Designated Indication:
Treatment of patients with Fredrickson type I or V

Generic Name:
Implitapide
hyperlipoproteinemia

Trade Name (if present):

Sponsor Contact Information
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated 8/18/2004
Date Approved

Designated Indication:
The treatment of congenital ichthyosis

Generic Name:
Liarozole

Trade Name (if present):

Sponsor Contact Information
Barrier Therapeutics, Inc
600 College Road East
Princeton NJ 08540

Date Designated 6/18/2004
Date Approved

Designated Indication:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Generic Name:
mannopentaose phosphate sulfate

Orphan Products Designations and Approvals List

August 2004

Trade Name (if present):

Date Designated 4/27/2004

Date Approved

Sponsor Contact Information
Progen Industries Limited
P. O. Box 28
Richlands 4077

AUSTRALIA

Generic Name:

mecloroethamine or nitrogen mustard

Designated Indication:
Treatment of mycosis fungoides.

Trade Name (if present):

Date Designated 8/12/2004

Date Approved

Sponsor Contact Information
Yaupon Therapeutics, Inc.
259 Radnor Chester Road
Radnor PA 19087

Generic Name:

Melatonin
without light

Designated Indication:
Treatment of non-24-hour sleep-wake disorder in blind individuals
perception

Trade Name (if present):

Circadin

Date Designated 7/9/2004

Date Approved

Sponsor Contact Information
Neurim Pharmaceuticals, Ltd.
8 Hanechoshet St.
Tel-Aviv

ISRAEL

Generic Name:

mepolizumab

Designated Indication:
For first-line treatment in patients with hypereosinophilic syndrome

Trade Name (if present):

Date Designated 5/28/2004

Date Approved

Sponsor Contact Information
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Philadelphia PA 19101

Generic Name:

Multi-ligand somatostatin analogue

gastrinoma,

Designated Indication:
Treatment of patients with functional gastroenteropancreatic (GEP)
neuroendocrine tumors (specifically, carcinoid, insulinoma,
somastatinoma, GRFoma, VIPoma and glucagonoma).

Trade Name (if present):

Date Designated 7/27/2004

Date Approved

Sponsor Contact Information
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover NJ 07936-1080

Generic Name:

multi-vitamin infusion without vitamin K

Designated Indication:
Prevention of vitamin deficiency and thromboembolic

Orphan Products Designations and Approvals List

August 2004

complications	
anticoagulant	in people receiving home parenteral nutrition and warfarin-type therapy
Trade Name (if present):	
M.V.I.-12	Sponsor Contact Information Mayne Pharma (USA) Inc. Mack-Cali Centre II Second Floor Paramus NJ 07652
Date Designated 3/8/2004	
Date Approved	
*****	*****
Generic Name:	Designated Indication:
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide	Treatment of stages IIB-IV melanoma
Trade Name (if present):	
	Sponsor Contact Information 3M Pharmaceuticals 3M Center Building 270-3A-08 St. Paul MN 55144-1000
Date Designated 8/13/2004	
Date Approved	
*****	*****
Generic Name:	Designated Indication:
nelarabine	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma
Trade Name (if present):	
	Sponsor Contact Information GlaxoSmithKline One Franklin Plaza Philadelphia PA 19101
Date Designated 8/10/2004	
Date Approved	
*****	*****
Generic Name:	Designated Indication:
Nucleic acid aptamer binding to tumor cell nucleolin	Treatment of pancreatic cancer
Trade Name (if present):	
	Sponsor Contact Information Aptamera, Inc. 640 S. Fourth Street Louisville KY 40202
Date Designated 8/11/2004	
Date Approved	
*****	*****
Generic Name:	Designated Indication:
pral unfractionated heparin	Treatment of sickle cell disease
Trade Name (if present):	
	Sponsor Contact Information TRF Technologies, Inc. 108 Eagle Trace Drive Half Moon Bay CA 94019
Date Designated 1/29/2004	
Date Approved	
*****	*****

Orphan Products Designations and Approvals List

August 2004

Generic Name: pentetate trisodium contamination with	Designated Indication: Treatment of patients with known or suspected internal plutonium, americium, or curium.
Trade Name (if present): diethylenetriaminepentaacetate	Sponsor Contact Information Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG Goerzallee 253 Fedderal of Republic of Germany
Date Designated 4/12/2004	
Date Approved	
	GERMANY
*****	*****
Generic Name: posaconazole	Designated Indication: Treatment of zygomycosis
Trade Name (if present): Posoril	Sponsor Contact Information Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Date Designated 7/16/2004	
Date Approved	
*****	*****
Generic Name: Quinine Sulfate	Designated Indication: Treatment of malaria
Trade Name (if present):	Sponsor Contact Information Mutual Pharmaceutical Company, Inc. 1100 Orthodox Street Philadelphia PA 19124
Date Designated 6/3/2004	
Date Approved	
*****	*****
Generic Name: recombinant human fibroblast growth factor-20	Designated Indication: Treatment of radiation induced oral mucositis
Trade Name (if present):	Sponsor Contact Information CuraGen Corporation 322 East Main Street Branford CT 06405
Date Designated 1/29/2004	
Date Approved	
*****	*****
Generic Name: Recombinant Porcine Factor VIII, B-domain inhibitor Deleted	Designated Indication: Treatment and prevention of episodic bleeding in patients with antibodies to human coagulation factor VIII
Trade Name (if present):	Sponsor Contact Information Ipsen Limited 190 Bath Road Berkshire S11 3XE
Date Designated 3/16/2004	
Date Approved	

Orphan Products Designations and Approvals List
August 2004

UNITED KINGDOM

Generic Name: rh-microplasmin	Designated Indication: Adjunct to surgery in cases of pediatric vitrectomy
----------------------------------	---

Trade Name (if present):	Sponsor Contact Information ThromboGenics Ltd Unit 14 Bridgecourt Office Park Dublin 12
Date Designated 3/16/2004	
Date Approved	IRELAND

Generic Name: Rituximab	Designated Indication: Treatment of chronic lymphocytic leukemia
----------------------------	---

Trade Name (if present): Rituxan	Sponsor Contact Information Biogen IDEC, Inc. 3030 Callan Road San Diego CA 92121
Date Designated 1/29/2004	
Date Approved	

Generic Name: rofecoxib	Designated Indication: Treatment of juvenile rheumatoid arthritis
----------------------------	--

Trade Name (if present): VIOXX	Sponsor Contact Information MERCK & Co., Inc. 126 East Lincoln Ave. Rahway NJ 07065
Date Designated 3/16/2004	
Date Approved	

Generic Name: sarsasapogenin	Designated Indication: Treatment of amyotrophic lateral sclerosis (ALS)
---------------------------------	--

Trade Name (if present):	Sponsor Contact Information Phytopharm plc Corpus Christi House Godmanchester, Cambridgeshire PE29 2HY
Date Designated 6/18/2004	
Date Approved	

UNITED KINGDOM

Generic Name: SGN-30 (anti-CD30 antibody)	Designated Indication: For the treatment of CD30 positive T-cell lymphomas
--	---

Trade Name (if present):	Sponsor Contact Information Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021
Date Designated 2/18/2004	
Date Approved	

Orphan Products Designations and Approvals List
August 2004

Generic Name: SGN-40 (anti-CD40 antibody)	Designated Indication: Treatment of multiple myeloma.
Trade Name (if present):	Sponsor Contact Information Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021
Date Designated 8/13/2004	
Date Approved	
Generic Name: sodium thiosulfate	Designated Indication: Prevention of platinum-induced ototoxicity in pediatric patients
Trade Name (if present):	Sponsor Contact Information Adherex Technologies, Inc. 600 Peter Morand Crescent Ottawa, Ontario
Date Designated 3/17/2004	
Date Approved	
CANADA	
Generic Name: somatropin syndrome	Designated Indication: Treatment of patients with HIV-associated adipose redistribution
Trade Name (if present): Serostim	Sponsor Contact Information Serono, Inc. One Technology Place Rockland MA 02370
Date Designated 3/16/2004	
Date Approved	
Generic Name: Staphylococcus aureus Immune Globulin weight neonates (Human)	Designated Indication: Prophylaxis against Staphylococcus aureus infections in low birth
Trade Name (if present): Altastaph	Sponsor Contact Information Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville MD 20852
Date Designated 1/29/2004	
Date Approved	
Generic Name: Suberoylanilide Hydroxamic Acid	Designated Indication: Treatment of mesothelioma
Trade Name (if present):	Sponsor Contact Information Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated 3/17/2004	
Date Approved	

Orphan Products Designations and Approvals List
August 2004

Generic Name: Suberoylanilide Hydroxamic Acid (SAHA)	Designated Indication: Treatment of T-cell non-Hodgkin's lymphoma
Trade Name (if present):	Sponsor Contact Information Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Date Designated 3/16/2004	
Date Approved	
Generic Name: temocillin sodium	Designated Indication: Treatment of pulmonary infections caused by Burkholderia cepacia
Trade Name (if present): Negaban	Sponsor Contact Information Belpharma N.V. 67 Winston Churchill Avenue Brussels
Date Designated 4/21/2004	
Date Approved	
BELGIUM	
Generic Name: tetrahydrobiopterin	Designated Indication: For treatment of hyperphenylalaninemia
Trade Name (if present):	Sponsor Contact Information Biomarin Pharmaceutical Inc. 371 Bel Marin Blvd. Novato CA 94949
Date Designated 1/29/2004	
Date Approved	
Generic Name: Thymosin Beta 4	Designated Indication: Treatment of Epidermolysis Bullosa
Trade Name (if present):	Sponsor Contact Information RegeneRx Biopharmaceuticals, Inc. 3 Bethesda Metro Center Suite 700 Bethesda MD 20814
Date Designated 5/28/2004	
Date Approved	
Generic Name: Tipifarnib	Designated Indication: Treatment of acute myeloid leukemia
Trade Name (if present): Zarnestra	Sponsor Contact Information Johnson & Johnson Pharmaceutical Research & Dev. 920 U.S. Highway 202 Raritan NJ 08869
Date Designated 7/6/2004	
Date Approved	

Orphan Products Designations and Approvals List

August 2004

Generic Name: Trisodium zinc Diethylenetriaminepentaacetate contamination with	Designated Indication: Treatment of patients with known or suspected internal plutonium, americium, or curium to increase the rate of elimination.
Trade Name (if present):	Sponsor Contact Information CustomCare Pharmacy 5710 Hoover Blvd Tampa FL 33634
Date Designated 2/27/2004 Date Approved	
Generic Name: Ubiquinol	Designated Indication: Treatment of Huntington's Disease
Trade Name (if present): Ubi-Q-Nol, Li-Q-Nol	Sponsor Contact Information Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590
Date Designated 4/12/2004 Date Approved	
Generic Name: ubiquinol, coenzyme Q10, ubiquinone	Designated Indication: Treatment of pediatric congestive heart failure
Trade Name (if present): UBI-Q-NOL	Sponsor Contact Information Gel-Tec, Division of TISHCON Corporation 30 New York Avenue P.O. Box 331 Westbury NY 11590
Date Designated 4/12/2004 Date Approved	
Generic Name: Vaccinia Immune Globulin (Human) Intravenous	Designated Indication: Treatment of complications of vaccinia vaccination
Trade Name (if present): CNJ-016	Sponsor Contact Information Cangene Corporation 104 Chancellor Matheson Road Winnipeg, Manitoba R3T 5Y3
Date Designated 6/18/2004 Date Approved	
CANADA	
Generic Name: Vaccinia Immune Globulin (Human) Intravenous	Designated Indication: Treatment of severe complications from the smallpox vaccine
Trade Name (if present):	Sponsor Contact Information DynPort Vaccine Company LLC 64 Thomas Johnson Drive Frederick MD 21702
Date Designated 6/18/2004 Date Approved	

Orphan Products Designations and Approvals List
August 2004

Generic Name:
vapreotide

Designated Indication:
Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor Contact Information

H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

Date Designated 4/6/2004
Date Approved

CANADA

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE;ZIAGEN	5968895	DEC 11, 2016	DP	D-40	AUG 02, 2007
020978 001	ABACAVIR SULFATE;ZIAGEN	6180608	DEC 11, 2016	DP	D-40	AUG 02, 2007
021320 001	ABARELIX; PLENAXIS	6423686	JUN 07, 2015	DS		
		6455499	JUN 07, 2015	U549		
		5843901	DEC 01, 2015	DS		
		6699833	DEC 11, 2016	DP		
				NCE ODE	JUL 29, JAN 23,	2009 2011
021431 001	ACAMPROSATE CALCIUM;CAMPRAL	6451340	JUL 23, 2018	DS	DP U470	
021539 001	ACETYLCYSTEINE;ACETADOTE	5663159	SEP 02, 2014	DS	DP U470	
>ADD>	ADEFOVIR DIPIVOXIL;HEPSERA	6635278	DEC 15, 2018	DS	DP	
>ADD>		6723303	APR 20, 2021	DP		
020899 001	ALBUMIN HUMAN;OPTISON	6702997	DEC 28, 2021	U558		
020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
020949 002	ALBUTEROL SULFATE;ACCUNEB	6170717	DEC 23, 2017	DP		
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6315173	DEC 23, 2017	DP		
		6540969	DEC 23, 2017	DP		
		6111566	APR 14, 2015	DP U589		
		6532955	APR 14, 2015	DP U590	D-87	APR 16, 2007
					D-87	APR 16, 2007
020560 005	ALENDRONATE SODIUM;FOSAMAX	5926222	AUG 03, 2016	U562		
021575 001	ALENDRONATE SODIUM;FOSAMAX	52273995	DEC 28, 2010	DS	DP U162	
020886 001	ALITRETINOIN;PANRETIN	52273995*PED	JUN 28, 2011	NC	JAN 30,	2007
021540 001	AMLODIPINE BESYLATE;CADUET	6455574	AUG 11, 2018	U552		
		64569156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP	U213	
		5686104*PED	MAY 11, 2015	DP		
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		5969156	SEP 24, 2009	DS	DP U161	
		4681893	MAR 24, 2010	DS	DP	
		4681893*PED	MAR 25, 2007	DS	DP	
		4879303	SEP 25, 2007	DS	DP	
		4879303*PED	JUL 31, 2006	DS	DP U3	
		4572909	JAN 31, 2007	DS	DP	
		4572909*PED	SEP 24, 2009	DS	DP U161	
		4681893	MAR 24, 2010	DS	DP	
		4681893*PED	MAR 25, 2007	DS	DP	
		4879303	SEP 25, 2007	DS	DP	
		4572909	JUL 31, 2006	DS	DP U3	
		4572909*PED	JAN 31, 2017	DS	DP	
		4572909	NOV 11, 2014	DP	U213	
		52273995	DEC 28, 2010	DS	DP U162	
		52273995*PED	JUN 28, 2011	DS	DP	
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS	DP	
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP	U213	
		566104*PED	MAY 11, 2015	DP		
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			

021540 007	AMLODIPINE BESYLATE; CADUET	56686104 56686104*PED 6126971 6126971*PED	NOV 11, 2014 MAY 11, 2015 JAN 19, 2013 JUL 19, 2013	DP U213 DP DP	JAN 30, 2007
		4681893 4681893*PED	SEP 24, 2009 MAR 24, 2010 MAR 25, 2007 SEP 25, 2007	DS DP U161 DS DP DS DP	
		4879303 4879303*PED	JUL 31, 2006 JAN 31, 2007 DEC 28, 2010 JUN 28, 2011	DS DP U3 DS DP U162 DS DP	
		4879309 4879309*PED	AUG 11, 2018 JUL 08, 2016	U552 DS	
		4572909 4572909*PED	JAN 08, 2017 NOV 11, 2014 MAY 11, 2015 JAN 19, 2013	DP U213 DP U213 DP	
		56686104 56686104*PED	SEP 24, 2009 MAR 24, 2010 MAR 25, 2007 SEP 25, 2007	DS DP U161 DS DP DS DP	
		6126971 6126971*PED	JUL 31, 2006 JAN 19, 2013 JUL 31, 2007 DEC 28, 2010	DS DP U3 DS DP U3 DS DP U162 DS DP	
		4681893 4681893*PED	JAN 31, 2007 DEC 28, 2010 JUN 28, 2011 AUG 11, 2018	DS DP U3 DS DP U162 DS DP U552	
		4879303 4879303*PED	JUL 31, 2006 JUL 31, 2007 JUL 31, 2011 JUN 28, 2010	DS DP U3 DS DP DS DP U162 DS DP	
		4572909 4572909*PED	JUL 08, 2016 JAN 08, 2017 NOV 11, 2014 MAY 11, 2015	DS DP U213 DP U213 DS	
		56686104 56686104*PED	JAN 19, 2013 JUL 19, 2013	DP DP	
021540 008	AMLODIPINE BESYLATE; CADUET	56686104 56686104*PED 6126971 6126971*PED	NOV 11, 2017 NOV 11, 2017	DP DP	JAN 30, 2007
		4681893 4681893*PED	NOV 11, 2017 NOV 11, 2017	DP DP	
		5273995 5273995*PED	JUL 31, 2006 JUL 31, 2007 JUN 28, 2011 AUG 11, 2018	DS DP U3 DS DP DS DP U162 DS DP	
		6455574 6455574	JUL 08, 2016 JAN 08, 2017 NOV 11, 2014 MAY 11, 2015	DS DS DP U213 DP	
		5969156 5969156*PED	JAN 19, 2013 JUL 19, 2013	DP DP	
		56686104 56686104*PED	NOV 11, 2017 NOV 11, 2017	DP DP	
		6126971 6126971*PED	NOV 11, 2017 NOV 11, 2017	DP DP	
		6730679 6730679	NOV 10, 2018	U573	
>ADD>	021540 009	AMLODIPINE BESYLATE; CADUET			
>ADD>	021540 010	AMLODIPINE BESYLATE; CADUET			
>ADD>	021540 011	AMPRENAVIR; AGENERASE			
>ADD>	021007 001	AMPRENAVIR; AGENERASE			
>ADD>	021007 002	ANAGRELIDE HYDROCHLORIDE; AGRYLIN			
>ADD>	020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN			
	020333 002				
	021264 001	APOMORPHINE HYDROCHLORIDE; APOKYN			
	021264 002	APOMORPHINE HYDROCHLORIDE; APOKYN			
	021248 001	ARSENIC TRIOXIDE; TRISENOX			
	021248 001	ATAZANAVIR SULFATE; REYATAZ			
	021567 001	ATAZANAVIR SULFATE; REYATAZ			
	021567 002	ATAZANAVIR SULFATE; REYATAZ			
	021567 003	ATAZANAVIR SULFATE; REYATAZ			
	020702 001	ATORVASTATIN CALCIUM; LIPITOR			
>ADD>	021540 011	SEP 24, 2009 DEC 28, 2010	DS DP U161 DS DP U162		
>ADD>	5668104 5668104	NOV 11, 2014 JUL 08, 2016	DP U213 DS		
>ADD>	5969156 5969156	JAN 19, 2013	DP		
>ADD>	6126971				

021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL	6706681	MAR 16, 2021	DP		NP	FEB 24, 2007
021149 002	CHORIOGONADOTROPIN ALFA; OVIDREL	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011	
021688 001	CINACALCET HYDROCHLORIDE; SENSIPIAR	6211244	OCT 23, 2015	DS DP	U560	MAR 08, 2009	
		6313146	DEC 14, 2016	DS DP			
		6011068	DEC 14, 2016	DS DP			
		6031003	DEC 14, 2016	DS DP			
		6211244	OCT 23, 2015	DS DP	U560	ODE	MAR 08, 2011
		6313146	DEC 14, 2016	DS DP		MAR 08, 2009	
		6011068	DEC 14, 2016	DS DP			
		6031003	DEC 14, 2016	DS DP	U559	ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP	U560	MAR 08, 2009	
		6313146	DEC 14, 2016	DS DP			
		6011068	DEC 14, 2016	DS DP			
021688 002	CINACALCET HYDROCHLORIDE; SENSIPIAR						
021688 003	CINACALCET HYDROCHLORIDE; SENSIPIAR						
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO						
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO						
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO						
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC						
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC	5965549	JUN 06, 2015	DP		I-421	MAR 25, 2007
019847 001	CIPROFLOXACIN; CIPRO					PED	SEP 25, 2007
020780 001	CIPROFLOXACIN; CIPRO					I-421	MAR 25, 2007
020780 002	CIPROFLOXACIN; CIPRO					PED	SEP 25, 2007
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%					I-421	MAR 25, 2007
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO					PED	SEP 25, 2007
		4670444	DEC 09, 2003				
		4705789	NOV 10, 2004				
		4957922	SEP 18, 2007				
		4800583	FEB 28, 2006				
		4670444 * PED	JUN 09, 2004				
		4705789 * PED	MAY 10, 2005				
		4800583 * PED	AUG 28, 2006				
		4957922 * PED	MAR 18, 2008				
		4670444 * DEC	OCT 21, 2005				
		4670444 * PED	JUN 09, 2004				
		4659716	APR 21, 2005				
		4659716 * PED	OCT 21, 2005				
		4659716	APR 21, 2005				
		4659716 * PED	OCT 21, 2005				
		6716867	MAR 31, 2019				
		6528530	DEC 04, 2015				
		6528530	DEC 04, 2015				
		6528530	DEC 04,				
>ADD>	021473 002	CIPROFLOXACIN; CIPRO XR					
>ADD>	021644 001	CLOBETASOL PROPIONATE; CLOBEAX					
>ADD>	021165 001	DESLORATADINE; CLARINEX					
>ADD>	021312 001	DESLORATADINE; CLARINEX					
>ADD>	021038 001	DEXMEDETOMIDINE PRECEDEX					
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN					
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN					
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN					
	021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
	021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA					
		I-133	APR 09, 2007				
		I-133	APR 09, 2007				

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA	I-133	APR 09, 2007			
021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA	I-133	APR 09, 2007			
021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA	I-133	APR 09, 2007			
021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA	I-133	APR 09, 2007			
>ADD> 021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6528091 6528090 6713086 5212326	DEC 18, 2018 DEC 18, 2018 DEC 18, 2018 DEC 18, 2018	U106 DP U579 DS DP DP U579		
	DIVALPROEX SODIUM; DEPAKOTE ER	6528090 6713086 5212326	DEC 18, 2018 DEC 18, 2018 JAN 29, 2008	DP U579 DS DP DS DP		
021168 002	DOCEtaxel; TAXOTERE				1-429 I-436	MAY 19, 2007 AUG 18, 2007
>ADD> 020449 001	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020931 001	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020931 002	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020931 003	DOFETILIDE; TIKOSYN	6316443	JAN 29, 2008	DP U561		
020869 001	DORZOLAMIDE HYDROCHLORIDE; COSOPT	4797413	JAN 29, 2008	DS DP U103		
020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4619939	OCT 28, 2003	DP U104		
020862 001	DOXERCALCIFEROL; HECTOROL	5869473	AUG 02, 2008	U278		
020862 002	DOXERCALCIFEROL; HECTOROL	6703418	FEB 26, 2011	U563		
018651 001	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
018651 002	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
018651 003	DRONABINOL; MARINOL	6703418	AUG 31, 2020	DP		
021098 001	DROSPIRENONE; YASMIN	6787531				
>ADD> 021427 001	DULOXETINE HYDROCHLORIDE; CYMBALTA					
>ADD> 021427 002	DULOXETINE HYDROCHLORIDE; CYMBALTA					
>ADD> 021427 004	DULOXETINE HYDROCHLORIDE; CYMBALTA					
>ADD> 021500 001	EMTRICITABINE; EMTRIVA					
>ADD> 021504 001	EPINEPHRINE; LIDOSITE TOPICAL SYS					
>ADD> 021437 001	EPLERENONE; INSPRA					
021437 002	EPLERENONE; INSPRA					
021437 003	EPLERENONE; INSPRA					
>ADD> 021633 001	ESTRADIOL ACETATE; FEMTRACE					
>ADD> 021633 002	ESTRADIOL ACETATE; FEMTRACE					
>ADD> 021633 003	ESTRADIOL ACETATE; FEMTRACE					
>ADD> 021371 001	ESTRADIOL HEMIHYDRATE; ESTRASORB	5629021	JAN 31, 2015	DP		
021166 001	ESTRADIOL; ESTROGEL	5891868	NOV 21, 2017	DP U594		
>ADD> 021674 001	ESTRADIOL; MENOSTAR	6692163	JUN 29, 2010	DP U594		
>ADD>		5222621	MAR 20, 2020	U311		
>ADD> 021040 001	ESTRADIOL; PREFEST					
020992 002	ESTROGENS, CONJUGATED					
020992 003	ESTROGENS, CONJUGATED					
020992 004	ESTROGENS, CONJUGATED					
020992 006	ESTROGENS, CONJUGATED					

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME, TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020985 001	FLUOUROURACIL;CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
		5985322	MAY 29, 2017	U397		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	6107017	DEC 23, 2017	DP	NP	APR 21, 2007
021433 001	FLUTICASONE PROPIONATE;FLOVENT HFA	6315173	DEC 23, 2017	DP	NP	MAY 14, 2007
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP	U581	
		6253762	APR 14, 2015	DP	U582	
		6546928	APR 14, 2015	DP	U583	
021433 002	FLUTICASONE PROPIONATE;FLOVENT HFA	6107017	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP	U581	
		6253762	APR 14, 2015	DP	U582	
		6546928	APR 14, 2015	DP	U583	
021433 003	FLUTICASONE PROPIONATE;FLOVENT HFA	6107017	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP	U581	
		6253762	APR 14, 2015	DP	U582	
		6546928	APR 14, 2015	DP	U583	
021211 001	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP	U567	
		5767051	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
021211 002	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	4589402	JUL 26, 2004	U567		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
>ADD>	020378 004	FOLLITROPIN ALFA/BETA;GONAL-F	5767057	JUN 16, 2015	DS	
>ADD>	020378 005	FOLLITROPIN ALFA/BETA;GONAL-F			NP	MAR 25, 2007
>ADD>	021765 001	FOLLITROPIN ALFA/BETA;GONAL-F			NP	MAR 25, 2007
>ADD>	021765 002	FOLLITROPIN ALFA/BETA;GONAL-F			NP	MAR 25, 2007
>ADD>	021765 003	FOLLITROPIN ALFA/BETA;GONAL-F			NP	MAR 25, 2007
>ADD>	021684 001	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS	
>ADD>	021684 002	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS	
>ADD>	021684 003	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS	
>ADD>	021345 001	FONDAPARINUX SODIUM,ARIXTRA			I-426	MAY 31, 2007
>ADD>	021345 002	FONDAPARINUX SODIUM,ARIXTRA			I-427	MAY 31, 2007
>ADD>					I-426	MAY 31, 2007
>ADD>					I-427	MAY 31, 2007
>ADD>	021345 003	FONDAPARINUX SODIUM,ARIXTRA			I-426	MAY 31, 2007
>ADD>					NCE	DEC 07, 2006
>ADD>					I-397	JUN 17, 2006
>ADD>					NS	MAY 31, 2007
>ADD>					NS	MAY 31, 2007
>ADD>					I-397	JUN 17, 2006
>ADD>					I-427	MAY 31, 2007
>ADD>					I-426	MAY 31, 2007
>ADD>					I-426	MAY 31, 2007
>ADD>					I-426	MAY 31, 2007

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 021345 004	FONDAPARINUX SODIUM; ARIIXTRA				I-426	MAY 31, 2007
>ADD>					NCE	DEC 07, 2006
>ADD>					I-397	JUN 17, 2006
>ADD>					NS	MAY 31, 2007
>ADD>					I-427	MAY 31, 2007
>ADD> 021344 001	FULVESTRANT; FASLODEX				PC	FEB 14, 2005
>ADD> 076017 001	GABAPENTIN; GABAPENTIN				PC	FEB 14, 2005
>ADD> 076017 002	GABAPENTIN; GABAPENTIN				PC	FEB 14, 2005
>ADD> 076017 003	GABAPENTIN; GABAPENTIN				I-432	JUN 30, 2007
>ADD> 021061 001	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021061 002	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021062 001	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021062 002	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021062 003	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021062 004	GATIFLOXACIN; TEQUIN				I-432	JUN 30, 2007
>ADD> 021493 001	GATIFLOXACIN; ZYMAR				I-432	JUN 30, 2007
020509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	6774122	JAN 09, 2021	U596	PC	FEB 14, 2005
020509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR				PC	FEB 14, 2005
021158 001	GEMIFLOXACIN MESYLATE; FACTIVE				PC	FEB 14, 2005
021667 001	GLUTAMINE; NUTRESTORE	6723734	MAR 20, 2018	DS DP	NCE	JUN 10, 2009
076345 001	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 002	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 003	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
>ADD> 021640 001	HYALURONIDASE; VITRASE				NP	MAY 05, 2007
>ADD> 020758 001	HYDROCHLOROTHIAZIDE; AVALIDE					
>ADD> 020758 002	HYDROCHLOROTHIAZIDE; AVALIDE					
>ADD> 020758 003	HYDROCHLOROTHIAZIDE; AVALIDE					
>ADD> 076604 001	HYDROCODONE BITARTRATE; HYDROCODONE BITARTRA					
021604 001	IBUPROFEN; CHILDREN'S ELIXSURE					
076478 001	IBUPROFEN; IBUPROFEN AND PSEUDO					
020723 001	IMIQUIMOD; ALDARA					
020685 001	INDINAVIR SULFATE; CRIXIVAN					
020685 003	INDINAVIR SULFATE; CRIXIVAN					
020685 005	INDINAVIR SULFATE; CRIXIVAN					
020685 006	INDINAVIR SULFATE; CRIXIVAN					
021629 001	INSULIN GLULISINE RECOMBINANT; APIDRA					
020563 001	INSULIN LISPRO RECOMBINANT; HUMALOG PEN					
020563 002	INSULIN LISPRO RECOMBINANT; HUMALOG PEN					
021425 003	TOPROMIDE; ULTIVAST (PHARMACY)					
>ADD> 020757 001	IRBESARTAN; AVAPRO					
>ADD> 020757 002	IRBESARTAN; AVAPRO					
>ADD> 020757 003	IRBESARTAN; AVAPRO					
>ADD> 020757 005	IRBESARTAN; AVAPRO					
>ADD> 020757 003	IRBESARTAN; AVAPRO					
>ADD> 020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
>ADD> 020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
4364921	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
5270317*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
634224*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
527031*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
634224*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
5270317*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
4604463	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
6403569	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
4604463*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
6403569*PED	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
021066 001	KETOTIFEN FUMARATE;ZADITOR	6777429 6774137 6776982	JAN 13, 2019 JAN 13, 2019 JAN 13, 2019	DP DP	U599	AUG 30, 2005 M-12 M-12 M-12
>ADD>						
021281 001	LANSOPRAZOLE; PREVACID	6451289	JAN 05, 2010	U332	DP	M-12
021281 002	LANSOPRAZOLE; PREVACID	5362755	MAR 21, 2021	U332	DP	AUG 30, 2005
021428 001	LANSOPRAZOLE; PREVACID	5362755	NOV 08, 2011	U332	DP	AUG 30, 2005
021428 002	LANSOPRAZOLE; PREVACID	5547994	AUG 20, 2013	U332	DP	AUG 30, 2005
021566 001	LANSOPRAZOLE; PREVACID IV	5760090	JAN 05, 2010	U5	NP	MAY 27, 2007
020905 001	LEFLUNOMIDE;ARAVA	5844002	JAN 05, 2010	U5	NP	MAR 05, 2007
020905 002	LEFLUNOMIDE;ARAVA	5053407	JAN 16, 2021	DS	DP U600	SEP 05, 2007
020905 003	LEFLUNOMIDE;ARAVA	5785053	DEC 05, 2015	DP	NP	MAR 01, 2007
020837 004	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 29, 2021	DS	DP	SEP 05, 2007
>ADD>						
020182 001	LEVOCARNITINE;CARNITOR	6031007	API 01, 2017	DP U553	PC	AUG 20, 2004
021571 001	LEVOFLOXACIN;IQUIX	5688792	NOV 18, 2014	DS U319	NPP	MAR 11, 2007
021225 001	LEVONORGESTREL;MIRENA	6559305	JAN 29, 2021	DS	PED	SEP 11, 2007
021451 001	LIDOCAINE;ORAQIX	5688792	NOV 18, 2014	DS U319	NPP	MAR 11, 2007
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	PED	SEP 11, 2007
021130 002	LINEZOLID;ZYVOX	6559305	JAN 29, 2021	DS	NP	MAR 11, 2007
021131 001	LINEZOLID;ZYVOX	6559305	JAN 29, 2021	DS	NP	MAR 11, 2007
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	PC	AUG 20, 2004
021226 001	LOPINAVIR;KALETRA	6559305	JAN 29, 2021	DS	NPP	MAR 11, 2007
021251 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257	PED	SEP 11, 2007
075505 001	LORATADINE;LORATADINE	6703403	JUN 26, 2016	U257	NP	MAR 11, 2007
020386 001	LOSARTAN POTASSIUM;COZAAR	5747061	OCT 25, 2013	DP U576	NP	MAR 11, 2007
020386 002	LOSARTAN POTASSIUM;COZAAR	5747061	OCT 25, 2013	DP U575	PED	SEP 11, 2007
020386 003	LOSARTAN POTASSIUM;COZAAR	6676967	SEP 20, 2013	U548	NP	MAR 11, 2007
020603 001	LOTEPREDNOL ETABONATE;ALREX	6746691	SEP 20, 2013	U586	NP	MAR 11, 2007
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	6676967	SEP 20, 2013	U548	NP	MAR 11, 2007
021249 001	LOVASTATIN;ADVICOR	6746691	SEP 20, 2013	U586	NP	MAR 11, 2007
021249 002	LOVASTATIN;ADVICOR	6676967	SEP 20, 2013	U548	NP	MAR 11, 2007
021249 003	LOVASTATIN;ADVICOR	6746691	SEP 20, 2013	U586	NP	MAR 11, 2007
020938 001	MELOXICAM;MOBIC	5747061	OCT 25, 2013	DP U576	I-430	JUL 16, 2007
020938 002	MELOXICAM;MOBIC	5747061	OCT 25, 2013	DP U575	I-430	JUL 16, 2007
021530 001	MELOXICAM;MOBIC	6746691	SEP 20, 2013	U548	NCE	APR 13, 2005
>ADD>						
6184220		MAR 25, 2019	DP			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

A-1.1

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
013217 001	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189	NP	APR 27, 2007
013217 002	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189	NP	APR 27, 2007
021574 001	METFORMIN HYDROCHLORIDE; FORTAMET				PC	DEC 14, 2004
021574 002	METFORMIN HYDROCHLORIDE; FORTAMET				PC	MAY 29, 2004
076172 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				ME	JUL 27, 2007
076545 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL					
021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	DP	U591
021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	DP	U591
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	DP	U591
021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	DP	U591
021284 004	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	DP	U591
022308 001	MICONAZOLE NITRATE; MONISTAT 1 COMBINATI	6635284	DEC 04, 2015	DP	DP	U591
076307 001	MIRTAZAPINE					
076307 002	MIRTAZAPINE MIRTAZAPINE					
020762 001	MOMETASONE FURETATE MONOHYDRATE; NASONEX	6723713	JAN 27, 2014	U574	RTO	JUN 29, 2004
021671 001	MORPHINE SULFATE; DEPODUR	6723713*PED	JUL 27, 2014		PC	JUN 14, 2004
		5723147	MAR 03, 2015		PC	JUN 14, 2004
		5807572	SEP 15, 2015		DP	U584
		5891467	JAN 31, 2017		DP	
		5931089	JUL 14, 2015		DP	U584
		5997899	SEP 01, 2016		DP	
		5962016	JAN 31, 2017		DP	U584
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016		DP	
		6193998	SEP 01, 2016		DP	
		6241999	SEP 01, 2016		DP	
		5723147	MAR 03, 2015		DP	U584
		5807572	SEP 15, 2015		DP	
		5891467	JAN 31, 2017		DP	
		5931089	JUL 14, 2015		DP	U584
		5997899	SEP 01, 2016		DP	
		5962016	JAN 31, 2017		DP	U584
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016		DP	
		6193998	SEP 01, 2016		DP	
		6241999	SEP 01, 2016		DP	
		5723147	MAR 03, 2015		DP	U584
		5807572	SEP 15, 2015		DP	
		5891467	JAN 31, 2017		DP	
		5931089	JUL 14, 2015		DP	U584
		5997899	SEP 01, 2016		DP	
		5962016	JAN 31, 2017		DP	U584
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016		DP	
		6193998	SEP 01, 2016		DP	
		6241999	SEP 01, 2016		DP	
		6716830	SEP 20, 2019		DP	
		6716830*PED	MAR 29, 2020		NCE	DEC 10, 2004
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX				PC	JUN 10, 2005

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020381 001	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 002	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 003	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 004	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 005	NIACIN; NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
021497 001	NITAZOXANIDE; ALINIA					
021498 001	NITAZOXANIDE; ALINIA					
076648 001	NITROFURANTOIN; NITROFURANTOIN (MONO) NIZATIDINE; AXID	5229382	APR 23, 2011	DS DP U149	NDF	MAY 25, 2007
021494 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2001	U547	1-417	JAN 14, 2007
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	1-417	JAN 14, 2007
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	1-417	JAN 14, 2007
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	1-417	JAN 14, 2007
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149		
021086 001	OLANZAPINE; ZYPREXA ZYDIS	6780682	JUL 16, 2016	DS DP	U588	
021086 002	OLANZAPINE; ZYPREXA ZYDIS	5840737	JUL 16, 2016	DS DP	U588	
021086 003	OLANZAPINE; ZYPREXA ZYDIS	6645988	JUL 16, 2016	DS DP	U588	
021086 004	OLANZAPINE; ZYPREXA ZYDIS	6489346	JUL 16, 2016	DS DP	U588	
<u>>ADD></u> 021636 001	OMEPRAZOLE; ZEGERID	66999885	JUL 16, 2016	DS DP	U588	
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483	DEC 27, 2016			
		58666601	FEB 02, 2016			
		58666601	FEB 02, 2016			
		5952375	FEB 02, 2016			
		5763483*PED	JUN 27, 2017			
		58666601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			
		58666601	FEB 02, 2016			
		5763483	DEC 27, 2016			
		5763483*PED	JUN 27, 2017			
		58666601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU					

021492 001	OXALIPLATIN; ELOXATIN	5872147	DEC 05, 2017	I-425	JAN 09, 2007	
021492 002	OXALIPLATIN; ELOXATIN	6670351	OCT 20, 2012	U585	U585	
013718 001	OXANDROLONE; OXANDRIN	6576659	DEC 05, 2017	U585	U585	
013718 002	OXANDROLONE; OXANDRIN	6090799	JUL 18, 2017	U585	U585	
021351 002	OXYBUTYNIN; OXYNTROL	5872147	DEC 05, 2017	I-425	JAN 09, 2007	
076168 001	OXYCODEONE HYDROCHLORIDE; OXYCODONE HCL	6670351	OCT 20, 2012	U585	U585	
020819 001	PARTICALCITOL; ZEMPLAR	5872147	JUL 18, 2017	U585	U585	
020819 002	PARTICALCITOL; ZEMPLAR	6576659	OCT 20, 2012	U585	U585	
021351 002	OXYBUTYNIN; OXYNTROL	6090799	JUL 18, 2017	U585	U585	
076168 001	OXYCODEONE HYDROCHLORIDE; OXYCODONE HCL	6743441	APR 26, 2020	DP U318	PC	
020819 001	PARTICALCITOL; ZEMPLAR	5246925	APR 17, 2012	U314	SEP 26, 2004	
020819 002	PARTICALCITOL; ZEMPLAR	5246925+PED	OCT 17, 2012	U314	M-31, 2007	
021462 001	PEMETREXED DISODIUM; ALIMTA	5587497	DEC 24, 2013	PED	OCT 01, 2007	
020629 001	PENCICLOVIR SODIUM; DENAVIR	5587497+PED	JUN 24, 2014	M-31, 2007	MAR 31, 2007	
021462 001	PEMETREXED DISODIUM; ALIMTA	6136799	APR 08, 2018	DP	OCT 01, 2007	
020629 001	PENCICLOVIR SODIUM; DENAVIR	6136799+PED	OCT 08, 2019	DP	PC	
021749 001	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TRISODIUM; PENTETATE ZINC TRISODIUM; PENTETATE ZINC TRISODIUM	6361758	APR 08, 2018	DP	SEP 26, 2004	
021751 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	6361758+PED	OCT 08, 2018	DP	M-31, 2007	
021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5217974	MAR 29, 2011	DS DP	PC	
021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5344932	SEP 06, 2011	DS DP	PC	
020639 001	QUETIAPINE FUMARATE; SEROQUEL	5840763	SEP 01, 2015	U501	NCE	
020639 002	QUETIAPINE FUMARATE; SEROQUEL	5866581	SEP 04, 2014	U501	ODE	
020639 003	QUETIAPINE FUMARATE; SEROQUEL	5916893	SEP 01, 2015	U501	NCE	
020639 004	QUETIAPINE FUMARATE; SEROQUEL	6124304	SEP 04, 2014	U501	ODE	
021749 001	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TRISODIUM; PENTETATE ZINC TRISODIUM; PENTETATE ZINC TRISODIUM	6361758	APR 08, 2018	DP	SEP 26, 2004	
021751 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	6361758+PED	OCT 08, 2018	DP	M-31, 2007	
021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5217974	MAR 29, 2011	DS DP	PC	
021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5344932	SEP 06, 2011	DS DP	PC	
020639 001	QUETIAPINE FUMARATE; SEROQUEL	5840763	SEP 01, 2015	U501	NCE	
020639 002	QUETIAPINE FUMARATE; SEROQUEL	5866581	SEP 04, 2014	U501	ODE	
020639 003	QUETIAPINE FUMARATE; SEROQUEL	5916893	SEP 01, 2015	U501	NCE	
020639 004	QUETIAPINE FUMARATE; SEROQUEL	6124304	SEP 04, 2014	U501	ODE	
>ADD>	021749 001	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TRISODIUM; PENTETATE ZINC TRISODIUM; PENTETATE ZINC TRISODIUM	6361758	APR 08, 2018	DP	SEP 26, 2004
>ADD>	021751 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	6361758+PED	OCT 08, 2018	DP	M-31, 2007
021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5217974	MAR 29, 2011	DS DP	PC	
021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS	5344932	SEP 06, 2011	DS DP	PC	
020639 001	QUETIAPINE FUMARATE; SEROQUEL	5840763	SEP 01, 2015	U501	NCE	
020639 002	QUETIAPINE FUMARATE; SEROQUEL	5866581	SEP 04, 2014	U501	ODE	
020639 003	QUETIAPINE FUMARATE; SEROQUEL	5916893	SEP 01, 2015	U501	NCE	
020639 004	QUETIAPINE FUMARATE; SEROQUEL	6124304	SEP 04, 2014	U501	ODE	
>ADD>	021698 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	6677358	JUN 12, 2018	DS DP	U546
020741 001	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP	U546	
020741 002	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP	U546	
020741 003	REPAGLINIDE; PRANDIN	6677358	NOV 01, 2016	U454	U454	
020903 002	RIBAVIRIN; REBETOL	6177074+PED	MAY 01, 2017	U478	U478	
020903 005	QUETIAPINE FUMARATE; SEROQUEL	6461605	MAY 01, 2017	U478	U478	
>ADD>	021698 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	6461605+PED	MAY 01, 2017	U479	U479
020741 001	REPAGLINIDE; PRANDIN	6472373	SEP 21, 2017	U479	U479	
020741 002	REPAGLINIDE; PRANDIN	6472373+PED	MAR 21, 2018	U479	U479	
020741 003	REPAGLINIDE; PRANDIN	6524570	NOV 01, 2016	U499	U499	
020903 002	RIBAVIRIN; REBETOL	6524570+PED	MAY 01, 2017	U499	U499	

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
076203 001	RIBAVIRIN; RIBASPHERE	JUL 17, 2018	U595	PC	OCT 03, 2004	
076192 001	RIBAVIRIN; RIBAVIRIN	AUG 14, 2018	DP	PC	OCT 03, 2004	
021361 001	RIFAXIMIN; XIFAXAN	JUN 26, 2016	U564	NCE	MAY 25, 2009	
^{>ADD:} 020835 003	RISEDRONATE SODIUM; ACTONEL	6432932				
		6465443				
		6703403				
		5474995				
020659 001	RITONAVIR; NORVIR	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004	
020445 001	RITONAVIR; NORVIR	MAY 18, 2015			AFR 11, 2005	
021042 001	ROfecoxib; VIOXX	MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	AUG 06, 2006	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
021042 002	ROfecoxib; VIOXX	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004	
		MAY 18, 2015			AFR 11, 2005	
		MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	PED	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
		6063811				
		6239173				
		5474995				
		5691374*PED				
		6063811*PED				
		6239173*PED				
021042 003	ROfecoxib; VIOXX	JUN 24, 2013	DS DP U266	NCE	MAY 20, 2004	
		MAY 18, 2015			AFR 11, 2005	
		MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	PED	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
		6239173				
		5474995				
		5691374				
		6063811				
		6239173				
		5474995				
		5691374				
		6063811				
		6239173				
021052 001	ROfecoxib; VIOXX	JUN 24, 2013	U266	NCE	MAY 20, 2004	
		MAY 18, 2015			AFR 11, 2005	
		MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	PED	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
		6239173				
		5474995				
		5691374				
		6063811				
		6239173				
021052 002	ROfecoxib; VIOXX	JUN 24, 2013	U266	NCE	MAY 20, 2004	
		MAY 18, 2015			AFR 11, 2005	
		MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	PED	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
		6239173				
		5474995				
		5691374				
		6063811				
		6239173				
021256 001	SECRETIN SYNTHETIC HUMAN; HUMAN SECRETIN	JUN 24, 2013	U266	NCE	MAY 20, 2004	
		MAY 18, 2015			AFR 11, 2005	
		MAY 06, 2017	U266		AUG 06, 2006	
		JUN 24, 2013	DS DP U266	M-27	PED	
		DEC 24, 2013		PED	NOV 20, 2004	
		5474995*PED		PED	OCT 11, 2005	
		5691374*PED		PED	FEB 06, 2007	
		6063811*PED		PED	MAR 26, 2007	
		6239173*PED		I-423		
		6239173				
		5474995				
		5691374				
		6063811				
		6239173				
020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	OCT 11, 2019	U266	NCE	MAY 20, 2004	
020926 001	SEVELAMER HYDROCHLORIDE; RENAGEL	AUG 11, 2013	U266	NCE	AFR 11, 2005	
021179 001	SEVELAMER HYDROCHLORIDE; RENAGEL	AUG 11, 2013	U266	NCE	AUG 09, 2009	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

A-15

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL	PATENT CODE (\$)	EXCLUS CODE	EXCLUS EXPRES
021110 003	SIROLIMUS;RAPAMUNE			NCE	SEP 15, 2004 I-386	
>ADD>	021196 001 SODIUM FERRIC GLUCONATE COMPLEX; FERRLECIT 020180 004 SODIUM OXYBATE;XYREM 020168 001 SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT 020168 002 SOMATROPIN RECOMBINANT; NUTROPIN 020522 001 SOMATROPIN RECOMBINANT; NUTROPIN AQ 020522 002 SOMATROPIN RECOMBINANT; NUTROPIN AQ PEN 020080 001 SUMATRIPTAN SUCCINATE; IMITREX	6780889 4968299 5096885 5096885 5763394 5763394 4816470 5037845 4816470*PED 5037845*PED 4816470 5037845 6020001 6020001*PED 6368627 5863559 6020001 4816470 5037845 6368627 5863559 5863559*PED 6020001*PED 6368627*PED 4816470*PED 5037845*PED 5863559*PED 5037845 4816470 6368627 5863559 6020001 5037845 6368627 4816470*PED 5037845*PED 5863559*PED 6020001*PED 6368627*PED 4816470 5037845*PED 5863559*PED 4816470 5037845 530793 5554439 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED	DEC 22, 2019 JUN 28, 2008 MAR 17, 2009 MAR 17, 2009 JUN 09, 2015 JUN 09, 2015 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 DEC 28, 2006 AUG 06, 2008 JUN 02, 2012 JAN 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 AUG 06, 2008 DEC 28, 2006 MAR 02, 2012 SEP 02, 2012 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 SEP 02, 2012 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013			
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470 5037845 4816470 5037845 6020001 4816470 5037845 6368627 5863559 5863559*PED 6020001*PED 6368627*PED 4816470*PED 5037845*PED 5863559*PED 5037845 4816470 6368627 5863559 6020001 5037845 6368627 4816470 5037845*PED 5863559*PED 4816470 5037845 530793 5554439 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED	DEC 22, 2019 JUN 28, 2008 MAR 17, 2009 MAR 17, 2009 JUN 09, 2015 JUN 09, 2015 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 DEC 28, 2006 AUG 06, 2008 JUN 02, 2012 JAN 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013			
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	4816470 5037845 4816470 5037845 6020001 4816470 5037845 6368627 5863559 5863559*PED 6020001*PED 6368627*PED 4816470*PED 5037845*PED 5863559*PED 5037845 4816470 6368627 5863559 6020001 5037845 6368627 4816470 5037845*PED 5863559*PED 4816470 5037845 530793 5554439 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED	DEC 22, 2019 JUN 28, 2008 MAR 17, 2009 MAR 17, 2009 JUN 09, 2015 JUN 09, 2015 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 DEC 28, 2006 AUG 06, 2008 JUN 02, 2012 JAN 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013			
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	4816470 5037845 4816470 5037845 6020001 4816470 5037845 6368627 5863559 5863559*PED 6020001*PED 6368627*PED 4816470*PED 5037845*PED 5863559*PED 5037845 4816470 6368627 5863559 6020001 5037845 6368627 4816470 5037845*PED 5863559*PED 4816470 5037845 530793 5554439 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED	DEC 22, 2019 JUN 28, 2008 MAR 17, 2009 MAR 17, 2009 JUN 09, 2015 JUN 09, 2015 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 DEC 28, 2006 AUG 06, 2008 JUN 02, 2012 JAN 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013			
020626 001	SUMATRIPTAN;IMITREX	4816470 5037845 530793 5554439 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED	DEC 22, 2019 JUN 28, 2008 MAR 17, 2009 MAR 17, 2009 JUN 09, 2015 JUN 09, 2015 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 DEC 28, 2006 AUG 06, 2008 JUN 02, 2012 JAN 26, 2016 MAR 02, 2012 SEP 02, 2012 SEP 02, 2012 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 JUN 28, 2007 FEB 06, 2009 JUL 26, 2016 DEC 28, 2006 AUG 06, 2008 SEP 02, 2012 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013			

PREScription AND OTC DRUG PRODUCT

PATIENT AND EXCLUDED VADS: MORE INFORMATION REGARDING REPORT CONTENT

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)
020626 002	SUMATRIPTAN;IMITREX	4816470 5037845 5307953 5554639 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED 4816470 5037845 5307953 5554639 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED 5850006 614329 5850006 614329 5850006 614329	DEC 28, 2006 AUG 06, 2008 DEC 02, 2012 SEP 10, 2013 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013 DEC 28, 2006 AUG 06, 2008 DEC 02, 2012 SEP 10, 2013 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016	U72 U232 U232
020626 003	SUMATRIPTAN;IMITREX	5037845 5307953 5554639 5705520 5554639*PED 5705520*PED 4816470*PED 5037845*PED 5307953*PED 5850006 614329 5850006 614329 5850006 614329	AUG 06, 2008 DEC 02, 2012 SEP 10, 2013 DEC 10, 2011 MAR 10, 2014 JUN 10, 2012 JUN 28, 2007 FEB 06, 2009 JUN 02, 2013 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016 JUL 12, 2016	U232 U232
021368 001	TADALAFIL;CIALIS	D459798 5635485 5681849 4755534 4680291 6121314 5681849 6121314 6121314 6005001 6005001 6005001 5856355 5856355 5856355 6770623 6770623	SEP 24, 2015 APR 21, 2015 OCT 28, 2014 DEC 30, 2006 JUL 14, 2004 MAY 18, 2012 OCT 26, 2014 MAY 18, 2012 MAY 18, 2012	I-435 I-435 NICE DP DP U578
021368 002	TADALAFIL;CIALIS	021124 002	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	
021368 003	TADALAFIL;CIALIS	020846 001	TERBINAFINE;LAMISIL	
021368 001	TALC;TALC	5045302	FEB 09, 2010	
020372 001	TECHNETIUM TC-99M TROPOSMIN KIT;MYOVIEW			
021200 001	TEGASEROD MALEATE;ZELNORM			
021200 002	TEGASEROD MALEATE;ZELNORM			
021144 001	TELITHROMYCIN;KETEK			
>ADD>				
>ADD>				
>ADD>				
021318 001	TERIPARATIDE RECOMBINANT HUMAN;PORTEO			
020785 001	THALIDOMIDE;THALOMID			
020785 002	THALIDOMIDE;THALOMID			
020785 003	THALIDOMIDE;THALOMID			
020898 001	THYROTROPIN ALFA;HYDROGEN			
021618 001	TINIDAZOLE;TINDAMAX			

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME: TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021618 002	TINIDAZOLE; TINDAMAX	5610163	MAR 11, 2014	DS DP U566	NCE	MAY 17, 2009
021395 001	TIOTROPIUM BROMIDE MONOHYDRATE; SPIRIVA	6770295	AUG 26, 2019	DP U544	NCE	JAN 30, 2009
021228 001	TOLTERODINE TARTRATE; DETROL LA	6770295* PED	FEB 26, 2020	DP U544		
021228 002	TOLTERODINE TARTRATE; DETROL LA	6770295	AUG 26, 2019	DP U544		
020505 001	TOPIRAMATE; TOPAMAX	6770295* PED	FEB 26, 2020	DP U544		
020505 001	TOPIRAMATE; TOPAMAX	5998380	SEP 13, 2015	U598	D-88	DEC 16, 2006
020505 002	TOPIRAMATE; TOPAMAX	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
020505 003	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
020505 004	TOPIRAMATE; TOPAMAX	5998380	SEP 13, 2015	U598	D-88	DEC 16, 2006
020505 005	TOPIRAMATE; TOPAMAX	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	5998380	SEP 13, 2015	U598	D-88	DEC 16, 2006
020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
021257 001	TRAVOPROST; TRAVATAN	5998380	SEP 13, 2015	U598	D-88	DEC 16, 2006
021272 001	TREPROSTINIL SODIUM; REMODULIN	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
021272 002	TREPROSTINIL SODIUM; REMODULIN	6011062	DEC 22, 2014	DP U383		
021272 003	TREPROSTINIL SODIUM; REMODULIN	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
021272 004	TREPROSTINIL SODIUM; REMODULIN	5889052	SEP 13, 2015	U598	D-88	DEC 16, 2006
021595 001	TROSPIUM CHLORIDE; SANCTURA	5510383	AUG 03, 2013	DP U383		
020675 001	URSODIOL; URSO 250	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
021630 001	VORICONAZOLE; VFEND	6765117	OCT 24, 2017	DS		
020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	5366938	NOV 15, 2011	DS	I-409	NOV 14, 2006
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	5567817	OCT 22, 2013	DS DP U540		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	5773443	JAN 25, 2011	DS DP U540		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP U540		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	5312925	SEP 01, 2012	DS DP		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019	DP		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6245766	DEC 18, 2018	U601		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019	DP		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6245766	DEC 18, 2018	U601		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	5312925	SEP 01, 2012	DS DP		

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON >ADD>	4831031	MAR 02, 2007	DS DP		
>ADD> 020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON >ADD>	5312925	SEP 01, 2012	DS DP		
>ADD> 021450 004	ZOLMITRIPTAN; ZOMIG >ADD>	6150366	MAY 27, 2019	DP	U601	
		6245766	DEC 18, 2018	DS DP		
		4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP	U601	
		6245766	DEC 18, 2018	DS DP		
		6750237	NOV 28, 2020	DP		
		6750237*PED	MAY 28, 2021			

Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c) (3) (5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 DS = Drug Substance claim
 DP = Drug Product claim
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at
<http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM).

PATENT & EXCLUSIVITY ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
 D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
 D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
 D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
 D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS

EXCLUSIVITY INDICATION

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
 I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
 I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
 I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
 I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
 I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
 I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
 I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
 I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
 I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
 I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
 I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
 I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
 I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT

- I-433 STREPTOCOCCUS PNEUMONIAE
TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDERS



Order Processing Code:
8414

Approved Drug Products, ADP SUBSCRIPTION ORDER FORM

Easy Secure Internet:
bookstore.gpo.gov
Mail: Superintendent of Documents
Toll Free: (866) 512-1800
Phone: (202) 512-1800
Fax: (202) 512-2250
P.O. Box 371954
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:

 subscriptions of Approved Drug Products with Therapeutic Equivalence Evaluations, ADP, and the monthly Cumulative Supplements, for \$110.00 per year. The total cost of my order is \$. Price includes regular shipping and handling and is subject to change. International customers please add 40%.


Personal name _____
(Please type or print)

Company name _____

Street address _____
City, State, Zip code _____

Daytime phone including area code _____

Purchase order number (optional) _____



Check method of payment:

- Check payable to Superintendent of Documents
 SOD Deposit Account —
 VISA MasterCard Discover/NOVUS American Express

 (expiration date)

Thank you for your order!

Authorizing signature _____

02/04

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90044 0070

Approved drug products with
therapeutic equivalence evaluations.
Cumulative supplement.

RM 301.45 .A66 2004 v.24 suppl.8

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

Library Use Only